AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 24, 2000
REGISTRATION STATEMENT NO. 333-33822
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
AMENDMENT NO. 2
TO
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
---------------
ANDRX CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
---------------
<TABLE>
<S> <C>
FLORIDA 65-0366879
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
</TABLE>
DR. ELLIOT F. HAHN, PRESIDENT
ANDRX CORPORATION
4001 SOUTHWEST 47TH AVENUE
FORT LAUDERDALE, FLORIDA 33314
(954) 584-0300
(ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER,
INCLUDING AREA CODE, OF REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES AND AGENTS FOR
SERVICE OF PROCESS)
---------------
COPIES OF COMMUNICATIONS TO:
<TABLE>
<S> <C>
DALE S. BERGMAN, P.A.
MICHAEL D. KARSCH, P.A. JONATHAN I. MARK, ESQ.
BROAD AND CASSEL CAHILL GORDON & REINDEL
201 SOUTH BISCAYNE BOULEVARD 80 PINE STREET
MIAMI, FLORIDA 33131 NEW YORK, NEW YORK 10005
TELEPHONE: (305) 373-9400 TELEPHONE: (212) 701-3000
TELECOPIER: (305) 373-9443 TELECOPIER: (212) 269-5420
---------------
</TABLE>
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:
AS SOON AS PRACTICABLE AFTER THIS REGISTRATION STATEMENT BECOMES EFFECTIVE.
If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [ ]
If any of the securities being registered on this Form are to be offered
on a delayed or continuous basis pursuant to Rule 415 under the Securities Act
of 1933, other than securities offered only in connection with dividend or
interest reinvestment plans, check the following box: [ ]
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
---------------
================================================================================
<PAGE>
6,350,000 SHARES
[ANDRX CORPORATION LOGO]
COMMON STOCK
----------------
Andrx Corporation is offering 5,185,128 shares of common stock and a
selling shareholder is offering 1,164,872 shares of our common stock in a
firmly underwritten offering. We will not receive any proceeds from the sale of
shares of common stock by the selling shareholder.
----------------
Our common stock is quoted on the Nasdaq National Market under the symbol
"ADRX." The last reported sale price of our common stock on the Nasdaq National
Market on May 23, 2000, was $50.00 per share.
----------------
INVESTING IN THE COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. SEE "RISK
FACTORS" ON PAGE 5.
<TABLE>
<CAPTION>
Per Share Total
----------- ------
<S> <C> <C>
Offering Price $48.00 $304,800,000
Discounts and Commissions to Underwriters $ 2.34 $ 14,859,000
Offering Proceeds to Andrx $45.66 $236,752,944
Offering Proceeds to a Selling Shareholder $45.66 $ 53,188,056
</TABLE>
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if
this prospectus is truthful or complete. Any representation to the contrary is
a criminal offense.
Some selling shareholders have granted the underwriters the right to
purchase up to 952,500 additional shares of common stock to cover any
over-allotments. The underwriters can exercise this right at any time within 30
days after the offering. The underwriters expect to deliver the shares of common
stock to investors on May 30, 2000.
JOINT BOOK-RUNNING MANAGERS
BANC OF AMERICA SECURITIES LLC BEAR, STEARNS & CO. INC.
----------------
CIBC WORLD MARKETS UBS WARBURG LLC
----------------
May 24, 2000
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
-----
<S> <C>
Note Regarding Forward-Looking Statements ............................................ ii
Prospectus Summary ................................................................... 1
Risk Factors ......................................................................... 5
Use of Proceeds ...................................................................... 12
Price Range of Common Stock and Dividend Policy ...................................... 13
Capitalization ....................................................................... 14
Selected Consolidated Financial Data ................................................. 15
Unaudited Pro Forma Condensed Consolidated Financial Data ............................ 16
Management's Discussion and Analysis of Financial Condition and Results of Operations 23
Business ............................................................................. 32
Management ........................................................................... 50
Selling Shareholders ................................................................. 52
Description of Capital Stock ......................................................... 53
Shares Eligible for Future Sale ...................................................... 55
Underwriting ......................................................................... 56
Legal Matters ........................................................................ 58
Experts .............................................................................. 58
Where You Can Find More Information .................................................. 58
Index to Financial Statements ........................................................ F-1
</TABLE>
----------------
As used in this prospectus, the terms "we," "us," "our," the "Company" and
"Andrx" mean Andrx Corporation and its subsidiaries and the term "common stock"
means Andrx Corporation's common stock, $0.001 par value per share (unless the
context indicates a different meaning).
The information in this prospectus gives effect to two-for-one stock
splits in June 1999 and April 2000. Unless otherwise stated, all information
contained in this prospectus assumes no exercise of the over-allotment option
granted to the underwriters.
The underwriters are offering the shares subject to various conditions and
may reject all or part of any order.
We were incorporated on August 28, 1992 under the name "Andrx
Pharmaceuticals, Inc.," commenced operations and assumed our present name in
November 1992. We are located at 4001 Southwest 47th Avenue, Fort Lauderdale,
Florida 33314. Our telephone number is (954) 584-0300 and our website address
is www.andrx.com. The website address of Cybear, Inc., Andrx' majority owned
subsidiary, is www.cybear.com. Information contained on our websites is not
part of this prospectus.
You should rely only on the information contained in this prospectus. We
have not authorized anyone to provide you with information different from that
which is contained in this prospectus. We are offering to sell shares of common
stock and seeking offers to buy shares of common stock only in jurisdictions
where offers and sales are permitted. The information contained in this
prospectus is accurate only as of the date of this prospectus, regardless of
the time of delivery of this prospectus or of any sale of the common stock.
i
<PAGE>
NOTE REGARDING FORWARD-LOOKING STATEMENTS
We caution readers that certain important factors may affect our actual
results and could cause such results to differ materially from any
forward-looking statements which may be deemed to have been made in this
prospectus or which are otherwise made by us or on our behalf. For this
purpose, any statements contained in this prospectus that are not statements of
historical fact may be deemed to be forward-looking statements. Without
limiting the generality of the foregoing, words such as "may", "will",
"expect", "believe", "anticipate", "intend", "could", "would", "estimate", or
"continue" or the negative other variations thereof or comparable terminology
are intended to identify forward-looking statements. Factors which may affect
our results include, but are not limited to, the risks and uncertainties of
being a company which has only commercialized a few products, relies on new
technologies, has limited manufacturing experience, faces current and potential
competitors with significant technical and marketing resources, needs future
capital and depends on collaborative partners and on key personnel. We are also
subject to the risks and uncertainties of being a drug delivery company,
including changes in regulatory scheme, compliance with government regulations
and patent infringement and other litigation. Additionally, we are subject to
risks and uncertainties of being a drug distribution company including, but not
limited to, decreasing gross profits. In addition, our Internet based
healthcare solutions subsidiary is subject to the risks and uncertainties of an
early development stage Internet company including, but not limited to, limited
operating history, uncertainty of market acceptance, changes in technology,
operating losses, and dependence on the adoption of the Internet by the
healthcare industry. We are also subject to other risks detailed herein or
detailed from time to time in our filings with the U.S. Securities and Exchange
Commission.
ii
<PAGE>
PROSPECTUS SUMMARY
THIS IS ONLY A SUMMARY AND DOES NOT CONTAIN ALL OF THE INFORMATION THAT
MAY BE IMPORTANT TO YOU. YOU SHOULD READ THE MORE DETAILED INFORMATION
CONTAINED IN THIS PROSPECTUS AND ALL OTHER INFORMATION, INCLUDING THE FINANCIAL
INFORMATION AND STATEMENTS WITH NOTES, AS DISCUSSED IN THE "WHERE YOU CAN FIND
MORE INFORMATION" SECTION OF THIS PROSPECTUS.
ANDRX CORPORATION
OVERVIEW
We formulate and commercialize controlled-release oral pharmaceuticals
using our proprietary drug delivery technologies. We market and sell our
generic or bioequivalent versions of Cardizem/registered trademark/ CD and
Dilacor XR/registered trademark/. Through our distribution operations, we also
sell drugs manufactured by third parties primarily to independent pharmacies,
pharmacy chains which do not maintain their own central warehousing facilities
and pharmacy buying groups. Through our Cybear subsidiary, we develop Internet
applications to improve the efficiency of day-to-day administrative and
communications tasks for various participants in the healthcare industry.
We have eight proprietary drug delivery technologies that we have patented
for certain applications or for which we have filed for patent protection for
certain applications. We believe our technologies are flexible and can be
modified to apply to a variety of pharmaceutical products. We use our
proprietary drug delivery technologies and formulation skills to develop:
/bullet/ bioequivalent versions of selected controlled-release brand name
pharmaceuticals; and
/bullet/ brand name controlled-release formulations of existing
immediate-release or controlled-release drugs where we believe that the
application of our drug delivery technologies may improve the efficacy or
other characteristics of those products.
We believe that pharmaceutical companies are increasingly using
controlled-release drug delivery technologies to improve drug therapy.
Controlled-release drug delivery technologies generally provide more consistent
and appropriate drug levels in the bloodstream than immediate-release dosage
forms and may improve drug efficacy and reduce side effects by releasing drug
dosages at specific times and in specific locations in the body. These
technologies also allow for the development of "patient-friendly" dosage forms,
which reduce the number of times a drug must be taken, thus improving patient
compliance.
PRODUCT DEVELOPMENT AND COMMERCIALIZATION
BIOEQUIVALENT CONTROLLED-RELEASE PHARMACEUTICALS
We market and sell our bioequivalent versions of Cardizem CD and Dilacor
XR. The U.S. Food and Drug Administration, or FDA, recently gave us tentative
approval of the Abbreviated New Drug Applications, or ANDAs, for our
bioequivalent versions of Prilosec/registered trademark/ and
Naprelan/registered trademark/. Prilosec and Naprelan had U.S. brand sales in
excess of $3.5 billion in 1999. We do not expect to begin marketing our
bioequivalent version of Prilosec before the favorable resolution of related
patent litigation or the expiration of the composition of matter patent in
April 2001, and this period may be extended for six months under regulatory
provisions that reward pediatric studies. We filed ANDAs and are awaiting FDA
approval for seven additional products, bioequivalent versions of
Tiazac/registered trademark/, Wellbutrin SR/registered trademark/,
Zyban/registered trademark/, K-Dur/registered trademark/, Depakote/registered
trademark/, Claritin D-24/registered trademark/ and Lodine/registered
trademark/ XL. These products had U.S. brand sales of approximately $2.2
billion in 1999. Additionally, ANCIRC, our 50/50 joint venture with Watson
Pharmaceuticals, Inc., contemplates the development of up to eight
bioequivalent products, two of which, our bioequivalent versions of
Trental/registered trademark/ and Oruvail/registered trademark/, have been
approved by the FDA.
1
<PAGE>
We currently intend to develop 25 additional bioequivalent versions of
either controlled-release or difficult to copy drugs, including the remaining
products to be developed by ANCIRC. Total U.S. sales for the brand versions of
these products were approximately $8.0 billion in 1999. We continually evaluate
other potential product candidates. In selecting our product candidates, we
focus on pharmaceuticals which we anticipate will have high sales volume and
for which marketing exclusivity or patent rights have expired or are near
expiration.
BRAND NAME CONTROLLED-RELEASE PHARMACEUTICALS
We apply our proprietary drug delivery technologies to the development of
brand name controlled-release formulations of existing immediate-release and
controlled-release drugs. The FDA approval process for these products will
require the filing of New Drug Applications, or NDAs. In selecting our product
candidates, we focus on pharmaceuticals with high sales volume whose patent
rights will expire in a time frame that allows us to complete the development
prior to patent expiration. Our most advanced brand products, Lovastatin
XL/registered trademark/, for the treatment of elevated cholesterol, is in
Phase III trials, and Metformin XT/registered trademark/, for the treatment of
diabetes, is expected to commence Phase III trials in 2000. These products are
in markets which are addressed by pharmaceutical products which had
approximately $7.7 billion in U.S. sales in 1999. We are also in various early
stages of development for controlled-release versions of Omeprazole
DR/registered trademark/ (a reformulated version of Prilosec), an analgesic
product and two central nervous system products.
PHARMACEUTICAL DISTRIBUTION OPERATIONS
We market and distribute drugs manufactured by third parties. Our
customers consist primarily of independent pharmacies, pharmacy chains which do
not maintain their own central warehousing facilities and pharmacy buying
groups. Our distribution operations assist in the marketing of our
bioequivalent versions of Cardizem CD, Dilacor XR and Trental and we plan to
use these operations to assist in the marketing of other controlled-release
products being developed by us and our collaborative partners. These operations
allow us to observe and participate directly in developments and trends in the
pharmaceutical industry.
CYBEAR, INC.
Cybear is an information technology company that is using the Internet to
improve the efficiency of the administrative and communications tasks of
managing patient care with secure and reliable transmission of information.
Cybear is an Internet Service Provider, or ISP, and an Application Services
Provider, or ASP, for the healthcare industry. Cybear uses or intends to use
its own secure private network to provide access to the Internet, e-mail and
productivity applications to physicians, physician organizations, pharmacies
and hospitals. In March 1999, Cybear introduced its first product, dr.cybear,
its physician practice portal, which addresses the communications and
operational needs of physicians and other healthcare providers. dr.cybear is
marketed to physicians, physician organizations, hospitals, managed care
organizations and integrated delivery networks throughout the United States. In
September 1999, Cybear entered into an arrangement with Andrx for the sale by
Cybear of prescription vaccines and injectables and other items to physicians'
offices on orders placed through Cybear's physician practice portal.
RECENT DEVELOPMENTS
REORGANIZATION
In March 2000, we entered into a definitive agreement for a corporate
reorganization plan which would give Andrx shareholders the ability to
distinguish between their investments in Andrx and Cybear. This plan will
create a new class of Andrx common stock, called Cybear Group Common Stock, to
track the performance of Cybear. In exchange for their Andrx shares, Andrx
shareholders will receive shares of Andrx Group Common Stock representing the
equity interests of Andrx other than its ownership of Cybear, and Cybear Group
Common. The plan will be submitted for approval to the shareholders of Andrx
and Cybear later this year.
2
<PAGE>
THE OFFERING
Common stock offered by Andrx......... 5,185,128 shares
Common stock offering by a
selling shareholder................... 1,164,872 shares
Common stock to be outstanding
after the offering................... 68,840,890 shares(1)
Use of proceeds....................... For expansion of manufacturing,
research and development and
administrative facilities; research and
development of branded and
bioequivalent products; acquisitions of
products, product candidates and/or
companies; working capital requirements
and other general corporate purposes.
Nasdaq National Market symbol......... ADRX
- ----------------
(1) As of May 19, 2000, excludes (a) 5,498,800 shares of common stock issuable
upon the exercise of outstanding stock options, and (b) 11,987,200 shares of
common stock reserved for future issuance under our existing stock option
plans.
3
<PAGE>
SUMMARY CONSOLIDATED FINANCIAL DATA
<TABLE>
<CAPTION>
THREE MONTHS ENDED
YEARS ENDED DECEMBER 31, MARCH 31,
-------------------------------------------- -----------------------------
1997 1998 1999 1999 2000
-------------- -------------- -------------- -------------- --------------
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
<S> <C> <C> <C> <C> <C>
STATEMENT OF INCOME DATA:(1)
Revenues
Distributed products ........................... $ 146,237 $ 215,903 $ 262,402 $ 63,025 $ 67,826
Manufactured products. ......................... 3,324 11,472 134,796 4,373 44,114
Stipulation fees ............................... -- 19,130 70,733 10,000 --
Licensing and other. ........................... 137 552 8,059 526 3,538
----------- ----------- ----------- ----------- -----------
Total revenues ............................... 149,698 247,057 475,990 77,924 115,478
----------- ----------- ----------- ----------- -----------
Operating expenses
Cost of goods sold ............................. 126,802 188,226 235,346 52,826 63,204
Selling, general and administrative ............ 18,934 30,646 55,266 9,591 11,542
Research and development ....................... 11,251 16,837 25,697 4,315 8,211
Cybear, Inc. Internet operating expenses ....... 1,473 4,090 14,744 2,795 6,339
Cybear, Inc. merger costs ...................... -- -- -- -- 832
----------- ----------- ----------- ----------- -----------
Total operating expenses ..................... 158,460 239,799 331,053 69,527 90,128
----------- ----------- ----------- ----------- -----------
Income (loss) from operations ................... (8,762) 7,258 144,937 8,397 25,350
Other income (expense)
Minority interest. ............................. 31 85 1,937 51 1,820
Gain on sale of Cybear, Inc. shares. ........... -- 700 643 300 --
Interest income ................................ 1,585 1,064 3,603 366 1,531
Interest expense ............................... (490) (380) (1,661) (154) (474)
----------- ----------- ----------- ----------- -----------
Income (loss) before income taxes ............... (7,636) 8,727 149,459 8,960 28,227
Income taxes .................................... -- 333 55,405 2,016 11,856
----------- ----------- ----------- ----------- -----------
Net income (loss) ............................... $ (7,636) $ 8,394 $ 94,054 $ 6,944 $ 16,371
=========== =========== =========== =========== ===========
Basic net income (loss) per share ............... $ (0.13) $ 0.14 $ 1.52 $ 0.11 $ 0.26
=========== =========== =========== =========== ===========
Diluted net income (loss) per share ............. $ (0.13) $ 0.13 $ 1.45 $ 0.11 $ 0.25
=========== =========== =========== =========== ===========
Basic weighted average shares of common stock
outstanding .................................... 56,852,400 60,090,800 61,979,800 60,871,900 63,212,600
=========== =========== =========== =========== ===========
Diluted weighted average shares of
common stock outstanding ....................... 56,852,400 63,706,800 64,953,200 64,625,300 65,832,200
=========== =========== =========== =========== ===========
</TABLE>
<TABLE>
<CAPTION>
MARCH 31, 2000
------------------------------
ACTUAL AS ADJUSTED(2)
-------------- ---------------
(IN THOUSANDS)
<S> <C> <C>
BALANCE SHEET DATA:(1)
Cash, cash equivalents and investments available-for-sale(3) $ 114,771 $ 350,419
Working capital ............................................. 185,842 421,490
Total assets ................................................ 363,126 598,774
Short-term borrowings ....................................... 20,370 20,370
Total shareholders' equity .................................. 246,638 482,286
</TABLE>
- --------------
(1) Certain prior years' amounts have been reclassified to conform with the
current year presentation.
(2) Gives effect to the sale of 5,185,128 shares of common stock offered by
Andrx at a public offering price of $48.00 per share, and after deducting
the underwriting discount and estimated expenses of this offering payable
by Andrx and the application of the net proceeds therefrom.
(3) Includes $26.7 million of cash, cash equivalents and investments
held-for-sale by Cybear as of March 31, 2000.
4
<PAGE>
RISK FACTORS
YOU SHOULD CAREFULLY CONSIDER THE FOLLOWING RISKS BEFORE MAKING AN
INVESTMENT DECISION. THE TRADING PRICE OF OUR COMMON STOCK COULD DECLINE DUE TO
ANY OF THESE RISKS, AND YOU COULD LOSE ALL OR PART OF YOUR INVESTMENT. YOU
SHOULD ALSO REFER TO THE OTHER INFORMATION SET FORTH IN THIS PROSPECTUS,
INCLUDING OUR CONSOLIDATED FINANCIAL STATEMENTS AND THE RELATED NOTES THERETO.
THESE ARE NOT THE ONLY RISKS AND UNCERTAINTIES THAT WE FACE. ADDITIONAL RISKS
AND UNCERTAINTIES THAT WE DO NOT CURRENTLY KNOW ABOUT OR THAT WE CURRENTLY
BELIEVE ARE IMMATERIAL MAY ALSO HARM OUR BUSINESS OPERATIONS. IF ANY OF THESE
RISKS OR UNCERTAINTIES ACTUALLY OCCUR, OUR BUSINESS, FINANCIAL CONDITION,
RESULTS OF OPERATIONS OR PROSPECTS COULD BE MATERIALLY ADVERSELY AFFECTED. IN
SUCH CASE, THE TRADING PRICE OF OUR COMMON STOCK COULD DECLINE, AND YOU MAY
LOSE ALL OR PART OF YOUR INVESTMENT.
OUR BUSINESS IS SUBJECT TO SUBSTANTIAL LITIGATION WHICH COULD EXPOSE US TO
UNFAVORABLE CLAIMS.
We have and continue to face substantial patent infringement litigation
with respect to the manufacture, use and sale of our products. To date, actions
have been filed against us in connection with substantially all of the ANDAs we
have filed containing certifications relating to infringement, validity or
enforceability of patents. In these applications, we have certified that we
believe an unexpired patent which is listed with the FDA and covers the brand
name product will not be infringed by our product and/or is invalid or
unenforceable. We anticipate that additional actions may be filed as we or our
collaborative partners file additional ANDAs. Patent litigation may also be
brought against us in connection with certain NDA products that we may pursue.
The outcome of this type of litigation is difficult to predict because of the
uncertainties inherent in patent litigation. Prior to filing an ANDA or NDA, we
evaluate the probability of patent infringement litigation on a case-by-case
basis and have reserved for the estimated patent infringement litigation costs.
Our business and financial results could be materially harmed by the delays in
marketing our products as a result of litigation, an unfavorable outcome in any
litigation or the expense of litigation whether or not it is successful.
WE ARE SUBJECT TO ANTITRUST LITIGATION AND AN FTC ADMINISTRATIVE PROCEEDING
RELATING TO A STIPULATION WE ENTERED INTO WITH AVENTIS AND ITS AFFILIATES
WHICH, IF ADVERSELY DETERMINED, WOULD HARM OUR BUSINESS AND FINANCIAL RESULTS.
Putative class actions and individual actions have been filed against us
in a number of state and federal courts. In each of these suits, Aventis S.A.,
formerly Hoechst Marion Roussel, Inc., and some of its affiliates, have been
named as co-defendants. We entered into a stipulation and agreement with
Aventis pursuant to which the parties agreed to maintain the status quo during
the patent infringement litigation that Aventis brought against us. In the
stipulation we agreed not to commence marketing our bioequivalent version of
Cardizem CD until the earlier of final resolution of the Aventis litigation or
certain dates specified in the stipulation in exchange for the right to obtain
a license to the relevant Aventis' patents in the event we lost the patent
infringement litigation or if other events occurred as well as payments made by
Aventis to us, and other things. The complaint in each of the class actions
alleges that Aventis alone and Aventis along with us, by way of the
stipulation, engaged in antitrust and other statutory and common law violations
which allegedly have, among other things, given Aventis and us a monopoly in
the U.S. market for Cardizem CD and a bioequivalent version of that
pharmaceutical product or otherwise restrained trade.
On May 11, 2000, the United States District Court for the Eastern District
of Michigan denied our and Aventis' motions to dismiss the consolidated class
action and other complaints pending before this court, which is handling the
multi-district litigation challenging the stipulation. The motions to dismiss
were premised upon legal arguments as to why the causes of action asserted by
the various claimants are legally inadequate. In denying the motions, the court
was required to assume the truth of the claimants' factual allegations and
rejected our view of certain aspects of state and federal law upon which our
defenses are
5
<PAGE>
premised. We and Aventis will now be required to continue to submit to
discovery and make a substantive response to the factual allegations of each of
the consolidated complaints. The court's interpretation of the applicable law,
with which we disagree, may make our defense of the allegations more difficult.
In addition, on March 16, 2000, we were named as a respondent by the FTC
in an administrative action seeking a cease and desist order against future
agreements similar to the stipulation and other remedies. The complaint in the
administrative proceeding does not seek any monetary remedies from us of any
kind.
An adverse outcome in the class actions, individual actions and FTC
administrative action or the expense to us of defending such actions, whether
or not there is an adverse outcome, could materially harm our business and
financial results.
WE ONLY HAVE A LIMITED NUMBER OF COMMERCIALIZED PRODUCTS AND THESE AND OTHER
PRODUCTS TYPICALLY HAVE DECLINING REVENUES OVER THEIR PRODUCT LIFE.
To date, the FDA has approved or tentatively approved the ANDAs for six of
our products and we have commenced marketing only four of these (including the
two ANCIRC products). We cannot assure you that our other products under
development or products submitted to the FDA will be approved by the FDA or
other regulatory authorities or that our development efforts will be
successfully completed. Our future results of operations will depend
significantly upon our ability to develop and market new pharmaceutical
products and our existing ones. Our operating results may vary significantly on
an annual or quarterly basis depending on the timing of, and our ability to
obtain, FDA approvals for such new products. Newly introduced bioequivalent
pharmaceuticals with limited or no competition are typically sold at higher
selling prices, often resulting in higher gross profit margins. As competition
from other manufacturers intensifies, selling prices and gross profit margins
typically decline, which has been our experience with our existing products.
The timing of our future operating results may also be affected by a variety of
additional factors, including the results of future patent challenges and the
market acceptance of our new products.
THE STRINGENT GOVERNMENTAL REGULATION IN OUR BUSINESS SUBJECTS US TO A COSTLY
AND TIME CONSUMING APPROVAL PROCESS FOR OUR PRODUCTS.
Drug manufacturers are required to obtain FDA approval before marketing
their new drug product candidates. The FDA approval requirements are costly and
time consuming. We cannot assure you that our bioequivalence or clinical
studies and other data will result in FDA approval to market our new drug
products. We believe that the FDA's abbreviated new drug application procedures
will apply to our bioequivalent versions of controlled-release drugs. We cannot
assure you that any of our bioequivalent versions of controlled-release drugs
will be suitable for, or approved as part of, abbreviated applications.
Moreover, once a drug is approved (under either procedure) we cannot assure you
that we will not have to withdraw such product from the market if it is not
manufactured in accordance with FDA standards or our own internal standards.
Some abbreviated application procedures for bioequivalent
controlled-release drugs and other products are presently the subject of
petitions filed by brand name drug manufacturers, which seek changes from the
FDA in the approval requirements for particular bioequivalent drugs. We cannot
predict at this time whether the FDA will make any changes to its abbreviated
application requirements as a result of these petitions or the effect that any
changes may have on us. Any changes in FDA regulations or policies may make
abbreviated application approvals more difficult and thus may materially harm
our business and financial results.
In order to market a new drug that does not qualify for the FDA's
abbreviated application procedures, we must conduct extensive clinical trials
to demonstrate product safety and efficacy and submit an NDA. The process of
completing clinical trials and preparing an NDA may take several years and
requires substantial resources. We have never submitted an NDA. We cannot
assure you that our studies and filings will result in FDA approval to market
our new drug products or the timing of any approval.
Patent certification requirements for bioequivalent controlled-release
drugs and for some new drugs could also result in significant delays in
obtaining FDA approval if patent infringement litigation is initiated by the
holder or holders of the brand name patents. Delays in obtaining FDA approval
of abbreviated applications and some new drug applications can also result from
a marketing exclusivity period and/or an extension of patent terms.
6
<PAGE>
PROPOSED FDA REGULATIONS AND RECENT FDA GUIDELINES MAY RESULT IN OUR
BIOEQUIVALENT PRODUCTS NOT BEING ABLE TO FULLY UTILIZE THE 180-DAY MARKETING
EXCLUSIVITY PERIOD.
In August 1999, the FDA proposed to amend its regulations relating to
180-day marketing exclusivity for which certain bioequivalent drugs may
qualify. We cannot predict whether or what changes the FDA may make to its
regulations. In March 2000, the FDA issued new guidelines regarding the timing
of approval of ANDAs following a court decision in patent infringement actions
and the start of the 180-day marketing exclusivity period provided for in the
Waxman-Hatch amendments applicable to generic pharmaceuticals. These guidelines
could result in us not being able to utilize all or any portion of the 180-day
marketing exclusivity period on ANDA products we were first to file on,
depending on the timing of court decisions in patent litigation. We are unable
to predict what impact, if any, the FDA's new guidelines may have on our
business or financial condition. These guidelines are discussed in further
detail under the heading "Business--
Government Regulation--ANDA Process."
WE FACE UNCERTAINTIES RELATED TO CLINICAL TRIALS WHICH COULD RESULT IN DELAYS
IN PRODUCT DEVELOPMENT AND COMMERCIALIZATION.
Prior to seeking FDA approval for the commercial sale of brand name
controlled-release formulations under development, we must demonstrate through
clinical trials that these products are safe and effective for use. We have
limited experience in conducting and supervising clinical trials. There are a
number of difficulties associated with clinical trials. The results of these
clinical trials may not be indicative of results that would be obtained from
large-scale testing. Clinical trials are often conducted with patients having
advanced stages of disease and, as a result, during the course of treatment
these patients can die or suffer adverse medical effects for reasons that may
not be related to the pharmaceutical agents being tested, but which
nevertheless, affect the clinical trial results. Moreover, we cannot assure you
that our clinical trials will demonstrate sufficient safety and efficacy to
obtain FDA approval. A number of companies in the pharmaceutical industry have
suffered significant setbacks in advanced clinical trials even after promising
results in pre-clinical studies. These failures have often resulted in
decreases in stock prices. If any of our products under development are not
shown to be safe and effective in clinical trials, our business and financial
results could be materially harmed by any resulting delays in developing other
compounds and conducting related clinical trials.
RESTRICTIVE FDA REGULATIONS GOVERN THE MANUFACTURING AND DISTRIBUTION OF OUR
PRODUCTS.
The FDA also regulates the development, manufacture, distribution,
labeling and promotion of prescription drugs, requires that certain records be
kept and reports be made, mandates registration of drug manufacturers and
listing of their products and has the authority to inspect manufacturing
facilities for compliance with Current Good Manufacturing Practices, or cGMP,
standards. As a wholesale distributor of bioequivalent pharmaceuticals
manufactured by third parties, we are subject to state licensure and other
requirements pertaining to the wholesale distribution of prescription drugs.
Our business and financial results could be materially harmed by any failure to
comply with licensing and other requirements.
Other requirements exist for controlled drugs, such as narcotics, which
are regulated by the U.S. Drug Enforcement Administration or DEA and comparable
state-level agencies. Further, the FDA has the authority to withdraw approvals
of previously approved drugs for cause, to request recalls of products, to bar
companies and individuals from future drug application submissions and, through
action in court, to seize products, institute criminal prosecution or close
manufacturing plants in response to violations. The DEA has similar authority
and may also pursue monetary penalties. Our business and financial results
could be materially harmed by these requirements or FDA or DEA actions.
WE HAVE LIMITED MANUFACTURING CAPACITY AND NEED TO ACQUIRE OR BUILD ADDITIONAL
CAPACITY FOR PRODUCTS IN OUR PIPELINE. OUR MANUFACTURING FACILITIES MUST COMPLY
WITH STRINGENT FDA AND OTHER REGULATORY REQUIREMENTS.
We have an approximately 35,000 square foot commercial manufacturing
facility. This facility is currently being used to manufacture the
bioequivalent versions of Dilacor XR and Cardizem CD. Although
7
<PAGE>
this facility is expected to be sufficient for these products and for our
bioequivalent versions of Tiazac, Oruvail, Naprelan and K-Dur, it will not be
suitable for the manufacture of all of the products we intend to develop and
manufacture. We will need to scale up our current manufacturing operations
significantly. We are in the process of expanding our facilities for
manufacturing operations.
In addition to obtaining the appropriate licenses and permits to build the
new facilities, the new manufacturing facilities, once completed, will need to
be in compliance with cGMP and inspected. We cannot assure you that such
permits, licenses and approvals will be obtained or, if obtained, obtained in
time to manufacture additional products as they are approved. Our facilities
will be subject to periodic inspections by the FDA and we cannot assure you
that the facilities will continue to be in compliance with cGMP or other
regulatory requirements. Failure to comply with such requirements could result
in significant delays in the development, approval and distribution of our
planned products, and may require us to incur significant additional expense to
comply with cGMP or other regulatory requirements. Our business and financial
results could be materially harmed by an adverse determination by the FDA as a
result of any such inspection. Further, we will depend on other companies to
manufacture certain of the product candidates under development.
The DEA also periodically inspects facilities for compliance with
security, recordkeeping, and other requirements that govern controlled
substances. Our business and financial results could be materially harmed by an
adverse determination by the DEA as a result of any such inspection.
IF WE ARE UNABLE TO MANAGE OUR RAPID GROWTH, OUR BUSINESS WILL SUFFER.
We have experienced rapid growth of our operations. This growth has
required us to expand, upgrade and improve our administrative, operational and
management systems, controls and resources. We anticipate additional growth in
connection with the expansion of our manufacturing operations, development of
our brand products, our marketing and sales efforts for the products we
develop, the development and manufacturing efforts for our products and
Internet operations. If we fail to manage growth effectively or to develop a
successful marketing approach, our business and financial results will be
materially harmed.
WE FACE INTENSE COMPETITION IN THE PHARMACEUTICAL INDUSTRY FROM BOTH BRAND-NAME
AND BIOEQUIVALENT MANUFACTURERS, WHOLESALERS AND DISTRIBUTORS THAT COULD
SEVERELY LIMIT OUR GROWTH.
The pharmaceutical industry is highly competitive and many of our
competitors have longer operating histories and greater financial, research and
development, marketing and other resources than us. We are subject to
competition from numerous other entities that currently operate or intend to
operate in the pharmaceutical industry, including companies that are engaged in
the development of controlled-release drug delivery technologies and products
and other manufacturers that may decide to undertake in-house development of
these products. Our bioequivalent products may be subject to competition from
competing bioequivalent products marketed by the patent holder. In our
pharmaceutical distribution business, we compete with a number of large
wholesalers and other distributors of pharmaceuticals. We cannot assure you
that we will be able to continue to compete successfully with these companies.
WE DEPEND ON OUR PATENTS AND TRADE SECRETS AND OUR FUTURE SUCCESS IS DEPENDENT
ON OUR ABILITY TO PROTECT THESE SECRETS AND NOT INFRINGE ON THE RIGHTS OF
OTHERS.
We believe that patent and trade secret protection is important to our
business and that our future success will depend in part on our ability to
obtain patents, maintain trade secret protection and operate without infringing
on the rights of others. We have been issued a number of U.S. patents and have
filed additional U.S. and various foreign patent applications relating to our
drug delivery technologies. We expect to apply for additional U.S. and foreign
patents in the future. The issuance of a patent is not conclusive as to its
validity or as to the enforceable scope of the claims of the patent. We cannot
assure you that:
/bullet/ our patents or any future patents will prevent other companies
from developing similar or functionally equivalent products or
from successfully challenging the validity of our patents;
8
<PAGE>
/bullet/ any of our future processes or products will be patentable;
/bullet/ any pending or additional patents will be issued in any or all
appropriate jurisdictions;
/bullet/ our processes or products will not infringe upon the patents of
third parties; or
/bullet/ we will have the resources to defend against charges of patent
infringement by third parties or to protect our own patent rights
against infringement by third parties.
Our business and financial results could be materially harmed if we fail
to avoid infringement of the patent or proprietary rights of others or to
protect our patent rights.
We also rely on trade secrets and proprietary knowledge, which we
generally seek to protect by confidentiality and non-disclosure agreements with
employees, consultants, licensees and pharmaceutical companies. We cannot
assure that these agreements will not be breached, that we will have adequate
remedies for any breach or that our trade secrets will not otherwise become
known by competitors.
WE DEPEND UPON MANAGEMENT AND KEY PERSONNEL AND DO NOT HAVE EMPLOYMENT
AGREEMENTS WITH THEM.
Our success for the foreseeable future depends upon the services of Dr.
Chih-Ming J. Chen, Co-Chairman and Chief Scientific Officer; Alan P. Cohen, Co-
Chairman and Chief Executive Officer; and Dr. Elliot F. Hahn, President. We do
not have employment agreements with these individuals. Dr. Chen receives a
3.33% royalty on all sales of our bioequivalent version of Cardizem CD,
regardless of his employment status. In addition, our success will depend in
large part on our ability to attract and retain highly qualified scientific,
technical and business personnel experienced in the development, manufacture
and marketing of pharmaceuticals. Our business and financial results would be
materially harmed by the loss of the services of any of these three officers,
or the inability to attract or retain qualified personnel.
WE WILL NEED AN EFFECTIVE SALES ORGANIZATION TO MARKET AND SELL OUR FUTURE
BRAND PRODUCTS AND OUR FAILURE TO HAVE AN EFFECTIVE SALES ORGANIZATION MAY HARM
OUR BUSINESS.
We do not have a sales organization to market and sell our brand products
that we may develop or acquire. We cannot assure you that prior to the time
these products are available for commercial launch we will be able to license
our products to pharmaceutical companies with sales organizations, enter into a
favorable co-promotion or contract sales arrangement, or recruit or acquire an
effective sales organization. Our inability to enter into satisfactory sales
and marketing arrangements in the future may materially harm our business and
financial results. We may have to rely on collaborative partners to market our
products. These partners may not have the same interests as us in marketing the
products and we may lose control over the sales of these products.
DECREASES IN HEALTHCARE REIMBURSEMENTS COULD LIMIT OUR ABILITY TO SELL OUR
PRODUCTS OR DECREASE OUR REVENUES.
Our ability to maintain profitability in our distribution business or to
commercialize our product candidates depends in part on the extent to which
reimbursement for the cost of pharmaceuticals will be available from government
health administration agencies, private health insurers and other
organizations. In addition, third party payors are attempting to control costs
by limiting the level of reimbursement for medical products, including
pharmaceuticals, which may adversely affect the pricing of our product
candidates. Moreover, healthcare reform has been, and may continue to be, an
area of national and state focus, which could result in the adoption of
measures which could adversely affect the pricing of pharmaceuticals or the
amount of reimbursement available from third party payors. We cannot assure you
that healthcare providers, patients or third party payors will accept and pay
for our pharmaceuticals. In addition, there is no guarantee that healthcare
reimbursement laws or policies will not materially harm our ability to sell our
products profitably or prevent us from realizing an appropriate return on our
investment in product development.
9
<PAGE>
WE MAY BE SUBJECT TO PRODUCT LIABILITY CLAIMS AND WE MAY NOT HAVE ADEQUATE
INSURANCE.
The design, development and manufacture of our products or the products we
distribute involve a risk of product liability claims. We have obtained product
liability insurance and believe that it is adequate for our current operations,
but may seek to increase our coverage prior to the commercial introduction of
our new product candidates. We cannot assure you that the coverage limits of
our insurance will be sufficient to cover potential claims. Product liability
insurance is expensive and difficult to obtain and may not be available in the
future on acceptable terms or in sufficient amounts, if available at all. Our
business and financial results could be materially harmed by a successful claim
against us in excess of our insurance coverage.
CYBEAR OPERATES IN AN EVOLVING MARKET DEPENDENT ON THE INTERNET AND MAY HAVE
LOSSES FOR THE FORESEEABLE FUTURE.
Cybear operates in a market that is at an early stage of development, is
rapidly evolving and is characterized by an increasing number of market
entrants who have introduced or developed competing products and services.
Cybear introduced its first product in March 1999 and has realized only minimal
revenues. As is typical in the case of a new and rapidly evolving industry,
demand and market acceptance for Cybear's products and services are subject to
a high level of uncertainty and risk. Cybear is also dependent on the adoption
of the Internet for commerce and broad acceptance of new methods of conducting
business and exchanging information, particularly by those individuals and
companies in the healthcare industry that historically have relied upon
traditional means of commerce. We cannot guarantee that the market for Cybear's
products and services will develop or that demand for Cybear's services will
emerge or be sustainable. Moreover, operating on the Internet raises a number
of additional risks, including reliance on independent content providers,
possible system failures and possible security breaches that could harm
Cybear's business. If the market fails to develop, develops more slowly than
expected or becomes saturated with competitors, or if Cybear's products or
services do not achieve or sustain market acceptance, Cybear's business would
be harmed. Cybear also expects to report losses for the foreseeable future,
which may affect our operating results. Also, Cybear may be required to fund
its losses by raising outside financing and we cannot guarantee you that
outside financing alternatives will be available to Cybear at such time. As a
result of our ownership of Cybear, our business and financial results could
also be materially harmed.
THE VOLATILITY OF OUR STOCK PRICE COULD AFFECT AN INVESTMENT IN OUR STOCK.
The market prices for securities of companies engaged in pharmaceutical
development activities have been highly volatile. The market price of our
common stock may be impacted by:
/bullet/ developments or disputes concerning patent or proprietary rights;
/bullet/ threatened litigation and any settlements;
/bullet/ progress in the development or approval of our product candidates;
/bullet/ publicity regarding actual or potential medical results relating
to products under development by us or our competitors;
/bullet/ announcements of technological innovations or new products by us
or our competitors;
/bullet/ regulatory developments in both the U.S. and foreign countries;
/bullet/ public concern as to the safety of drug technologies;
/bullet/ economic and other external factors;
/bullet/ period-to-period fluctuations in financial results;
10
<PAGE>
/bullet/ the volatility of the market price for Cybear's common stock; and
/bullet/ Cybear's financial performance.
Cybear's common stock also could be subject to fluctuations in response to
the above and other more specific factors. The market prices of equity
securities of technology companies generally and Internet-related companies in
particular, the business in which Cybear operates, are characterized by highly
volatile stock prices. This volatility has included rapid and significant
increases in the trading prices of certain Internet companies to levels that do
not bear any reasonable relationship to the operating performance of such
companies.
A SUBSTANTIAL NUMBER OF OUR SHARES ARE ELIGIBLE FOR FUTURE SALE AND THE SALE OF
ANDRX SHARES INTO THE MARKET MAY DEPRESS OUR STOCK PRICE.
Our stock price may be depressed by future sales of our shares or the
perception that such sales may occur. We had 63,655,762 shares outstanding as of
May 19, 2000 of which 13,206,972 shares are owned by our officers and directors
and are considered restricted shares. As of May 19, 2000, Watson owned 5,763,476
shares, of which, 4,415,160 are freely tradeable, 1,164,872 shares are being
sold in this offering and the remaining 183,444 shares are considered restricted
shares. We are unable to estimate the amount, timing or nature of future sales
of outstanding common stock. Sales of substantial amounts of the common stock in
the public market by these holders may lower the common stock's market price.
OWNERSHIP OF OUR COMMON STOCK IS CONCENTRATED AMONG DIRECTORS, EXECUTIVE
OFFICERS AND WATSON.
As of May 19, 2000, our directors and executive officers beneficially owned
approximately 22.6% of the outstanding common stock prior to this offering and
21.0% after giving effect to this offering. As of March 31, 2000, Watson owned
approximately 9.1% of the issued and outstanding common stock and will own 6.7%
after this offering. There are no agreements between management and Watson with
respect to voting of their respective common stock. Although we have a
standstill agreement with Watson which prevents it from increasing its equity
interest in Andrx or merging with or into Andrx without the approval of our
board of directors, the agreement expires June 13, 2000 and we have no plans to
renew or extend it. Management will and Watson may have the ability to
influence significantly our affairs and operations.
WE WILL HAVE SUBSTANTIAL DISCRETION OVER THE USE OF THE NET PROCEEDS WE RECEIVE
IN THIS OFFERING.
We estimate that the net proceeds from the sale of the 5,185,128 shares of
common stock offered by us will be approximately $235.6 million, after deducting
estimated underwriting discounts and commissions and estimated offering
expenses. We intend to use the net proceeds for various purposes. Consequently,
our board of directors and management will have significant flexibility in
applying the net proceeds of this offering. The failure of management to apply
such funds effectively could materially harm our business and financial results.
THE ANTI-TAKEOVER PROVISIONS OF OUR CHARTER DOCUMENTS AND FLORIDA AND DELAWARE
LAW COULD AFFECT SHAREHOLDERS.
Certain provisions of our amended and restated articles of incorporation
and bylaws may have anti-takeover effects and may delay, defer or prevent a
takeover attempt of Andrx. In addition, Florida has enacted legislation that
may deter or hinder takeovers of Florida corporations. The Florida Control
Share Act generally provides that shares acquired in excess of certain
specified thresholds will not have any voting rights unless such voting rights
are approved by a majority of the corporation's disinterested shareholders. The
Florida Affiliated Transactions Act generally requires supermajority approval
by disinterested shareholders of certain specified transactions between a
public corporation and holders of more than 10% of the outstanding voting
shares of the corporation or their affiliates. As part of the planned
reorganization of Andrx and Cybear, we will reincorporate in the State of
Delaware and will be subject to the anti-takeover provisions of the Delaware
General Business Corporation Law.
11
<PAGE>
WE DO NOT PLAN TO DECLARE DIVIDENDS.
We have not paid any cash dividends on our common stock and we do not plan
to pay any cash dividends in the foreseeable future. We plan to retain any
earnings for the operation and expansion of our business.
USE OF PROCEEDS
The net proceeds to us from this offering are estimated to be
approximately $235.6 million, after deducting the underwriting
discount and estimated expenses of the offering payable by us. We will not
receive any proceeds from the sale of shares of common stock by the selling
shareholders.
We intend to use the net proceeds of this offering for:
/bullet/ expansion of our manufacturing, research and development and
administrative facilities;
/bullet/ research and development for branded and bioequivalent products;
/bullet/ acquisitions of products, product candidates and/or companies; and
/bullet/ working capital and other general corporate purposes.
Our existing commercial manufacturing facility is sufficient for
manufacturing our bioequivalent versions of Dilacor XR, Cardizem CD, Tiazac,
Naprelan and K-Dur and ANCIRC's bioequivalent version of Oruvail. However, we
need additional capacity to manufacture all the products we intend to develop
and manufacture. Thus, we intend to convert portions of our existing facilities
to additional manufacturing and related warehousing space. In addition, we are
building approximately 160,000 square feet of office, warehouse and
manufacturing space on a 15-acre tract of land we purchased adjacent to one of
our existing facilities.
We also intend to build a dedicated sales force for our brand name
products, which we may do internally, through the acquisition of products with
existing sales forces or otherwise.
The amount and timing of the above expenditures may vary and will depend
on numerous factors, including, but not limited to, results of our research and
development, timing of receipt of FDA product approvals, if any, the rate of
growth of our bioequivalent drug distribution business, the extent to which
additional collaborative arrangements are entered into and other factors.
We are evaluating possible acquisitions of, or investments in,
complementary businesses and product candidates, including products to sell
under a brand name. We may use net proceeds from the offering for these
purposes. While we from time to time consider potential investments or
acquisitions, we have no firm plans, commitments or agreements with respect to
any of these types of investments or acquisitions.
We do not anticipate using any of the proceeds from this offering to fund
Cybear.
Pending use of the proceeds as described above, we intend to invest the
net proceeds of the offering in government securities and other
investment-grade, interest-bearing securities.
12
<PAGE>
PRICE RANGE OF COMMON STOCK AND DIVIDEND POLICY
Our common stock has been listed for trading on the Nasdaq National Market
under the symbol ADRX since June 14, 1996. The following table sets forth, for
the calendar quarters indicated, the range of high and low sale prices per
share of common stock as reported by the Nasdaq National Market adjusted for
the stock splits in June 1999 and April 2000:
<TABLE>
<CAPTION>
HIGH LOW
---------- ----------
<S> <C> <C>
1998
First Quarter ................................. $ 9.57 $ 6.13
Second Quarter ................................ 10.66 7.04
Third Quarter ................................. 10.75 6.47
Fourth Quarter ................................ 12.93 6.16
1999
First Quarter ................................. $23.13 $11.13
Second Quarter ................................ 39.00 15.41
Third Quarter ................................. 39.00 28.57
Fourth Quarter ................................ 29.00 19.25
2000
First Quarter ................................. $64.41 $20.13
Second Quarter (through May 23, 2000) ......... 68.31 43.63
</TABLE>
On May 23, 2000, the last sale price of the common stock as reported by
the Nasdaq National Market was $50.00 per share.
We have not paid cash dividends on our common stock and do not intend to
pay cash dividends for the foreseeable future. We intend to retain earnings, if
any, to finance the development and expansion of our business. Payment of cash
dividends in the future will depend, among other things, upon our ability to
generate earnings, our need for capital and our overall financial condition.
13
<PAGE>
CAPITALIZATION
The following table sets forth as of March 31, 2000 (1) our actual cash,
cash equivalents and investments available-for-sale, short-term borrowings and
capitalization; and (2) the cash, cash equivalents and investments
available-for-sale, short-term borrowings and capitalization, as adjusted to
give effect to the sale of 5,185,128 shares of common stock offered by us and
after deducting the underwriting discounts and commissions and other estimated
expenses of the offering and the receipt of the net proceeds. This table should
be read in conjunction with our Consolidated Financial Statements and the Notes
thereto included elsewhere in the prospectus.
<TABLE>
<CAPTION>
MARCH 31, 2000
--------------------------
ACTUAL AS ADJUSTED
----------- ------------
(UNAUDITED)
(IN THOUSANDS)
<S> <C> <C>
Cash, cash equivalents and investments available-for-sale(1) ................... $114,771 $350,419
======== ========
Short-term borrowings(2) ....................................................... $ 20,370 $ 20,370
======== ========
Shareholders' equity:
Preferred Stock, $.001 par value, 1,000,000 shares authorized, no shares issued
and outstanding ............................................................. -- --
Common Stock, $.001 par value, 100,000,000 shares authorized; 63,484,700 shares
issued and outstanding, actual and 68,669,828 shares issued and outstanding,
as adjusted(3) .............................................................. 63 69
Additional paid-in capital .................................................... 149,968 385,610
Retained earnings ............................................................. 96,674 96,674
Accumulated other comprehensive loss .......................................... (67) (67)
-------- --------
Total shareholders' equity .................................................. 246,638 482,286
-------- --------
Total capitalization ........................................................... $246,638 $482,286
======== ========
</TABLE>
- ----------------
(1) See Note 5 to Consolidated Financial Statements.
(2) See Note 8 to Consolidated Financial Statements.
(3) Excludes (a) 5,697,696 shares of common stock issuable upon the exercise of
outstanding stock options at March 31, 2000, and (b) 11,987,200 shares of
common stock reserved for future issuance under our existing stock option
plans.
14
<PAGE>
SELECTED CONSOLIDATED FINANCIAL DATA
The following selected consolidated financial data as of and for the years
ended December 31, 1995, 1996, 1997, 1998 and 1999 are derived from our
consolidated financial statements and have been audited by Arthur Andersen LLP,
independent certified public accountants. The following selected financial data
is qualified by reference to, and should be read in conjunction with, our
Consolidated Financial Statements, our unaudited Consolidated Financial
Statements and related notes thereto appearing elsewhere in this prospectus.
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
--------------------------------------------------------------------------
1995 1996 1997 1998 1999
-------------- -------------- -------------- -------------- --------------
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
<S> <C> <C> <C> <C> <C>
STATEMENT OF INCOME DATA:(1)
Revenues
Distributed products ......................... $ 50,468 $ 86,721 $ 146,237 $ 215,903 $ 262,402
Manufactured products ........................ -- -- 3,324 11,472 134,796
Stipulation fees ............................. -- -- -- 19,130 70,733
Licensing and other .......................... 165 50 137 552 8,059
------------ ------------ ------------ ------------ ------------
Total revenues ............................. 50,633 86,771 149,698 247,057 475,990
------------ ------------ ------------ ------------ ------------
Operating expenses
Cost of goods sold ........................... 41,781 72,400 126,802 188,226 235,346
Selling, general and administrative .......... 9,847 13,778 18,934 30,646 55,266
Research and development ..................... 3,895 5,066 11,251 16,837 25,697
Cybear, Inc. Internet operating expenses ..... -- -- 1,473 4,090 14,744
Cybear, Inc. merger costs .................... -- -- -- -- --
------------ ------------ ------------ ------------ ------------
Total operating expenses ................... 55,523 91,244 158,460 239,799 331,053
------------ ------------ ------------ ------------ ------------
Income (loss) from operations ................. (4,890) (4,473) (8,762) 7,258 144,937
Other income (expense)
Minority interest ............................ -- -- 31 85 1,937
Gain on sale of Cybear, Inc. shares .......... -- -- -- 700 643
Interest income .............................. 339 1,210 1,585 1,064 3,603
Interest expense ............................. (636) (765) (490) (380) (1,661)
------------ ------------ ------------ ------------ ------------
Income (loss) before income taxes ............. (5,187) (4,028) (7,636) 8,727 149,459
Income taxes .................................. -- -- -- 333 55,405
------------ ------------ ------------ ------------ ------------
Net income (loss) ............................. $ (5,187) $ (4,028) $ (7,636) $ 8,394 $ 94,054
============ ============ ============ ============ ============
Basic net income (loss) per share ............. $ (0.14) $ (0.08) $ (0.13) $ 0.14 $ 1.52
============ ============ ============ ============ ============
Diluted net income (loss) per share ........... $ (0.14) $ (0.08) $ (0.13) $ 0.13 $ 1.45
============ ============ ============ ============ ============
Basic weighted average shares of
common stock outstanding ..................... 37,787,200 48,592,000 56,852,400 60,090,800 61,979,800
============ ============ ============ ============ ============
Diluted weighted average shares of
common stock outstanding ..................... 37,787,200 48,592,000 56,852,400 63,706,800 64,953,200
============ ============ ============ ============ ============
<PAGE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
-----------------------------
1999 2000
-------------- --------------
(UNAUDITED)
(IN THOUSANDS, EXCEPT FOR
SHARE AND PER SHARE
AMOUNTS)
<S> <C> <C>
STATEMENT OF INCOME DATA:(1)
Revenues
Distributed products ......................... $ 63,025 $ 67,826
Manufactured products ........................ 4,373 44,114
Stipulation fees ............................. 10,000 --
Licensing and other .......................... 526 3,538
------------ ------------
Total revenues ............................. 77,924 115,478
------------ ------------
Operating expenses
Cost of goods sold ........................... 52,826 63,204
Selling, general and administrative .......... 9,591 11,542
Research and development ..................... 4,315 8,211
Cybear, Inc. Internet operating expenses ..... 2,795 6,339
Cybear, Inc. merger costs .................... -- 832
------------ ------------
Total operating expenses ................... 69,527 90,128
------------ ------------
Income (loss) from operations ................. 8,397 25,350
Other income (expense)
Minority interest ............................ 51 1,820
Gain on sale of Cybear, Inc. shares .......... 300 --
Interest income .............................. 366 1,531
Interest expense ............................. (154) (474)
------------ ------------
Income (loss) before income taxes ............. 8,960 28,227
Income taxes .................................. 2,016 11,856
------------ ------------
Net income (loss) ............................. $ 6,944 $ 16,371
============ ============
Basic net income (loss) per share ............. $ 0.11 $ 0.26
============ ============
Diluted net income (loss) per share ........... $ 0.11 $ 0.25
============ ============
Basic weighted average shares of
common stock outstanding ..................... 60,871,900 63,212,600
============ ============
Diluted weighted average shares of
common stock outstanding ..................... 64,625,300 65,832,200
============ ============
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
DECEMBER 31,
--------------------------------------------------------------------------
1995 1996 1997 1998 1999
-------------- -------------- -------------- -------------- --------------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
BALANCE SHEET DATA:(1)
Cash, cash equivalents and investments
available-for-sale(2) ................... $ 13,841 $ 30,320 $ 25,543 $ 23,092 $ 123,418
Working capital .......................... 14,402 32,963 45,144 51,345 180,863
Total assets ............................. 36,010 66,538 90,845 121,198 357,954
Short-term borrowings .................... 6,101 6,563 546 4,107 20,226
Total shareholders' equity ............... 18,325 42,762 60,861 72,583 220,972
<CAPTION>
MARCH 31, 2000
---------------
(UNAUDITED)
(IN THOUSANDS)
<S> <C>
BALANCE SHEET DATA:(1)
Cash, cash equivalents and investments
available-for-sale(2) ................... $114,771
Working capital .......................... 185,842
Total assets ............................. 363,126
Short-term borrowings .................... 20,370
Total shareholders' equity ............... 246,638
</TABLE>
- --------------
(1) Certain prior years' amounts have been reclassified to conform with the
current year presentation.
(2) Includes $26.7 million of cash, cash equivalents and investments
held-for-sale by Cybear as of March 31, 2000.
15
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL DATA
The unaudited pro forma condensed consolidated balance sheets as of March
31, 2000 and the unaudited pro forma condensed consolidated statements of
operations for the three months ended March 31, 2000 and for the year ended
December 31, 1999 give pro forma effect to the corporate reorganization plan
(the "Reorganization") which will create two classes of Andrx common stock,
Cybear Group Common Stock, to separately track the performance of Cybear, and
Andrx Group Common Stock to represent the equity interests of Andrx other than
its ownership of Cybear. The unaudited pro forma condensed consolidated
financial statements do not give pro forma effect to the shares of common stock
offered in this registration statement.
In connection with the Reorganization, we will acquire all of the publicly
traded shares of common stock of Cybear in what should be a tax-free
reorganization. Cybear's public shareholders currently own approximately 4.9
million shares or 27.6% of the common shares of Cybear as of March 31, 2000 and
those shareholders will receive one share of Cybear Group Common Stock for
every share of Cybear common stock they currently own. In the Reorganization,
the number of Cybear shares held by Andrx will be reduced from 12.9 million
shares to 10.8 million shares so as to provide the equivalent of a 20% increase
in shares held by the non-Andrx shareholders of Cybear. Upon completion of the
Reorganization, the non-Andrx shareholders of Cybear will own approximately
31.2% of the Cybear Group Common following the closing of the transaction.
Pursuant to the Reorganization, each Andrx common share will be converted into
(i) one share of Andrx Group Common Stock and (ii) approximately .1622 shares
of Cybear Group Common Stock. Upon completion of the Reorganization, (i) Cybear
will be a wholly owned subsidiary of Andrx with 100% of its value publicly
traded in the form of Cybear Group Common Stock, (ii) current Cybear public
shareholders will own approximately 31.2% of the Cybear Group Common Stock; and
(iii) current Andrx shareholders will own 100% of the Andrx Group Common Stock
and approximately 68.8% of the Cybear Group Common Stock. The preceding share
ownership and percentages exclude the potential exercise by Edward E. Goldman,
M.D., Cybear's Chief Executive Officer, of an outstanding warrant to acquire
525,000 shares of Cybear common stock currently owned by Andrx.
The unaudited pro forma condensed consolidated balance sheets give effect
to the Reorganization as if it occurred as of March 31, 2000. The unaudited pro
forma condensed consolidated statements of operations give effect to the
Reorganization as if it occurred at the beginning of the periods presented.
Prior to the Reorganization, Andrx Corporation and subsidiaries had a
single class of common stock outstanding and, accordingly, presented
consolidated financial statements relating to that one class. As a result of
the Reorganization, Andrx Corporation will have two classes of common stock as
follows:
1. Cybear Group Common Stock representing the equity interest and
businesses of the Cybear Group comprised of Andrx' Cybear subsidiary, and
2. Andrx Group Common Stock representing the equity interests and
businesses of the Andrx Group comprised of Andrx Corporation and its
subsidiaries other than the Cybear Group.
Accordingly, under the Reorganization, Andrx will present consolidated
financial statements and also separate financial statements relating to each
class of common stock.
Cybear Group and Andrx Group financial statements will include basic and
diluted earnings (loss) per share based on each group's respective operating
results and basic and diluted shares outstanding. The Andrx Corporation and
subsidiaries consolidated financial statements will not reflect consolidated
basic and diluted earnings (loss) per share since there will be no underlying
equity security related to the consolidated financial results. In connection
with the Reorganization, Cybear and members of the Andrx consolidated group
will enter into, among other things, a Federal and state tax sharing agreement.
The financial statements of Andrx Group and Cybear Group will utilize the
separate company method of accounting for purposes of allocating Federal and
state consolidated tax liabilities among group members. Under the terms of the
tax sharing
16
<PAGE>
agreement, a member of the group will be entitled to its income tax benefits in
the year generated to the extent that the member can utilize such tax benefits
in the year generated. To the extent that a member cannot utilize its income
tax benefits in the year generated, the member will not be compensated in that
year by other members of the Andrx consolidated group for any utilization of
those benefits. Instead, if and when a member leaves the group, Andrx may elect
to reimburse that member for any unreimbursed income tax benefits utilized.
That reimbursement will take the form of a capital investment by Andrx, for
which it will receive stock. In the case of any "tracking stock" members, such
as the Cybear Group, the stock received by Andrx shall be in the form of
tracking shares. In addition, if any member of the group causes another member
to become subject to state tax in a state where it would otherwise not be taxed
on a separate company basis, the member causing the tax liability shall be
fully responsible for the state tax of the other member.
For financial statement purposes, at such time as the Cybear Group
achieves profitability, if ever, or is otherwise able to recognize its tax
benefits under accounting principles generally accepted in the United States,
the Cybear Group will recognize the benefit of its accumulated income tax
benefits (which had previously been utilized by the Andrx Group) in its
statement of operations with a corresponding decrease to the Cybear Group's
shareholders' equity (i.e., effectively accounted for as a non-cash dividend).
To the extent the Andrx Group is profitable and is able to utilize such tax
benefit and the Cybear Group is generating losses, it is expected that the
Andrx Group effective tax rate will be less than the statutory Federal and
state rate. If the Cybear Group is ever able to attain profitability or is
otherwise able to recognize its tax benefits, the Andrx Group effective tax
rate may be greater than the statutory Federal and state income tax rate to the
extent of the Cybear Group's then unreimbursed accumulated tax benefits that
can be realized (the Andrx Group will then reverse the tax benefits previously
recorded, i.e., effectively transferring such tax benefits to the Cybear Group
in the form of a non-cash equity transaction.)
The unaudited pro forma condensed consolidated financial data are provided
for informational purposes only and are not necessarily indicative of the
results of operations or financial position had the transactions assumed
therein occurred, nor are they necessarily indicative of the results of
operations that may be expected to occur in the future. Consummation of the
transaction is subject to various conditions, including approval by
shareholders of Andrx and Cybear. In addition to shareholder approval, the
transaction will be subject to various Federal and state regulatory approvals,
and accordingly, no assurance can be given that this transaction will be
consummated. We and Cybear will file a joint proxy statement and registration
statement with respect to the proposed transaction. Furthermore, the unaudited
pro forma condensed consolidated financial data are based upon assumptions that
we believe are reasonable and should be read in conjunction with the unaudited
consolidated financial statements and the accompanying notes thereto included
elsewhere in this prospectus and the consolidated financial statements and
accompanying notes thereto for the year ended December 31, 1999, included in
Andrx's Annual Report on Form 10-K for the year ended December 31, 1999.
17
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
<TABLE>
<CAPTION>
MARCH 31, 2000
-----------------------------------------------------------------------------
HISTORICAL PRO FORMA PRO FORMA PRO FORMA
ANDRX PRO FORMA ANDRX CYBEAR ANDRX
CONSOLIDATED ADJUSTMENTS CONSOLIDATED GROUP GROUP
-------------- -------------------- -------------- ----------- ------------
<S> <C> <C> <C> <C> <C>
ASSETS
Current assets ....................................
Cash and cash equivalents ........................ $ 26,904 $ -- $ 26,904 $ 1,040 $ 25,864
Investments available-for-sale ................... 87,867 -- 87,867 25,703 62,164
Accounts receivable, net ......................... 64,280 -- 64,280 162 64,118
Inventories ...................................... 78,263 -- 78,263 -- 78,263
Deferred income tax assets, net .................. 18,435 -- 18,435 -- 18,435
Prepaid and other current assets, net ............ 14,552 -- 14,552 7,853 6,699
--------- ----------- --------- -------- ---------
Total current assets ........................... 290,301 -- 290,301 34,758 255,543
Property, plant and equipment, net ............... 48,157 -- 48,157 3,608 44,549
Other assets, net ................................ 24,668 2,700 (A) 43,050 26,814 16,236
15,682 (C)
-----------
Total assets ................................... $ 363,126 $ 18,382 $ 381,508 $ 65,180 $ 316,328
========= =========== ========= ======== =========
LIABILITIES AND
SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable ................................. $ 46,325 $ 4,000 (A) $ 50,993 $ 3,016 $ 47,977
668 (B)
Accrued liabilities .............................. 28,377 28,377 779 27,598
Bank loan ........................................ 20,370 -- 20,370 -- 20,370
Income taxes payable ............................. 9,387 -- 9,387 -- 9,387
--------- ----------- --------- -------- ---------
Total current liabilities ...................... 104,459 4,668 109,127 3,795 105,332
Commitments and contingencies
Minority interest ................................. 12,029 (12,029) (C) -- -- --
Shareholders' equity .............................. 246,638 (1,300) (A) 272,381 61,385 210,996
(668) (B)
27,711 (C)
------------
Total liabilities and shareholders' equity ..... $ 363,126 $ 18,382 $ 381,508 $ 65,180 $ 316,328
========= ============ ========= ======== =========
</TABLE>
The accompanying notes to the unaudited pro forma condensed consolidated
balance sheets are an integral part of these statements.
18
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
(A) Reflects the estimated fees and expenses of $2,700 incurred by Andrx Group
with respect to the acquisition of the historical minority interest which
was allocated to Cybear Group goodwill and $1,300 with respect to the
Reorganization which was charged to shareholders' equity. As the effect of
the costs of $1,300 is non-recurring it has not been included in the
unaudited pro forma condensed consolidated statements of operations.
(B) Reflects the estimated remaining fees and expenses of $668 to be incurred
by Cybear Group in connection with the Reorganization which will be
charged to shareholders' equity. As the effect of the costs is
non-recurring, they have not been included in the unaudited pro forma
condensed consolidated statements of operations.
(C) Reflects the effects of the Reorganization, as follows:
<TABLE>
<CAPTION>
ADJUSTED
SHARES SHARES
OUTSTANDING AT REORGANIZATION OUTSTANDING AT
MARCH 31, 2000 ELIMINATION MARCH 31, 2000
---------------- ---------------- ---------------
<S> <C> <C> <C>
Andrx ownership of Cybear ........................................ 12,877,000 (2,058,700) 10,818,300
Minority ownership of Cybear ..................................... 4,896,000 -- 4,896,000
---------- ---------- ----------
Total Cybear shares outstanding .................................. 17,773,000 (2,058,700) 15,714,300
==========
Times assumed per share price .................................... $ 5.00 $ 5.66
------------ ------------
Total Cybear market capitalization ............................... $ 88,865 $ 88,865
============ ============
Minority ownership of Cybear ..................................... 4,896,000
Times adjusted market price ...................................... $ 5.66
------------
Purchase price of minority interest acquired ..................... 27,711
Less: minority interest historical basis ......................... (12,029)
------------
Goodwill--Purchase price of minority interest in excess of its
historical basis ............................................... 15,682
Goodwill--Andrx group estimated fees and expenses (See Note
A) ............................................................. 2,700
------------
Total Goodwill allocated to Cybear Group ......................... $ 18,382
============
</TABLE>
For purposes of the unaudited pro forma condensed consolidated financial
statements, the market price of Cybear, Inc. common stock was assumed to be
$5.00 per share, which was adjusted to $5.66 per share resulting from the
elimination of 2,058,700 Cybear shares due to the exchange rate included in the
Reorganization. As provided under the Reorganization terms, the shares
eliminated in the Reorganization are calculated excluding the potential
exercise by Edward E. Goldman, M.D., Cybear's Chief Executive Officer, of an
outstanding warrant to acquire 525,000 shares of Cybear common stock currently
owned by Andrx. In connection with the Reorganization, the resulting total
goodwill of $18,382 was allocated to Cybear Group Common shareholders. The
actual amount of goodwill will be determined based upon Cybear's common stock
price as of the closing of the transaction. An increase or decrease of $1.00 in
Cybear's common stock price will result in an increase or decrease of
approximately $5,500 to the goodwill and therefore in an increase or decrease
of approximately $550 to the annual goodwill amortization.
19
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31, 2000
--------------------------------------------------------------------------------------
HISTORICAL PRO FORMA PRO FORMA PRO FORMA
ANDRX PRO FORMA ANDRX CYBEAR ANDRX
CONSOLIDATED ADJUSTMENTS(J) CONSOLIDATED GROUP GROUP
-------------- ------------------- -------------- --------------------- --------------
<S> <C> <C> <C> <C> <C>
Revenues ................................ $ 115,478 $ -- $ 115,478 $ 231 $ 115,247
Operating expenses ...................... 90,128 460 (E) 89,756 7,027 82,729
(832) (F)
---------- --------- ------------- -----------
Income (loss) from operations ........... 25,350 372 25,722 (6,796) 32,518
Other income (expense), net ............. 2,877 (1,820) (D) 1,057 559 498
----------- ---------- --------- ------------- -----------
Income (loss) before income taxes ....... 28,227 (1,448) 26,779 (6,237) 33,016
Income tax benefit (provision) .......... (11,856) 2,101 (H) (9,755) -- (9,755)
----------- ---------- --------- ------------- -----------
Net income (loss) ....................... $ 16,371 $ 653 $ 17,024 $ (6,237) $ 23,261
=========== ========== ========= ============= ===========
Basic net income (loss) per share ....... $ 0.26 $ (0.40) $ 0.37
=========== ============= ===========
Diluted net income (loss) per share ..... $ 0.25 $ (0.40) $ 0.35
=========== ============= ===========
Basic weighted average shares of
common stock outstanding ............... 63,212,600 15,645,000 (I) 63,212,600
=========== ============= ===========
Diluted weighted average shares of
common stock outstanding ............... 65,832,200 15,645,000 (I) 65,832,200
=========== ============= ===========
</TABLE>
The accompanying notes to the unaudited pro forma condensed consolidated
statements of operations are an integral part of these statements.
20
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31, 1999
---------------------------------------------------------------------------------------
HISTORICAL PRO FORMA PRO FORMA PRO FORMA
ANDRX PRO FORMA ANDRX CYBEAR ANDRX
CONSOLIDATED ADJUSTMENTS(J) CONSOLIDATED GROUP GROUP
-------------- ---------------- -------------- --------------------- --------------
<S> <C> <C> <C> <C> <C>
Revenues ................................ $ 475,990 $ -- $ 475,990 $ 270 $ 475,720
Operating expenses ...................... 331,053 1,838 (E) 332,891 16,772 316,119
----------- --------- --------- ------------- -----------
Income (loss) from operations ........... 144,937 (1,838) 143,099 (16,502) 159,601
Other income (expense), net ............. 4,522 (1,937)(D) 2,585 1,066 1,519
----------- --------- --------- ------------- -----------
Income (loss) before income taxes ....... 149,459 (3,775) 145,684 (15,436) 161,120
Income taxes benefit (provision) ........ (55,405) (2,824)(G) (53,240) -- (53,240)
4,989 (H)
----------- --------- --------- -------------
Net income (loss) ....................... $ 94,054 $ (1,610) $ 92,444 $ (15,436) $ 107,880
=========== ========= ========= ============= ===========
Basic net income (loss) per share ....... $ 1.52 $ (1.15) $ 1.74
=========== ============= ===========
Diluted net income (loss) per share ..... $ 1.45 $ (1.15) $ 1.66
=========== ============= ===========
Basic weighted average shares of
common stock outstanding ............... 61,979,800 13,411,300 (I) 61,979,800
=========== ============= ===========
Diluted weighted average shares of
common stock outstanding ............... 64,953,200 13,411,300 (I) 64,953,200
=========== ============= ===========
</TABLE>
The accompanying notes to the unaudited pro forma condensed consolidated
statements of operations are an integral part of these statements.
21
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
(D) Reflects the elimination of the historical minority interest resulting from
the minority ownership of Cybear which is eliminated as a result of the
Reorganization.
(E) Reflects the amortization of $460 for the three months ended March 31, 2000
and $1,838 for the year ended December 31, 1999 of goodwill totaling
$18,382, consisting of $15,682 representing the excess of the purchase
price of $27,711 offset by historical minority interest of $12,029 and
Andrx Group's estimated Reorganization transaction costs and expenses of
$2,700 (see unaudited pro forma condensed consolidated balance sheets
Notes A and C). Such goodwill is amortized on a straight line basis over
an estimated life of ten years.
(F) For the three months ended March 31, 2000, reflects the elimination of fees
and expenses of $832 incurred by Cybear in connection with the
Reorganization. As the effect of the costs are non-recurring, they have
been eliminated in the unaudited pro forma condensed consolidated
statements of operations for the three months ended March 31, 2000.
(G) For the year ended December 31, 1999, reflects the elimination of Cybear's
historical $2,824 income tax benefit which would not have been used by
Cybear Group on a separate income tax return basis and would have been
included in the tax allocation to Andrx Group (Note H) pursuant to the
Reorganization.
(H) Represents the Cybear Group income tax benefit allocated to Andrx Group
pursuant to the Reorganization as follows:
<TABLE>
<CAPTION>
THREE MONTHS ENDED YEAR ENDED
MARCH 31, 2000 DECEMBER 31, 1999
-------------------- ------------------
<S> <C> <C>
Cybear Group loss before income taxes ...... $ 6,237 $ 15,436
Nondeductible goodwill amortization
(including historical amortization) ...... 558 1,953
-------- ---------
Loss before income taxes ................... 5,679 13,483
Federal and state statutory tax rate ....... 37% 37%
-------- ---------
Income tax benefit ......................... $ 2,101 $ 4,989
======== =========
</TABLE>
(I) Pro Forma Cybear Group weighted average shares outstanding consists of the
following:
<TABLE>
<CAPTION>
THREE MONTHS ENDED YEAR ENDED
MARCH 31, 2000 DECEMBER 31, 1999
-------------------- ------------------
<S> <C> <C>
Historical Cybear weighted average shares outstanding ... 17,703,700 15,470,000
Less: shares eliminated as a result of the Reorganization
(see unaudited pro forma condensed consolidated balance
sheets Note C) ........................................ (2,058,700) (2,058,700)
---------- ----------
Pro Forma Cybear Group Common weighted average
shares outstanding .................................... 15,645,000 13,411,300
========== ==========
</TABLE>
(J) Certain results of the Reorganization referred to in the notes to the
unaudited pro forma condensed consolidated balance sheets have been
excluded from the unaudited pro forma condensed consolidated statements of
operations due to their non-recurring nature.
22
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
INTRODUCTION
We were organized in August 1992, and commenced marketing and distributing
bioequivalent pharmaceuticals manufactured by third parties. In February 1993,
we began to engage in the development of bioequivalent versions of
controlled-release pharmaceuticals utilizing our proprietary drug delivery
technologies. During 1996, we commenced our efforts to develop brand name
controlled-released products and an Internet based software application for
healthcare providers. Through October 9, 1997, our distribution operations had
generated substantially all of our revenues. On October 10, 1997, the FDA
granted final approval of our ANDA for our bioequivalent version of Dilacor XR,
our first manufactured product, which we immediately launched as Diltia XT.
In September 1997, we entered into the stipulation in partial settlement
with Aventis of the patent infringement litigation involving Cardizem CD in
order to reduce the risks that both parties faced as the case was litigated to
its conclusion. We agreed to maintain the status quo in connection with the
marketing of our product and to dismiss certain claims against Aventis. Aventis
agreed to compensate us for our lost profits, which were stipulated to be
$100.0 million per year, if we ultimately prevailed in the litigation and to
grant us a license for their patents under certain conditions, including if we
ultimately lost the litigation. Aventis also agreed to make non-refundable
interim quarterly payments of $10.0 million to us, beginning upon our receipt
of final FDA approval for our bioequivalent version of Cardizem CD and
continuing until the litigation was resolved or certain other events occurred.
In July 1998, the FDA granted final marketing approval for our ANDA for a
bioequivalent version of Cardizem CD. In June 1999, the litigation concerning
Cardizem CD was resolved and on June 23, 1999, we launched our reformulated
bioequivalent version of Cardizem CD, Cartia XT which enjoyed a 180-day period
of marketing exclusivity through December 19, 1999. Accordingly, for the years
ended December 31, 1998 and 1999, we received a total $19.1 million and $70.7
million, respectively, in interim and final stipulation fees.
We are a 50% partner in ANCIRC, a joint venture with Watson, for the
development of up to eight controlled-release pharmaceutical products. Capital
contributions to, distributions from, and net income or losses generated by
ANCIRC are allocated equally between us and Watson. In September 1997, upon FDA
approval, ANCIRC launched its first product, a bioequivalent version of
Trental. On March 24, 1999, the FDA approved the ANDA for a second ANCIRC
product, a bioequivalent version of Oruvail, which was launched in April 1999.
ANCIRC halted the production and sale of ANCIRC's bioequivalent version of
Oruvail in June 1999 and is currently not producing or selling this product.
ANCIRC suspended the production of generic Oruvail as a result of two factors:
(i) while the product sold by ANCIRC met FDA standards, the manufacturing
process in some instances did not yield a product which met internal quality
standards, whereby product rejection rates (due to dissolution failures) was
higher than we would tolerate and the risk of product stability failures for
some batches was higher than we would tolerate, and (ii) with multiple
competitors for this product, the market opportunity for future sales did not
warrant the risk of continued sales in the short term. We expect to resume
production and sale of ANCIRC's bioequivalent version of Oruvail in 2000. This
did not have a material effect on our consolidated results of operations.
In June 1999, we entered into an agreement with Geneva Pharmaceuticals,
Inc. a member of the Novartis group, for the sale and marketing of specified
products. Geneva will fund the development of controlled-release dosage forms
of existing products that we are developing for submission as NDAs. We granted
marketing rights to Geneva in specified territories for certain products
including one of our NDA products for the United States. Upon approval by the
FDA or other regulatory agencies, we will receive royalties from the sale of
such products. We have also committed to continuing to sell Geneva's
bioequivalent products through Anda, Inc. We are party to other development and
licensing agreements with other pharmaceutical companies for additional
controlled-release products.
In 1997, we formed Cybear, our information technology subsidiary, which
uses the Internet to improve the efficiency of administrative and
communications tasks of managing the healthcare industry's need for the
23
<PAGE>
secure and reliable transmission of information. In June 1999, Cybear completed
a public offering of its common shares at $16.00 per share, thereby reducing
our ownership in Cybear below 80%.
Cybear is an Internet Service Provider, or ISP, and Application Services
Provider, or ASP, for the healthcare industry. Cybear uses or intends to use
its own secure private network to provide access to the Internet, e-mail and
productivity applications to physicians, physician organizations, pharmacies
and hospitals. These are available on a transaction or subscription basis to
physicians, physician organizations, pharmacies and hospitals. In March 1999,
Cybear introduced its first product, dr.cybear, a physician-oriented healthcare
Internet gateway site or portal that provides a combination of Internet access,
healthcare content, software applications to increase user productivity and
entry into a comprehensive private communications network. Cybear markets
dr.cybear to physicians and physician organizations throughout the United
States. In September 1999, we entered into an arrangement with Cybear for the
sale by Cybear of prescription vaccines and injectables and other items to
physicians' offices on orders placed through Cybear's physician practice
portal.
CYBEAR REORGANIZATION PLAN
In December 1999, we announced a corporate reorganization plan which,
among other things, would give our shareholders the ability to distinguish
between their investments in Andrx and Cybear. In March 2000, we and Cybear
entered into a definitive agreement with respect to this reorganization. This
plan, which was recommended to the Cybear Board of Directors by a special
committee and approved by the boards of both Cybear and Andrx, will create a
new class of Andrx common stock, Cybear Group Common, to separately track the
performance of Cybear. The plan will be submitted for approval to the
shareholders of Andrx and Cybear during 2000.
RESULTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 2000 AS COMPARED TO THREE MONTHS ENDED MARCH 31,
1999.
For the three months ended March 31, 2000, we reported net income of $16.4
million or $0.25 per diluted weighted average share of common stock as compared
to net income of $6.9 million or $0.11 per diluted weighted average share of
common stock for the three months ended March 31, 1999. The 136% increase in
net income was primarily attributable to sales of Cartia XT, our bioequivalent
version of Cardizem CD, which commenced on June 23, 1999 and enjoyed a 180-day
period of marketing exclusivity through December 19, 1999. In comparison, the
three months ended March 31, 1999 included interim fees pursuant to the
stipulation with Aventis related to the then-pending patent infringement
litigation involving Cartia XT. The increase in net income occurred while we
continued to increase our investment spending in research and development.
Total revenues increased by 48.2% to $115.5 million for the three months
ended March 31, 2000, as compared to $77.9 million for the three months ended
March 31, 1999.
Sales from distributed products were $67.8 million for the three months
ended March 31, 2000, an increase of 7.6%, as compared to $63.0 million for the
three months ended March 31, 1999. The increase in sales from distributed
products reflects an increase in sales to existing customers, an increase in
the number of customers, as well as the participation in the distribution of
new products launched by other pharmaceutical companies, offset by overall
price declines.
Sales from manufactured products increased to $44.1 million for the three
months ended March 31, 2000, as compared to $4.4 million for the three months
ended March 31, 1999. Sales from manufactured products include sales of Diltia
XT, our bioequivalent version of Dilacor XR, for the three months ended March
31, 2000 and the three months ended March 31, 1999, and Cartia XT for the three
months ended March 31, 2000. In comparison, the three months ended March 31,
1999 include interim stipulation fees of $10.0 million pursuant to the
stipulation with Aventis.
We generated $3.5 million of licensing and other revenues for the three
months ended March 31, 2000, as compared to $526,000 for the three months ended
March 31, 1999, primarily from our domestic and
24
<PAGE>
international licensing arrangements. The revenues for the three months ended
March 31, 2000, were primarily generated from the agreement with Geneva.
Gross profit from sales of distributed and manufactured products was $48.7
million or a gross margin of 43.5% for the three months ended March 31, 2000,
as compared to $14.6 million, or a gross margin of 21.6% for the three months
ended March 31, 1999. The increase in gross profit and gross margin percentage
is primarily the result of the increase in sales of manufactured products
within the product mix.
Selling, general and administrative expenses were $11.5 million or 10.0%
of total revenues for the three months ended March 31, 2000, as compared to
$9.6 million or 12.3% of total revenues for the three months ended March 31,
1999. The increase in selling, general and administrative expenses is primarily
due to an increase in the activities necessary to support the increased sales
from distributed and manufactured products, including a royalty paid to our
Co-Chairman and Chief Scientific Officer related to sales of Cartia XT for the
three months ended March 31, 2000, and the Aventis interim stipulation fees for
the three months ended March 31, 1999.
Research and development expenses were $8.2 million for the three months
ended March 31, 2000, as compared to $4.3 million for the three months ended
March 31, 1999. The increase in research and development expenses of $3.9
million or 90.3% reflects the continuing progress in and expansion of both our
bioequivalent (ANDA) and brand name (NDA) programs.
For the three months ended March 31, 2000, we incurred $6.3 million of
Cybear Internet operating expenses, as compared to $2.8 million for the three
months ended March 31, 1999. The increase in costs primarily relates to the
continuing development of Cybear's Internet applications and the establishment
and expansion of the operational and administrative infrastructure of Cybear
and also includes $1.2 million of non-recurring charges.
Cybear incurred merger costs of $832,000 for the three months ended March
31, 2000, related to the pending corporate reorganization with us.
Minority interest was $1.8 million for the three months ended March 31,
2000, as compared to $51,000 for the three months ended March 31, 1999. The
increase in minority interest is a result of the increase in minority ownership
of Cybear, primarily from Cybear's June 1999 public offering and the issuance
of Cybear common shares in the acquisition of Telegraph Consulting Corporation.
In addition, Cybear's net losses increased for the three months ended March 31,
2000 to $6.6 million from $1.5 million for the three months ended March 31,
1999.
For the three months ended March 31, 1999, we recognized a gain of
$300,000 on the sale of Cybear common stock to Cybear's then Chairman and its
Chief Executive Officer pursuant to an existing subscription and warrant
agreement.
Interest income was $1.5 million for the three months ended March 31,
2000, as compared to $366,000 for the three months ended March 31, 1999. The
increase in interest income is the result of the higher average level of cash,
cash equivalents and investments available-for-sale maintained during the three
months ended March 31, 2000, as compared to the three months ended March 31,
1999. The increase was primarily the result of the net cash provided by
operating activities and the net proceeds of $50.8 million received from
Cybear's June 1999 public offering.
Interest expense increased to $474,000 for the three months ended March
31, 2000, as compared to $154,000 for the three months ended March 31, 1999.
The increase in interest expense was primarily the result of a higher average
level of borrowings under our bank loan for the three months ended March 31,
2000, as compared to the three months ended March 31, 1999. The borrowings are
primarily utilized to fund our distribution operations.
For the three months ended March 31, 2000, we recorded Federal and state
income taxes of $11.9 million or 42% of income before income taxes. We recorded
Federal and state income taxes of $1.4 million in excess
25
<PAGE>
of the effective combined Federal and state statutory rate of 37%, primarily
due to our inability to utilize our portion of Cybear's losses, as our
ownership of Cybear was reduced below 80% on June 23, 1999. Accordingly, Cybear
is excluded from our consolidated income tax return and will file as a separate
tax entity. Cybear's net losses did not generate income tax benefits as
Cybear's tax benefits were fully offset by a corresponding increase in the
valuation allowance against its net deferred income tax assets due to the
uncertainty of realization. For three months ended March 31, 1999, we recorded
Federal and state income taxes of $2.0 million or 22.5% of income before income
taxes, which was our then estimated annual 1999 effective tax rate. We were not
required to record Federal and state income taxes for the three months ended
March 31, 1999 at the Federal and state statutory rate of 37% primarily due to
the reversal of a valuation allowance of $1.3 million relating to deferred tax
assets resulting from net operating loss carryforwards.
The diluted weighted average shares of common stock outstanding was 65.8
million for the three months ended March 31, 2000, as compared to 64.6 million
for the three months ended March 31, 1999. Such increase resulted primarily
from the exercises of stock options. All share and per share amounts reflect
the June 1999 and April 2000 two-for-one stock splits effected in the form of
100% stock dividends.
YEAR ENDED DECEMBER 31, 1999 AS COMPARED TO YEAR ENDED DECEMBER 31, 1998
For 1999, we reported net income of $94.1 million or $1.45 per diluted
weighted average share of common stock outstanding, as compared to net income
of $8.4 million or $0.13 per diluted weighted average share of common stock
outstanding for 1998. The significant increase in net income was a result of
the settlement of the litigation with Aventis and on June 23, 1999 the
commencement of the sale of our bioequivalent version of Cardizem CD, Cartia
XT, which enjoyed a 180-day period of marketing exclusivity through December
19, 1999. The increase in profitability occurred while we continued to increase
our investment spending in both research and development and Cybear Internet
operating expenses.
Total revenues increased by 92.7% to $476.0 million for 1999, as compared
to $247.1 million for 1998.
Sales from distributed products were $262.4 million for 1999, an increase
of $46.5 million or 21.5%, as compared to $215.9 million for 1998. The increase
in sales from distributed products reflects an increase in sales to customers,
an increase in the number of customers, as well as the participation in the
distribution of new products launched by other pharmaceutical companies, offset
by overall price declines.
Sales from manufactured products were $134.8 million for 1999, as compared
to $11.5 million in 1998. Sales from manufactured products include sales of
Diltia XT, our bioequivalent version of Dilacor XR, and commencing June 23,
1999, Cartia XT.
Pursuant to the stipulation with Aventis, we received a total of $70.7
million in interim and final fees in 1999, as compared to $19.1 million in
interim fees in 1998.
Licensing and other revenues were $8.1 million in 1999, as compared to
$552,000 in 1998 primarily from our domestic and international licensing
arrangements. These revenues in 1999 were primarily generated from our June
1999 agreement with Geneva.
Gross profits from sales of distributed and manufactured products were
$161.9 million or a gross margin of 40.7% in 1999, as compared to $39.1 million
or a gross margin of 17.2% in 1998. The increase in gross profit and gross
margin was primarily the result of an increase in sales of manufactured
products within the product mix.
Selling, general and administrative expenses were $55.3 million or 11.6%
of total revenues for 1999, as compared to $30.6 million or 12.4% of total
revenues for 1998. The increase in selling, general and administrative expenses
was primarily due to an increase in the activities necessary to support the
increase in sales of both distributed and manufactured products, including
legal costs related to patent infringement claims associated with our ANDA
filings and also includes a royalty to our Co-Chairman and Chief Scientific
Officer related to sales of Cartia XT in 1999 and the Aventis stipulation fees
in 1999 and 1998.
26
<PAGE>
Research and development expenses were $25.7 million in 1999, as compared
to $16.8 million in 1998. The increase in research and development expenses of
$8.9 million or 52.6% reflects the progress and expansion of our development
activities in our bioequivalent (ANDA) and brand name (NDA) programs.
In 1999, we incurred $14.7 million of Cybear Internet operating expenses,
as compared to $4.1 million in 1998. The increase in Cybear Internet operating
expenses primarily relates to the progress in the development of Cybear's
Internet based software applications for healthcare providers and the
establishment of the related administrative infrastructure.
Minority interest was $1.9 million in 1999, as compared to $85,000 in
1998. The increase in minority interest was a result of the increase in
minority ownership of Cybear, primarily from Cybear's June 1999 public offering
and the issuance of Cybear common shares in the acquisition of Telegraph
Consulting Corporation. In addition, Cybear's net loss increased to $10.8
million in 1999 from $2.5 million in 1998. As of December 31, 1999, Andrx owned
73% of Cybear.
In 1999, we recognized a gain on the sale of Cybear's common stock of
$643,000, as compared to $700,000 in 1998. Such sales were pursuant to existing
subscription and warrant agreements with Cybear's Chairman and its Chief
Executive Officer which were issued at the then current price of $3.00 per
share.
Interest income was $3.6 million in 1999, as compared to $1.1 million in
1998. The increase in interest income is the result of the higher average level
of cash, cash equivalents and investments available-for-sale maintained during
1999, as compared to 1998. The increase was primarily the result of the net
cash provided by operating activities and the net proceeds of $50.8 million
received from Cybear's June 1999 public offering.
Interest expense increased to $1.7 million in 1999, as compared to
$380,000 in 1998. The increase in interest expense was primarily the result of
a higher average level of borrowings under our distribution subsidiary's bank
loan during 1999, as compared to 1998. The borrowings are primarily utilized to
fund our distribution operations.
For 1999, we recorded Federal and state income taxes of $55.4 million or
37% of income before income taxes. We were not required to provide for income
taxes at the 39% effective Federal and state statutory rate due to the effect
of the utilization of our net operating loss carry forwards, offset by our
inability to utilize Cybear's losses after June 23, 1999, as our ownership in
Cybear was reduced below 80%. Accordingly, 1999 net income includes the net
reversal of a net tax valuation of $4.0 million. Our 1998 income tax provision
of $333,000 resulted from Federal alternative minimum income taxes. Andrx' 1998
regular income tax provision of $2.1 million was fully offset by the reversal
of a corresponding amount of valuation allowance against its net deferred
income tax assets.
The diluted weighted average shares of common stock outstanding was 65.0
million in 1999, as compared to 63.7 million for 1998. Such increase resulted
primarily from the exercises of stock options and warrants during 1999.
YEAR ENDED DECEMBER 31, 1998 AS COMPARED TO YEAR ENDED DECEMBER 31, 1997
For 1998, we reported net income of $8.4 million or $0.13 per diluted
weighted average share of common stock outstanding, as compared to a net loss
of $7.6 million or $0.13 per diluted weighted average share of common stock
outstanding for 1997. We became profitable in 1998 for the first time. This
profitability primarily resulted from interim stipulation fees generated by us
pursuant to the Aventis stipulation, the continued growth in profitability of
our distribution operation and a full year of profits realized from the sale of
our first manufactured product, Diltia XT. We recorded profitability in 1998
while we continued to increase investment spending in research and development.
Total revenues increased by 65.0% to $247.1 million for 1998, as compared
to $149.7 million for 1997.
Sales from distributed products were $215.9 million for 1998, an increase
of $69.7 million or 47.6%, as compared to $146.2 million for 1997.
27
<PAGE>
Sales from manufactured products were $11.5 million for 1998, as compared
to $3.3 million in 1997. We launched our first manufactured product, a
bioequivalent version of Dilacor XR, in October 1997.
Following the FDA's final approval of our ANDA for Cardizem CD on July 9,
1998, Andrx received a total of $19.1 million in interim fees pursuant to the
stipulation.
Licensing and other revenues of $552,000 were generated in 1998, as
compared to $137,000 in 1997 from our domestic and international licensing
arrangements.
Gross profits from sales of distributed and manufactured products were
$39.1 million or 17.2% in 1998, as compared to $22.8 million or a gross margin
15.2% in 1997. The increase in gross profit and gross margin was primarily the
result of an increase in sales of manufactured products within the mix.
Selling, general and administrative expenses were $30.6 million or 12.4%
of total revenues for 1998, as compared to $18.9 million or 12.6% of total
revenues for 1997. The increase in selling, general and administrative expenses
was primarily due to an increase in the activities necessary to support the
increase in sales of both distributed and manufactured products including legal
costs related to patent infringement claims associated with our ANDA filings,
and also includes a royalty to our Co-Chairman and Chief Scientific Officer
related to the Aventis stipulation fees.
Research and development expenses were $16.8 million in 1998, as compared
to $11.3 million in 1997. The increase in research and development expenses of
$5.6 million or 49.6% reflects the progress and expansion of our development
activities in our bioequivalent and brand programs.
In 1998, we incurred $4.1 million of Cybear Internet operating expenses,
as compared to $1.5 million in 1997. The increase in Cybear Internet operating
expenses primarily relates to the progress in the development of Cybear's
Internet-based software applications for healthcare providers and the
establishment of the related administrative infrastructure.
Minority interest in Cybear's net losses was $85,000 in 1998, as compared
to $31,000 in 1997. The increase in minority interest was a result of the
increase in minority ownership of Cybear, as well as an increase in Cybear's
net losses, which increased from $1.6 million in 1997 to $2.5 million in 1998.
In 1998, we recognized a gain of $700,000 on the sale of Cybear common
stock to Cybear's Chairman, pursuant to an existing subscription agreement.
This sale was at the then current market price of $3.00 per share.
Interest income was $1.1 million in 1998, as compared to $1.6 million in
1997. The decrease in interest income is the result of the lower average level
of cash, cash equivalents and investments available-for-sale maintained during
1998, as compared to 1997.
Interest expense decreased to $380,000 in 1998 from $490,000 in 1997. The
decrease in interest expense was primarily the result of a lower average level
of borrowings under Andrx' bank loan during 1998, as compared to 1997.
For 1998, our income tax provision of $333,000 resulted from Federal
alternative minimum income taxes. Our 1998 regular income tax provision of $2.1
million was fully offset by the reversal of a corresponding amount of valuation
allowance against its net deferred income tax assets. For 1997, we had no
income taxes as our income tax benefit was fully offset by a corresponding
increase to our valuation allowance against our net deferred income tax assets.
The diluted weighted average shares of common stock outstanding was 63.7
million in 1998, as compared to 56.9 million for 1997. Such increase resulted
primarily from the inclusion of stock equivalents in profitable 1998.
LIQUIDITY AND CAPITAL RESOURCES
THREE MONTHS ENDED MARCH 31, 2000 AS COMPARED TO THREE MONTHS ENDED MARCH 31,
1999
As of March 31, 2000, we had $114.8 million in cash, cash equivalents and
investments available-for-sale of which $26.7 million related to Cybear, and
$185.8 million of consolidated working capital.
28
<PAGE>
Net cash provided by operating activities was $7.6 million for the three
months ended March 31, 2000, as compared to $580,000 for the three months ended
March 31, 1999. The increase in net cash provided by operating activities for
the three months ended March 31, 2000 is due to our generating net income of
$16.4 million for the three months ended March 31, 2000, as compared to net
income of $6.9 million for the three months ended March 31, 1999. The three
months ended March 31, 2000 includes decreases in accounts receivable and
inventories, offset by decreases in current liabilities. In comparison the
quarter ended March 31, 1999 includes increases in accounts receivable and
inventories, offset by increases in current liabilities.
Net cash used in investing activities was $22.3 million for the three
months ended March 31, 2000, as compared to $15.8 million for the three months
ended March 31, 1999. For the three months ended March 31, 2000 and for the
three months ended March 31, 1999, we invested $10.3 million and $4.6 million,
respectively, in property, plant and equipment. For the three months ended
March 31, 2000, $3.0 million of investments available-for-sale matured, as
compared to the three months ended March 31, 1999, when we invested $11.2
million in investments available-for-sale. During the three months ended March
31, 2000, we acquired Valmed Pharmaceutical, Inc. for $15.1 million including
transaction costs, net of cash acquired, subject to certain adjustments.
Net cash provided by financing activities was $9.1 million for the three
months ended March 31, 2000, as compared to $9.4 million for the three months
ended March 31, 1999. Net cash provided by financing activities for the three
months ended March 31, 2000 consisted primarily of $3.0 million in proceeds
from the issuance of shares of common stock upon the exercises of stock options
and $6.3 million of income tax benefits relating to the exercises of stock
options. Net cash provided by financing activities for the three months ended
March 31, 1999 consisted of $1.5 million in proceeds from the issuance of
shares of common stock upon the exercises of stock options and warrants, $6.1
million of net borrowings under our bank loan and $1.5 million of income tax
benefits relating to the exercises of stock options.
YEAR ENDED DECEMBER 31, 1999 AS COMPARED TO YEAR ENDED DECEMBER 31, 1998 AND
1997
As of December 31, 1999, we had $123.4 million in cash, cash equivalents
and investments available-for-sale of which $38.0 million relates to Cybear,
and $180.9 million of consolidated working capital.
Net cash provided by operating activities was $39.8 million in 1999, as
compared to net cash used in operating activities of $1.6 million in 1998 and
$16.6 million for 1997. In 1999, operating activities provided net cash, as
compared to net cash used in 1998, primarily due to our generating $94.1
million of net income in 1999, as compared to $8.4 million in 1998. The
decrease in net cash used in operating activities in 1998, as compared to 1997
is due to our generating net income of $8.4 million in 1998, as compared to a
net loss of $7.6 million in 1997. In 1999, 1998 and 1997, operating activities
included increases in inventories, accounts receivable and prepaid and other
assets offset by increases in current liabilities. The increase in inventories
in 1999 and 1998 includes purchases of inventories for distribution in
anticipation of potential price increases by the generic drug manufacturers.
Net cash used in investing activities was $108.7 million in 1999, as
compared to net cash provided by investing activities of $5.3 million in 1998
and $291,000 in 1997. In 1999, we purchased $85.3 million of investments
available-for-sale, $22.2 million of property, plant and equipment and Cybear
acquired Telegraph Consulting Corporation for $1.2 million. The 1999 capital
expenditures included the construction of the new manufacturing, research and
development and corporate facility. Construction of the facility began in 1999
and is anticipated to be completed by the first quarter of 2001. The total
capital requirement for this project is approximately $55 million, of which
approximately $5.1 million was incurred in 1999. The balance of the 1999
capital expenditures was predominately the result of the capital procurement of
manufacturing equipment. In 1998, $13.2 million of investments
available-for-sale matured and we purchased $8.0 million of property, plant and
equipment. In 1997, $8.0 million of investments available-for-sale matured and
we purchased $7.7 million of property and equipment. In 1998 and 1997, the
capital expenditures were primarily for the procurement of manufacturing
equipment. The 1998 capital expenditures also included the purchase of
approximately 15 acres of land.
29
<PAGE>
Net cash provided by financing activities was $84.0 million in 1999, as
compared to $7.2 million in 1998 and $19.6 million in 1997. Net cash provided
by financing activities in 1999 consisted of net borrowings of $16.1 million
under our bank loan, $6.7 million in proceeds from the issuance of shares of
common stock upon the exercise of warrants and stock options, $9.4 million of
income tax benefits relating to the exercise of stock options, net proceeds of
$50.8 million from Cybear's June 1999 public offering, $379,000 of other
capital transactions of Cybear and $675,000 of proceeds from the sale of shares
of Cybear common stock. Net cash provided by financing activities in 1998
consisted of net borrowings of $3.6 million under our bank loan, $2.8 million
in proceeds from the issuance of shares of common stock upon the exercise of
warrants and stock options and $700,000 in proceeds from the gain on the sale
of shares of Cybear Common Stock. Net cash provided by financing activities for
1997 consisted of $21.3 million from the issuance of shares of common stock in
private placement transactions and $4.1 million in proceeds from the issuance
of shares of common stock upon the exercises of warrants and stock options
offset by $5.9 million of net repayments on our bank loan.
We had an outstanding short-term borrowing balance under our distribution
subsidiary's bank loan of $20.4 million as of March 31, 2000, $20.2 million as
of December 31, 1999 and $4.1 million as of December 31, 1998. Short-term
borrowing balances relate primarily to the financing of inventories for
distribution. Borrowings under the bank loan are secured by all of the assets
of the distribution operation, and are subject to a borrowing base related to
the value of that operation's accounts receivable and inventories. The bank
loan agreement requires we comply with certain covenants including the
maintenance of minimum working capital and net worth levels by the distribution
subsidiary. The bank loan currently provides that total available borrowings
are $30.0 million, and gives us the ability to further decrease the interest
rate if we maintain certain levels of average outstanding balance. As of March
31, 2000 the interest rate on the bank borrowings was 9.0%.
We anticipate that our cash requirements will continue to increase, due to
construction of our research and development, manufacturing and corporate
facilities, including the related equipment purchases. We anticipate that for
the year ending December 31, 2000, we will incur approximately $50 million in
research and development related to our bioequivalent and brand development
programs. We anticipate that our existing capital resources will be sufficient
to enable us to maintain our operations for the next 12 months and into the
foreseeable future.
YEAR 2000 SYSTEMS COSTS
Utilizing both internal and external resources to identify and assess
needed Year 2000 remediation, our Year 2000 identification, assessment,
remediation and testing efforts, which began in the first quarter 1998, were
completed by December 31, 1999, prior to any impact.
The cost of our Year 2000 identification, assessment, remediation and
testing efforts, as well as costs we incurred with respect to Year 2000 issues
of third parties, was approximately $1 million and was funded from existing
financial resources.
We are not aware of any difficulties that arose as a result of the Year
2000 issue.
RECENT ACCOUNTING PRONOUNCEMENTS
COMPREHENSIVE INCOME
Statement of Financial Accounting Standards ("SFAS") No. 130, "Reporting
Comprehensive Income", was issued by the Financial Accounting Standards Board
("FASB") in June 1997. This SFAS requires that all items that are required to
be recognized under accounting standards as components of comprehensive income
be reported in a financial statement that is displayed with the same prominence
as other financial statements. We adopted the provisions of SFAS No. 130 in the
year ended December 31, 1998, as required.
SEGMENT REPORTING
SFAS No. 131, "Disclosures about Segments of an Enterprise and Related
Information", was issued by the FASB in June 1997. This SFAS establishes
standards for reporting information about operating segments
30
<PAGE>
in annual financial statements and requires reporting of selected information
about operating segments in interim financial reports issued to shareholders.
It also establishes standards for related disclosures about products and
services, geographic areas and major customers. We adopted the provisions of
SFAS No. 131 in the year ended December 31, 1998, as required.
DERIVATIVES
SFAS No. 133, "Accounting for Derivative Instruments and Hedging
Activities", establishes accounting and reporting standards requiring that
every derivative instrument (including certain derivative instruments embedded
in other contracts) be recorded in the balance sheet as either an asset or
liability measured at its fair value. SFAS No. 133 requires that changes in the
derivative's fair value be recognized currently in earnings unless specific
hedge accounting criteria are met. Special accounting for qualifying hedges
allows a derivative's gains and losses to offset related results on the hedged
item in the income statement, and requires that a company must formally
document, designate, and assess the effectiveness of transactions that receive
hedge accounting. SFAS No. 133 must be applied to (a) derivative instruments
and (b) certain derivative instruments embedded in hybrid contracts that were
issued, acquired, or substantively modified after December 31, 1997 (and, at
our election, before January 1, 1998).
SFAS No. 137, "Accounting for Derivative Instruments and Hedging
Activities--Deferral of the Effective Date of FASB Statement No. 133", amends
the effective date of SFAS No. 133 to all fiscal years beginning after June 15,
2000.
We expect to adopt SFAS No. 133, as required, and do not expect the effect
of adoption to be significant to the consolidated financial statements.
STOCK SPLIT
On February 29, 2000, our Board of Directors approved a two-for-one stock
split in the form of a 100% stock dividend to shareholders of record at the
close of business on March 15, 2000. Such stock dividend was distributed in
April 2000. In connection with this stock split, our authorized shares of
common stock were increased from 50 million to 100 million. Anti-dilutive
adjustments have been made to our stock option plan and the options outstanding
thereunder. All share and per share amounts included herein give effect to the
two-for-one stock splits distributed in June 1999 and April 2000.
31
<PAGE>
BUSINESS
OVERVIEW
We formulate and commercialize controlled-release oral pharmaceuticals
using our proprietary drug delivery technologies. We market and sell our
generic or bioequivalent versions of Cardizem CD and Dilacor XR. Through our
distribution operations, we also sell drugs manufactured by third parties
primarily to independent pharmacies, pharmacy chains which do not maintain
their own central warehousing facilities and pharmacy buying groups. Through
our Cybear subsidiary, we develop Internet applications to improve the
efficiency of day-to-day administrative and communications tasks for the
various participants in the healthcare industry.
We have eight proprietary drug delivery technologies that we have patented
for certain applications or for which we have filed for patent protection for
certain applications. We believe our technologies are flexible and can be
modified to apply to a variety of pharmaceutical products. We use our
proprietary drug delivery technologies and formulation skills to develop:
/bullet/ bioequivalent versions of selected controlled-release brand name
pharmaceuticals; and
/bullet/ brand name controlled-release formulations of existing
immediate-release or controlled-release drugs where we believe
that the application of our drug delivery technologies may improve
the efficacy or other characteristics of that product.
We believe that pharmaceutical companies are increasingly using
controlled-release drug delivery technologies to improve drug therapy.
Controlled-release drug delivery technologies generally provide more consistent
and appropriate drug levels in the bloodstream than immediate-release dosage
forms and may improve drug efficacy and reduce side effects by releasing drug
dosages at specific times and in specific locations in the body. These
technologies also allow for the development of "patient-friendly" dosage forms,
which reduce the number of times a drug must be taken, thus improving patient
compliance.
PRODUCT DEVELOPMENT AND COMMERCIALIZATION
BIOEQUIVALENT CONTROLLED-RELEASE PHARMACEUTICALS
We apply our proprietary drug delivery technologies and formulation skills
to develop bioequivalent versions of selected controlled-release brand name
pharmaceuticals. Specifically, we apply our proprietary processes and
formulations to develop a product that will reproduce the brand product's
physiological characteristics but not infringe upon the patents of the brand
company or innovator. Next, we conduct studies to establish that our product is
bioequivalent to the brand product, and obtain legal advice that our products
will not infringe the innovator's patents or that such patents are invalid or
unenforceable. As required by the Drug Price Competition and Patent Restoration
Act of 1984, known as the Waxman-Hatch Amendments, we then assemble and submit
an ANDA to the FDA for review. As part of this ANDA, we certify to the FDA that
our product will not infringe the innovator's patents or that such patents are
invalid or unenforceable. This certification is called a Paragraph IV
Certification.
Once our ANDA is accepted for filing by the FDA, we must also send a
Paragraph IV Certification to the patent holder. The patent holder may then
initiate a legal challenge to our Paragraph IV Certification within 45 days of
their receipt of our Paragraph IV Certification, which will automatically
prevent the FDA from approving our ANDA until the earlier of 30 months,
expiration of the patent, or when the infringement case is decided in our
favor. Thus, the developer of bioequivalent products may invest a significant
amount of time and expense in the development of these products only to be
subject to significant delay and the uncertain results of patent litigation
before its products may be commercialized.
However, the Waxman-Hatch Amendments also provide an economic incentive
for the early development of bioequivalent pharmaceuticals. The developer of
the bioequivalent product which is the first to have its
32
<PAGE>
ANDA containing a Paragraph IV Certification for any bioequivalent drug
accepted for filing by the FDA is awarded a 180-day period of marketing
exclusivity against other companies that subsequently file Paragraph IV
Certifications. This means that the FDA may not approve the marketing of
another ANDA containing a Paragraph IV Certification for that product until the
first developer's 180-day period of marketing exclusivity has expired or has
been waived. This marketing exclusivity begins with the commercial marketing of
the product or a court determination that the relevant patents are invalid,
unenforceable or not infringed.
We believe this period of marketing exclusivity provides an opportunity
for the successful patent challenger to build its market share, to recoup the
expense of the lawsuit and to realize greater profit margins. In addition, once
that exclusivity period has lapsed, we believe the first successful developer
may more effectively defend its position against future competition. Our
ability to secure the benefit of 180-day exclusivity, however, depends on some
factors beyond our control, such as the date of filing and the results of
litigation involving other ANDA filers and proposed changes in FDA regulations
which may, for future ANDA filings, decrease the value of the exclusivity
period, as described in "--Government Regulation--ANDA Process." Therefore,
even if we qualify for 180-day exclusivity, we may not be able to benefit from
some or any of the 180-day period.
We have been sued for patent infringement on many of the products for
which we have filed ANDAs. In addition, in March 2000, the FTC initiated an
administrative proceeding against us relating to a stipulation and agreement we
entered into with respect to the then pending patent litigation involving
Cardizem CD.
We have submitted ANDAs for bioequivalent versions of the following
products:
Dilacor XR In October 1997, we received FDA approval and commenced
selling Diltia XT, our bioequivalent version of Dilacor XR.
This product is used for the treatment of hypertension and
chronic stable angina and is currently being marketed by
Watson Pharmaceuticals, Inc. Our marketing exclusivity
expired in April 1998. Total U.S. brand and bioequivalent
sales for Dilacor XR were approximately $105 million in
1999.
Cardizem CD In July 1998, we received FDA approval to sell our
bioequivalent version of Cardizem CD, which is used for the
treatment of hypertension and chronic stable angina and is
currently being marketed by Aventis. Although approved by
the FDA, we did not market the product due to the pending
patent infringement litigation against us with respect to
this product. In June 1999, the litigation was settled and
we commenced selling Cartia XT, a reformulated version of
our bioequivalent version of Cardizem CD. Our marketing
exclusivity expired on December 19, 1999. Total U.S. brand
and bioequivalent sales for Cardizem CD were approximately
$715 million in 1999.
Prilosec In March 2000, we received tentative FDA approval of our
bioequivalent version of Prilosec, which is used for the
treatment of ulcers and gastroesophageal reflux disease and
is currently being marketed by AstraZeneca PLC. Patent
infringement litigation was commenced by AstraZeneca
against us with respect to this product. We believe that we
were the first to have our ANDA for this product accepted
for filing by the FDA and that upon final FDA approval our
product should be entitled to the 180-day period of
marketing exclusivity. We do not expect to begin marketing
our bioequivalent version of Prilosec before the expiration
of the composition of matter patent in April 2001, which
may be extended for six months as a reward for pediatric
studies. Total U.S. brand sales for Prilosec were
approximately $3.5 billion in 1999.
Naprelan In March 2000, we received tentative FDA approval related
to our ANDA for our bioequivalent version of Naprelan,
which is used for the treatment of inflammation and is
currently being marketed by Elan Corporation plc. Elan
33
<PAGE>
commenced patent infringement litigation against us with
respect to this product which is continuing. As we were not
the first to have our ANDA for this product accepted for
filing, we cannot market our bioequivalent version of
Naprelan until the 180-day marketing exclusivity period of
the first ANDA filer expires or is waived, and either our
30-month waiting period expires or the litigation is
concluded in our favor and the FDA approves our ANDA. Total
U.S. brand sales for Naprelan were approximately $55
million in 1999.
Tiazac In September 1998, the FDA accepted our ANDA submission
for a bioequivalent version of Tiazac, which is used for
the treatment of hypertension and chronic stable angina and
is currently being marketed by Forest Laboratories, Inc.
Biovail Corporation International, the developer of Tiazac,
commenced patent infringement litigation against us with
respect to this product. In March 2000, the United States
District Court for the Southern District of Florida entered
an order that our product does not infringe the Biovail
patent, and Biovail filed a notice that it will appeal that
decision. We believe that we were the first to have our
ANDA for this product accepted for filing by the FDA and
our product should be entitled to the 180-day period of
marketing exclusivity. The 30-month period from our ANDA
filing expires in March 2001. Total U.S. brand sales for
Tiazac were approximately $170 million in 1999.
Wellbutrin SR In August 1999, the FDA accepted our ANDA submission for a
bioequivalent version of Wellbutrin SR, which is used to
treat depression and is currently being marketed by Glaxo
Wellcome Plc. Glaxo commenced patent infringement
litigation against us with respect to this product. We
believe that we were the first to have our ANDA for the 150
mg dosage of this product accepted for filing by the FDA
and that this dosage form of our product should be entitled
to 180-day marketing exclusivity. We do not expect to
market this product until the 30-month waiting period
expires or the litigation is concluded in our favor and the
FDA approves our ANDA. Total U.S. brand sales for
Wellbutrin SR were approximately $530 million in 1999.
Zyban In August 1999, the FDA accepted our ANDA submission for a
bioequivalent version of Zyban, which is prescribed for the
cessation of smoking and is currently being marketed by
Glaxo. Glaxo commenced patent infringement litigation
against us with respect to this product. We believe that we
were the first to have our ANDA for this product accepted
for filing by the FDA and that our product should be
entitled to the 180-day period of marketing exclusivity. We
do not expect to market this product until the 30-month
waiting period expires or the litigation is concluded in
our favor and the FDA approves our ANDA. Total U.S. brand
sales for Zyban were approximately $105 million in 1999.
K-Dur In August 1999, the FDA accepted our ANDA submission for a
bioequivalent version of K-Dur, a potassium supplement that
is currently being marketed by Key Pharmaceuticals, Inc., a
subsidiary of Schering-Plough Corporation. No patent
infringement suit related to the ANDA for K-Dur has been
filed against us. As we were not the first to have our ANDA
for this product accepted for filing, we cannot market our
bioequivalent version of K- Dur until the 180-day marketing
exclusivity period of the first ANDA filer expires or is
waived and the FDA approves our ANDA. Total U.S. brand
sales for K-Dur were approximately $245 million in 1999.
Claritin D-24 In February 2000, the FDA accepted our ANDA submission for
a bioequivalent version of Claritin D-24, which is a
once-a-day antihistamine for the treatment of
34
<PAGE>
allergies and is currently being marketed by
Schering-Plough Corporation. Schering-Plough has commenced
patent infringement litigation against us with respect to
this product. We believe that we were the first to have our
ANDA for this product accepted for filing by the FDA and
that our product should be entitled to the 180-day period
of marketing exclusivity. We do not expect to market this
product until the 30-month waiting period expires or the
litigation is concluded in our favor and the FDA approves
our ANDA. Total U.S. sales of Claritin D-24 were
approximately $370 million in 1999.
Depakote In March 2000, the FDA accepted our ANDA submission for a
bioequivalent version of Depakote, which is used to treat
epilepsy and is currently being marketed by Abbott
Laboratories Inc. Abbott has recently commenced patent
infringement litigation against us. As we were not the
first to have our ANDA for this product accepted for
filing, we cannot market our bioequivalent version of
Depakote until the 180-day marketing exclusivity period of
the first ANDA filer expires or is waived and either our
30-month waiting period expires or the litigation is
concluded in our favor and the FDA approves our ANDA. Total
U.S. sales of Depakote were approximately $700 million in
1999.
Lodine XL In May 2000, the FDA accepted our ANDA submission for a
bioequivalent version of Lodine XL, which is used to treat
both osteoarthritis and rheumatoid arthritis and is
currently being marketed by Wyeth-Ayerst Pharmaceuticals, a
division of American Home Products Corporation. No patent
infringement litigation has been commenced against us
although Wyeth-Ayerst has until July 2000 to commence
litigation in order to trigger the 30-month waiting period
on FDA approval. As we believe we were not the first to
have our ANDA for this product accepted for filing, we
cannot market our bioequivalent version of Lodine XL until
the 180-day marketing exclusivity period of the first ANDA
filer expires or is waived and we receive FDA approval. If
Wyeth-Ayerst commences patent infringement litigation prior
to July 2000, we will not be able to market our
bioequivalent version of Lodine XL until our 30-month
waiting period expires or the litigation is concluded in
our favor, the 180-day marketing exclusivity period of the
first ANDA filer expires or is waived and the FDA approves
our ANDA. Total U.S. sales of Lodine XL were approximately
$100 million in 1999.
In addition, ANCIRC Pharmaceuticals, our 50/50 joint venture with Watson
Pharmaceuticals, Inc. received FDA approval for bioequivalent versions of the
following products:
Trental In September 1998, ANCIRC received FDA approval to sell
its bioequivalent version of Trental. This product is for
the treatment of patients with chronic occlusion of
arteries of the limbs. This product was formulated by us,
is being manufactured by Watson and is being marketed by
us. Total U.S. brand and bioequivalent sales for Trental
were approximately $85 million in 1999. The ANDA for this
product did not contain a Paragraph IV certification.
Oruvail In March 1999, ANCIRC received FDA approval to sell its
bioequivalent version of Oruvail. This product is being
used for the treatment of patients with rheumatoid
arthritis and osteoarthritis. This product is to be
manufactured and marketed by us and was launched in April
1999, but was discontinued in June 1999 due to
manufacturing problems related to this product. We are in
the process of rectifying these problems and expect to
start producing and marketing this product again later in
2000. Total U.S. brand and bioequivalent sales for
35
<PAGE>
Oruvail were approximately $50 million in 1999. The ANDA
for this product did not contain a Paragraph IV
certification.
BIOEQUIVALENT PRODUCT PIPELINE. In addition to the products for which
ANDAs have been submitted, we, either directly or through ANCIRC or other
collaborative ventures, intend to develop approximately 25 additional
bioequivalent versions of brand name drugs. Total U.S. sales for the brand
versions of these products were approximately $8.0 billion in 1999. We are
continually evaluating potential product candidates, including specialty or
niche pharmaceutical products. In selecting our product candidates, we focus on
pharmaceuticals which we anticipate will have high sales volume and for which
marketing exclusivity or patent rights have expired or are near expiration.
BRAND NAME CONTROLLED-RELEASE PHARMACEUTICALS
We are developing brand name controlled-release formulations by applying
our proprietary drug delivery technologies to existing immediate-release and
controlled-release drugs. We believe that the application of our drug delivery
technologies will improve the characteristics of these products, for example,
by decreasing undesired side effects or reducing the frequency of
administration. In selecting our product candidates, we focus on high sales
volume pharmaceuticals that will lack patent protection at the time we plan to
market our product. We are continually evaluating potential product candidates
for this program.
In order to facilitate development of these products, we plan to undertake
formulation and development on our own and use contract research organizations
for clinical studies. Currently, we are evaluating entering into collaborative
arrangements with other pharmaceutical companies to commercialize these
products. These potential products generally require us to file an
Investigational Drug Application, or IND, with the FDA before commencing
clinical trials and a New Drug Application, or NDA, in order to obtain FDA
approval. We believe that the FDA approval process of our NDAs for these type
of brand name controlled-release formulations will be simpler than that
typically associated with most NDAs for new chemical entities because our
development efforts involve chemical entities which have been previously
approved by the FDA. We may also receive certain marketing exclusivity rights
for a controlled-release product we develop in our new drug program.
The following describes the status of our brand name controlled-release
products:
Lovastatin XL Our product, Lovastatin XL, is a newly developed
extended-release tablet which uses one of our proprietary
drug delivery technologies to treat elevated cholesterol or
hypercholesterolemia. Merck & Co., Inc. markets Lovastatin
immediate-release oral tablets under the brand name
Mevacor/registered trademark/. Mevacor immediate-release
tablets are currently marketed in 10 mg, 20 mg and 40 mg
strengths and are administered once a day. The usual
recommended starting dose is 20 mg once a day. The
recommended dosing range is 10 mg to 80 mg per day in one
or two doses. Mevacor belongs to a class of drugs known as
statins. Statin products had approximately $5.7 billion in
U.S. sales in 1999, of which Mevacor sales were
approximately $300 million.
Our tablet formulation also contains 10 mg, 20 mg, 40 mg or
60 mg doses. Several published studies suggest therapeutic
advantages may be achieved by an extended-release dosage
form of Lovastatin, including greater efficacy, resulting
in the need for fewer doses, and an improved safety profile
compared to the conventional immediate-release dosage form.
In a Phase II crossover study conducted by us in patients
with elevated cholesterol, Lovastatin XL produced a greater
reduction in mean LDL cholesterol than was produced by an
equivalent dose of Mevacor. There was little or no
difference in adverse events between Lovastatin XL and
Mevacor. In June 1999, we initiated Phase III studies of
Lovastatin XL with over 500 targeted patients in over 40
centers to further
36
<PAGE>
evaluate the efficacy and safety of our product before we
file an NDA, which we anticipate will occur in 2001.
Metformin XT We have developed Metformin XT, an oral extended-release
dosage form of metformin using our proprietary modified
release system, to treat non-insulin-dependent diabetes
mellitus, commonly referred to as Type II diabetes. Bristol
Myers Squibb Inc. markets metformin as an immediate-release
tablet under the brand name Glucophage/registered
trademark/. Our once daily product is intended to have
bioavailability equivalent to the currently marketed
Glucophage product. Glucophage tablets are marketed in 500
mg, 850 mg or 1000 mg doses. Although there is no fixed
dosage regimen, it is typically administered two to three
times per day with a maximum recommended dose of 2550 mg
per day. Bristol Myers Squibb filed an NDA for a once a day
metformin in late 1999. There were over $2 billion of U.S.
sales of glucose-lowering products in 1999 including
Glucophage, Glucotrol XL/registered trademark/ and
Glynase/registered trademark/. Metformin use has been
associated with gastrointestinal side effects. These
adverse events may be partially avoided using an
extended-release dosage form. Another advantage of an
extended-release dosage form is a reduction in the
frequency of administration, which we expect to increase
patient compliance.
In January 2000, we successfully completed Phase II
clinical studies and we expect to commence pivotal Phase
III clinical studies in the second quarter of 2000. We
believe that other companies may also be developing
once-a-day dosages of metformin for NDA filings in the near
future. We anticipate filing an NDA in 2001.
We are also in various early stages of development for controlled-release
versions of Omeprazole DR (a reformulated version of Prilosec), an analgesic
product and two central nervous system products.
BRAND SALES AND MARKETING STRATEGY. We are developing and evaluating
various strategies for the sale and marketing of our brand name
controlled-release pharmaceuticals. These strategies include licensing our
brand name products to other pharmaceutical companies with sales organizations
sufficient to support our products, entering into co-promotion or contract
sales arrangements with respect to the products, establishing our own sales
organization and related infrastructure to support and manage our sales effort
or any combination of the above. If we license our products or enter into
co-promotional or contract sales arrangements, we would not incur the
significant upfront expenses associated with building a sales organization, but
our potential profit margins for the product could be lower. Whichever strategy
we pursue, we expect that when our current brand name controlled-release
pharmaceuticals are ready to be launched we will have an established sales
organization in place or have entered into arrangements to market our products
to physicians and other healthcare professionals who prescribe that product. We
also expect to have the ability to access doctors through Cybear's online
communication system.
OUR PROPRIETARY DRUG DELIVERY TECHNOLOGIES
Both our bioequivalent controlled-release pharmaceuticals and our brand
name controlled release pharmaceuticals generally utilize our proprietary drug
delivery technologies to control the release characteristics of a variety of
orally administered drugs. Controlled-release products are formulations which
release active drug compounds in the body gradually and predictably over a 12
or 24-hour period and therefore need be taken only once or twice daily.
Controlled-release products typically provide numerous benefits over immediate
release drugs, including:
/bullet/ greater effectiveness in the treatment of chronic conditions;
/bullet/ reduced side effects;
37
<PAGE>
/bullet/ greater convenience (only once or twice a day); and
/bullet/ higher levels of patient compliance due to a simplified dosing
schedule.
We have eight proprietary drug delivery technologies that we have patented
for certain applications or for which we have filed for patent protection for
certain applications. We have been issued 38 patents with respect to these
technologies. We originally designed these controlled-release technologies
specifically for a drug that was being formulated. However, we believe that our
technologies are relatively flexible and can be modified to apply to a variety
of pharmaceutical products.
Our drug delivery technologies utilize a variety of polymers and other
materials to encapsulate or entrap the active drug compound and to release the
drug at varying rates at predetermined locations in the gastrointestinal tract.
In applying an appropriate drug delivery technology to a particular drug
candidate, we consider such factors as:
/bullet/ the desired release rates of the drug;
/bullet/ the physio-chemical properties of the drug;
/bullet/ the physiology of the gastrointestinal tract and the manner in
which the drug will be absorbed during passage through the
gastrointestinal tract; and
/bullet/ the effect of food on the absorption rate and transit time of the
drug.
38
<PAGE>
The following summarizes our drug delivery technologies:
<TABLE>
<CAPTION>
DRUG DELIVERY TECHNOLOGY DESCRIPTION
- ------------------------------------------ ----------------------------------------------------------------
<S> <C>
Pelletized Pulsatile Delivery System PPDS is designed for use with products that require a
("PPDS") pulsed release of the drug. This technology uses pellets that
are coated with specific polymers and agents to control the
release rate of the microencapsulated drug. By varying the
proportion and composition of the polymer mixtures, the
release rate of the drug may be specifically controlled.
Single Composition Osmotic Tablet System SCOT utilizes various osmotic modulating agents as well as
("SCOT") polymer coatings to provide a zero-order release of a drug
(a constant rate of release).
Solubility Modulating Hydrogel System SMHS is designed for products utilizing a hydrogel-based
("SMHS") dosage system that provides for sustained release without
the need to use special coatings or structures, which add to
the cost of manufacturing. This technology avoids the
"initial burst effect" commonly observed with other
sustained-release hydrogel formulations.
Delayed Pulsatile Hydrogel System DPHS is designed for use with hydrogel matrix products
("DPHS") that are characterized by an initial zero-order release of drug
followed by a rapid release. This release profile is achieved
by the blending of selected hydrogel polymers to achieve a
delayed pulse.
Stabilized Pellet Delivery System SPDS is designed specifically for unstable drugs,
("SPDS") incorporating a pellet core of drug and protective polymer
outer layer(s).
Granulated Modulating Hydrogel System GMHS incorporates hydrogel and binding polymers with the
("GMHS") drug, which is formed into granules and then pressed into
tablet form.
Pelletized Tablet System PELTAB utilizes polymer-coated drug pellets or drug
("PELTAB") crystals which are manufactured into tablets. In order to
provide a controlled release, a water insoluble polymer is
used to coat discrete drug pellets or crystals, which then can
resist the action of fluids in the gastrointestinal tract. This
technology incorporates a strong polymer coating enabling
the coated pellets to be compressed into tablets without
significant breakage.
Porous Tablet System PORTAB is designed for controlled-release dosage forms
("PORTAB") which utilize an osmotic core, typically containing a water
soluble drug. The core includes a water soluble component
and a continuous polymer coating. The purpose of the
soluble agent is to expand the core and thereby create
microporous channels through which the drug is released.
</TABLE>
COLLABORATIVE ARRANGEMENTS
We work with other pharmaceutical companies to formulate
controlled-release versions of their existing commercialized drugs and drugs
they are developing using our proprietary drug delivery technologies. In
39
<PAGE>
addition to improving drug efficacy, we believe that our drug delivery
technologies will provide these pharmaceutical companies with the opportunity
to enhance the commercial value of their existing drug products and new drug
candidates.
ANCIRC is a 50/50 joint venture between us and Watson for the development
of eight bioequivalent controlled-release pharmaceuticals. Capital
contributions, distributions and net income or losses are allocated equally
between us and Watson. Capital contributions are utilized by ANCIRC to pay
outside vendors, services rendered by Watson or us to ANCIRC and to purchase
finished goods inventory manufactured by Watson or us on ANCIRC's behalf. We
have made investments in ANCIRC totaling $7.9 million through December 31,
1999. From time to time, we have had discussions with Watson to potentially
restructure ANCIRC.
DEVELOPMENT AND LICENSING AGREEMENTS
In June 1999, we entered into an agreement with Geneva, a member of the
Novartis pharmaceutical group. Geneva has agreed to fund the development costs
of certain controlled-release products that we are developing for submission as
NDAs in exchange for exclusive marketing rights to those products in specified
territories. Under this arrangement, one of our NDA products has been
outlicensed for the U.S. Upon receiving approval from the FDA or other
regulatory agencies, we will receive royalties from the sale of these products
in the specified territories. We have committed to continuing to sell Geneva's
bioequivalent products in our Anda distribution operation.
We have entered into additional development and licensing agreements
covering bioequivalent pharmaceuticals with U.S. and foreign pharmaceutical
companies. Pursuant to these agreements, the licensees typically will fund the
cost of product development and will pay us royalties in exchange for a license
to market the products for a specified period in a specified territory.
MANUFACTURING
We presently have a manufacturing facility capable of producing the
projected necessary commercial quantities of our bioequivalent versions of
Dilacor XR, Cardizem CD, Tiazac, Oruvail, Naprelan and K-Dur. However, since
our existing manufacturing facility will not be suitable for the manufacture of
all of the products that we intend to develop and manufacture, we are in the
process of expanding our manufacturing capabilities by converting portions of
our existing facilities to additional manufacturing and related warehousing
space, and by building a new facility on an adjacent 15 acre parcel of property
that we own. Following the completion of these projects, we will have
approximately 200,000 square feet for the manufacture of our products.
We also depend upon Watson to manufacture certain products subject to the
ANCIRC joint venture and on other companies with which we have or may have
agreements to manufacture other products.
PHARMACEUTICAL DISTRIBUTION OPERATIONS
We market and distribute pharmaceuticals manufactured by third parties
through our Anda subsidiary formerly known as Anda Generics Inc. We purchase
pharmaceuticals directly from manufacturers and wholesalers and market them
through our in-house telemarketing staff primarily to independent pharmacies,
pharmacy chains which do not maintain their own central warehousing facilities
and pharmacy buying groups. We offer competitive pricing, quality products and
responsive customer service, which we believe are the critical elements to
competing effectively in this market. Our telemarketing staff currently has
approximately 130 persons and is supplemented by sales executives who are
responsible for national accounts.
In March 2000, we acquired Valmed Pharmaceutical, Inc., a privately owned
distributor of bioequivalent pharmaceuticals based in Grand Island, New York.
The purchase price was $15.1 million in cash including transaction costs, net
of cash acquired, subject to certain adjustments. The acquisition has been
recorded using the purchase method of accounting.
40
<PAGE>
We currently utilize our distribution operations' sales and marketing
personnel for the marketing of our bioequivalent versions of Dilacor XR,
Cardizem CD and ANCIRC's bioequivalent version of Trental. We plan to continue
to utilize Anda personnel and start to use the Valmed operations in the
marketing and distribution of our current products and other products being
developed by us, by ANCIRC and by our collaborative partners. Our distribution
operations allow us to observe and participate directly in developments and
trends in the pharmaceuticals industry.
We purchase our bioequivalent products for resale from a number of
pharmaceutical manufacturers and wholesalers. We believe that we are not
dependent upon any particular supplier and that alternative sources of supply
for most of our products are available if required.
CYBEAR
Cybear is an information technology company that is using the Internet to
improve the efficiency of administrative and communications tasks of managing
patient care while addressing the healthcare industry's need for the secure and
reliable transmission of information. Cybear is an Internet Service Provider,
or ISP, and Application Services Provider, or ASP, for the healthcare industry.
Cybear uses or intends to use its own secure private network to provide access
to the Internet, e-mail and productivity applications. These are available on a
transaction or subscription basis to physicians, physician organizations,
pharmacies and hospitals. Some of its online applications include or will
include business tools for hospital messaging, lab orders and results,
streamlined purchasing, prescription writing, claims processing, eligibility
verification, formulary compliance, credentialing, web site creation and
physician-patient communications via the Internet.
In March 1999, Cybear introduced its first product, dr.cybear, a physician
practice portal, which is designed to address the communications and
operational needs of physicians and other healthcare providers. The physician
practice portal is an Internet portal site that provides a combination of
healthcare content, practice management tools, the entry point to a
comprehensive communications network and ongoing access to further products and
services. dr.cybear is marketed to physicians, physician organizations,
hospitals, managed care organizations and integrated delivery networks
throughout the United States.
In September 1999, we entered into an arrangement with Cybear pursuant to
which prescription vaccines and injectables and other items distributed by Anda
can be ordered through Cybear's physician practice portal.
In March 2000, Cybear signed a one-year agreement, subject to additional
one-year period renewals by mutual agreement, with Novartis Pharmaceuticals
Corporation pursuant to which Cybear will provide secure on-line connectivity
and communications solution through dr.cybear to an initial group of 5,000
Novartis-selected physicians for monthly subscription fees commencing one month
after these physicians are registered. Novartis has committed to register 5,000
physicians by the end of 2000.
CYBEAR REORGANIZATION
In December 1999, we announced a corporate reorganization plan which,
among other things, would give Andrx shareholders the ability to distinguish
their investments in Andrx and Cybear. In March 2000, these two companies
entered into a definitive agreement with respect to this corporate
reorganization. This plan, which was recommended by a special committee of the
Board of Directors of Cybear, as well as by the boards of both Cybear and
Andrx, will create two new classes of Andrx common stock, Cybear Group Common
Stock, to separately track the performance of Cybear and Andrx Group Common
Stock to represent the equity interests of Andrx other than its ownership of
Cybear. The plan will be submitted for approval to the shareholders of Andrx
and Cybear later this year.
Pursuant to an Agreement and Plan of Merger and Reorganization, we will
acquire all of the publicly traded shares of common stock of Cybear in what
should be a tax-free reorganization. Cybear's public shareholders own
approximately 4.9 million shares as of March 31, 2000 (excluding the potential
exercise by Edward E. Goldman, M.D., Cybear's Chief Executive Officer, of an
outstanding warrant to acquire 525,000 shares of Cybear common stock currently
owned by Andrx), or 27.6%, of the common shares of Cybear, and
41
<PAGE>
those shareholders will receive one share of Cybear Group Common Stock for
every Cybear share they currently own. In the reorganization, the number of
Cybear shares held by Andrx will be reduced from 12.9 million shares to 10.8
million shares so as to provide the equivalent of a 20% increase in shares held
by the non-Andrx shareholders of Cybear. As a result, the non-Andrx
shareholders of Cybear will own approximately 31.2% of the Cybear Group Common
Stock following the closing of the transaction. Pursuant to the reorganization,
each Andrx common share will be converted into (i) one share of Andrx Group
Common Stock, and (ii) approximately .1622 shares of Cybear Group Common Stock.
Upon completion of the reorganization, (i) Cybear will be our wholly owned
subsidiary with 100% of its value publicly traded in the form of Cybear Group
Common Stock; (ii) current Cybear shareholders will own approximately 31.2% of
the Cybear Group Common Stock; and (iii) current Andrx shareholders will own
100% of the Andrx Group Common Stock and approximately 68.8% of the Cybear
Group Common Stock.
The reorganization plan is intended to (i) separate the operating losses
of Cybear from our operating results for financial reporting purposes (ii)
improve liquidity for the publicly traded equity of Cybear; (iii) provide
Cybear with a more viable currency for potential strategic acquisitions; and
(iv) preserve financial flexibility for our management to maximize the
long-term growth of shareholder value. In addition, the reorganization should
reestablish certain tax consolidation advantages for us.
Consummation of the transaction is subject to various conditions,
including approval by shareholders of Andrx and Cybear. In addition to
shareholder approval, the transaction will be subject to various Federal and
state regulatory approvals, and accordingly, no assurance can be given that
this transaction will be consummated. We and Cybear will file a joint proxy
statement and registration statement with respect to the proposed transaction.
COMPETITION
The pharmaceutical industry is highly competitive and is affected by new
technologies, new developments, government regulations, healthcare legislation,
availability of financing and other factors. Many of our competitors have
longer operating histories and greater financial, research and development,
marketing and other resources than us. We expect to be subject to competition
from numerous other entities that currently operate or intend to operate in the
pharmaceutical industry, including companies that are engaged in the
development of controlled-release drug delivery technologies and products, and
other manufacturers that may decide to undertake in-house development of these
products. In our pharmaceutical distribution business, we compete with a number
of large wholesalers and other distributors of pharmaceuticals. In our Cybear
subsidiary, competitors include online services or web sites, ISPs, publishers
and distributors of offline media, healthcare information companies and large
data processing and information companies. We cannot assure you that we will be
able to compete successfully with these companies.
PATENT LITIGATION AND PROPRIETARY RIGHTS
GENERAL
We believe that our future will depend in part on our ability to obtain
patents and trade secret protection, maintain trade secret protection and
operate without infringing the proprietary rights of others. We have been
issued numerous U.S. and foreign patents and notices of allowances relating to
our drug delivery technologies. In addition, we have filed additional U.S.
patent applications and various foreign patent applications relating to our
drug delivery technologies. We expect to apply for additional U.S. and foreign
patents in the future. The issuance of a patent is not conclusive as to its
validity or as to the enforceable scope of the claims of the patent. We depend
on our patents and trade secrets. Failure by us to protect our patent rights or
infringement by us of the patent or proprietary rights of others could have a
material adverse effect on our results of operations and financial position.
PATENT LITIGATION
There has been substantial litigation in the pharmaceutical, biomedical
and biotechnology industries with respect to the manufacture, use and sale of
new products that are the subject of patent rights. Most of the
42
<PAGE>
brand name controlled-release products for which we are developing
bioequivalent versions are covered by one or more patents. Under the
Waxman-Hatch Amendments, when a drug developer files an ANDA for a
bioequivalent drug, the developer must make a certification to the FDA as to
whether the developer believes that an unexpired patent which has been listed
with the FDA as covering the relevant brand-name product will be infringed by
the developer's product or is invalid or unenforceable. If the developer
believes that its product does not infringe the brand product's patents or that
the unexpired patent is invalid or unenforceable, it provides a Paragraph IV
Certification to the patent holder, who may then challenge the developer's
Paragraph IV Certification by filing a lawsuit for patent infringement. If a
lawsuit is filed within 45 days from the day the patent holder received the
Paragraph IV Certification, the FDA can review and tentatively approve the
ANDA, but cannot make the marketing approval effective until a judgment in the
action has been rendered in favor of the developer, 30 months from the date the
patent holder received the Paragraph IV Certification, or when the patent
expires, whichever is sooner. The outcome of such litigation is difficult to
predict because of the uncertainties inherent in patent litigation.
Numerous such actions have been filed against us. The Dilacor XR action
was dismissed without prejudice; the litigation relating to our bioequivalent
version of Cardizem CD was dismissed with prejudice; the trial court found in
our favor in the Tiazac litigation; and the other actions relating to our ANDAs
for bioequivalent versions of Prilosec, Wellbutrin SR and Zyban, Naprelan,
Depakote and Claritin D-24 are pending. We anticipate that additional actions
may be filed as we, ANCIRC, or our collaborative partners file additional ANDAs
containing Paragraph IV Certifications. Similar patent litigation may affect
NDAs that we file in the future. Our business could be harmed by the delay in
obtaining FDA approval to market our products as a result of litigation, the
expense of litigation whether or not we are successful, or an adverse outcome
in such litigation.
CARDIZEM CD LITIGATION AND THE STIPULATION
In September 1997, we entered into a stipulation in connection with the
patent infringement litigation brought against us by Aventis relating to the
sale of our bioequivalent version of Cardizem CD. In June 1999, the Aventis
litigation was resolved, the lawsuit was dismissed with prejudice and we
received the outstanding stipulation fees owed to us.
In May 1998, Biovail filed a claim against us alleging that the
stipulation violated Sections 1 and 2 of the Sherman-Antitrust Act and seeking
a declaratory judgment as to federal law as well as for alleged violations of
state common law of unfair competition, tortious interference with prospective
advantage and tortious interference with contract. Biovail sought injunctive
relief and treble the amount of its actual damages in an unspecified amount,
plus interest, with respect to its federal law claims, and actual and punitive
damages in unspecified amounts, plus interest, with respect to its common law
claims. In July 1998, we filed a motion to dismiss Biovail's claims. That
motion was granted with prejudice with respect to the federal antitrust claims
in January 2000. Biovail has both appealed that dismissal to the Court of
Appeals and also has requested that the District Court reconsider its
determination in light of certain facts that Biovail failed to provide the
court. These matters are still pending.
In March 2000, we received a letter from Purepac Pharmaceuticals Co., a
subsidiary of F.H. Faulding & Co., stating its belief that Cartia XT, our
bioequivalent version of Cardizem CD, infringed certain claims of a patent that
had been issued in its favor on March 7, 2000. The letter offered to license
that patent to us. On March 7, 2000, Purepac also filed an infringement suit
against us in the U.S. District Court for the Eastern District of Pennsylvania
regarding the same patent. Purepac seeks an injunction enjoining the sale of
Cartia XT, damages in an amount no less than a reasonable royalty, treble
damages for willful infringement and other relief. We responded to this claim
by denying infringement and by seeking a declaration that the patent is
invalid.
PRILOSEC LITIGATION
We made a Paragraph IV Certification in connection with the ANDA we filed
for our bioequivalent version of Prilosec. We believe that we were the first to
have our ANDA for this product accepted for filing
43
<PAGE>
by the FDA and that once final approval is received our product should be
entitled to the 180-day period of marketing exclusivity. In May 1998,
AstraZeneca filed suit against Andrx in the U.S. District Court for the
Southern District of Florida claiming patent infringement because of an ANDA
filed by Andrx with the FDA for a bioequivalent version of Prilosec. Andrx
responded to this claim by denying infringement, raising various other
defenses, filing certain counterclaims against AstraZeneca and by seeking a
declaration that there has been no infringement and that the patents are
invalid. AstraZeneca seeks an injunction enjoining Andrx from further
infringing the subject patents and an order directing that the effective date
of any FDA approval of Andrx' proposed bioequivalent version of Prilosec be no
earlier than the expiration date of its patents.
A second Paragraph IV Certification was made by Andrx with regard to a
different strength of Prilosec. This resulted in AstraZeneca filing another
suit in the U.S. District Court for the Southern District of Florida. Both of
these suits have been consolidated in the U.S. District Court for the Southern
District of New York, together with three other patent infringement suits
initiated by AstraZeneca involving ANDAs submitted by other companies for
bioequivalent versions of Prilosec. In May 2000, AstraZeneca filed two
additional patent infringement suits involving ANDAs submitted by other
companies for bioequivalent versions of Prilosec and is seeking to consolidate
these cases in the U.S. District Court for the Southern District of New York.
If these cases are consolidated, the ultimate resolution of Andrx's litigation
with AstraZeneca may be delayed.
TIAZAC LITIGATION
We made a Paragraph IV Certification in connection with the ANDA we filed
for our bioequivalent version of Tiazac. In October 1998, Biovail, Biovail
Laboratories Inc. and Galephar Puerto Rico, Inc., or the Biovail Group, filed
suit against Andrx in the U.S. District Court for the Southern District of
Florida claiming patent infringement because of the ANDA filed by Andrx with
the FDA for a bioequivalent version of Tiazac. Andrx responded to this claim by
denying infringement, raising various other defenses, filing certain
counterclaims against the Biovail Group and by seeking a declaration that there
has been no infringement and that the patent is invalid. The Biovail Group
sought an injunction enjoining Andrx from further infringing the subject patent
and an order directing that the effective date of any FDA approval of Andrx'
proposed bioequivalent version of Tiazac be no earlier than the expiration date
of the subject patent. In March 2000, the court entered an order that Andrx's
product does not infringe the Biovail patent. Biovail has filed a notice of
appeal of that order.
NAPRELAN LITIGATION
We made a Paragraph IV Certification in connection with the ANDA we filed
for our bioequivalent version of Naprelan. In October 1998, Elan filed suit
against Andrx in the U.S. District Court for the Southern District of Florida
claiming patent infringement because of the ANDA filed by Andrx with the FDA
for a bioequivalent version of Naprelan. Andrx responded to this claim by
denying infringement, raising various other defenses, filing certain
counterclaims against Elan and by seeking a declaration that there has been no
infringement and that the patent is invalid. Elan seeks a judgment enjoining
Andrx from further infringing the subject patent and ordering that the
effective date of any FDA approval of Andrx' proposed bioequivalent version of
Naprelan be no earlier than the expiration date of the patent.
WELLBUTRIN SR AND ZYBAN LITIGATION
We made Paragraph IV Certifications in connection with the ANDAs we filed
for our bioequivalent versions of Wellbutrin SR and Zyban. In September 1999,
Glaxo filed suit against Andrx in the U.S. District Court for the Southern
District of Florida claiming patent infringement because of the ANDAs filed by
Andrx with the FDA for bioequivalent versions of Wellbutrin SR and Zyban. Andrx
responded to this claim by denying infringement, raising various other
defenses, filing certain counterclaims against Glaxo and by seeking a
declaration that there has been no infringement and that the patent is invalid.
Glaxo seeks an injunction enjoining Andrx from further infringing the subject
patents and orders directing that the effective date of any FDA approval of
Andrx' proposed bioequivalent versions of Wellbutrin SR and Zyban be no earlier
that the expiration date of the subject patent.
44
<PAGE>
DEPAKOTE LITIGATION
We made a Paragraph IV certification relative to the ANDA we filed for our
bioequivalent version of Depakote. In March 2000, Abbott filed suit against
Andrx Corporation, Andrx Pharmaceuticals, Inc. and Andrx Pharmaceuticals L.L.C.
in the United States District Court for the Northern District Court of
Illinois, claiming infringement of two of its patents because of our filing the
aforementioned ANDA. Abbott seeks a judgment enjoing defendants from further
infringing the subject patents and ordering that the effective date of any FDA
approval of Andrx's proposed bioequivalent version of Depakote be no earlier
than the expiration dates of the two patents in suit. Following our filing of a
motion to dismiss for lack of jurisdiction, Abbott filed a second action
against the same defendants and for the same claims in the United States
District Court for the Southern District of Florida as well as a third action
against Andrx Pharmaceuticals L.L.C. for the same claims in the United States
District Court for the Eastern District of Virginia.
CLARITIN D-24 LITIGATION
We made a Paragraph IV Certification in connection with the ANDA we filed
for our bioequivalent version of Claritin D-24. In March 2000, Schering-Plough
filed suit against Andrx in the U.S. District Court for New Jersey claiming
patent infringement because of an ANDA filed by Andrx with the FDA for a
bioequivalent version of Claritin D-24.
While we believe our ANDA products do not infringe the patents that we
have been sued upon or that such patents are invalid and/or unenforceable, the
ultimate resolution of these patent litigation matters is not known and there
is no assurance our position will ultimately prevail.
GOVERNMENT REGULATION
Drug manufacturers are required to obtain FDA approval before marketing
their new drug product candidates. This approval process is often costly and
time consuming and we cannot assure you that any drug application will timely
be approved by the FDA or any other health authority, if at all.
ANDA PROCESS. FDA approval is required before a bioequivalent version of a
previously approved drug or a new dosage form of an existing drug can be
marketed. Approval is sought using an Abbreviated New Drug Application or ANDA.
Complete clinical studies are not required in support of an ANDA, although
typically bioavailability and bioequivalence studies must be conducted.
Bioavailability indicates the rate and extent of absorption and levels of
concentration of a drug product in the blood stream. Bioequivalence compares
the bioavailability of one drug product with another, and when established,
indicates that the rate of absorption and levels of concentration of a generic
drug in the body are substantially equivalent to the previously approved drug.
An ANDA may be submitted for a drug on the basis that it is the equivalent to a
previously approved drug or, in the case of a new dosage form, is suitable for
use for the indications specified.
Under the Waxman-Hatch Amendments, the developer of a bioequivalent drug
which is the first to have its ANDA accepted for filing by the FDA and includes
a Paragraph IV Certification is awarded a 180-day period of marketing
exclusivity. This means that the FDA may not approve another ANDA containing a
Paragraph IV Certification for that product until the first developer's 180-day
period of marketing exclusivity has expired or has been waived. This marketing
exclusivity period begins with the commercial marketing of the product or a
court determination that the relevant patents are invalid, unenforceable or not
infringed. Also, a court decision triggering the 180-day period can occur
either in litigation involving the first Paragraph IV filer or a subsequent
filer.
Until recently, the FDA has interpreted the reference in the statute to a
court determination to mean a court determination which is final and
non-appealable. This interpretation was challenged in litigation in which the
courts disagreed with the FDA's interpretation. Prompted in part by those
decisions, the FDA issued guidelines in March 2000 in which it announced a
change in its interpretation of the statute for ANDAs and the publication of
the guidelines. The new guidelines state that the FDA now will view a court
decision to be
45
<PAGE>
the first court decision which finds a patent at issue to be invalid,
unenforceable or not infringed. The FDA stated that when a lower court renders
such a decision, the FDA may approve an ANDA as of the date of that decision
and the 180-day exclusivity period will commence on that date, unless the
marketing of the product has already commenced. If the lower court decision
finds the patent is infringed, but the decision is reversed on appeal, the FDA
may approve the ANDA on the date a judgment is entered that the patent is
invalid, unenforceable or not infringed. The FDA stated that neither a stay or
a reversal of a district court decision finding the patent invalid,
unenforceable or not infringed will have an effect on the approval of an ANDA
or on the beginning, or continued running, of the exclusivity period.
The FDA's new interpretation of the statute may substantially decrease the
value of the 180-day exclusivity period. A patent holder whose patent is found
invalid, unenforceable or not infringed in a lower court decision may seek to
reverse such a ruling on appeal. Under the new FDA interpretation, even if such
an appeal is taken, however, the 180-day period would start once the lower
court rendered its decision. The developer of the product for which the
relevant ANDA was approved would thus be faced with the prospect of beginning
marketing of its product despite the pending appeal and lack of final
resolution of the litigated issue or delaying marketing at a time when under
the FDA's new interpretation the 180-day exclusivity period had started. A
decision to delay marketing of the product following a lower court decision
which is subject to an appeal would mean that the developer of the product
would have less than 180 days, and possibly no days, in which it was the
exclusive marketer of that bioequivalent product.
We are unable to predict what impact, if any, the FDA's new guidelines may
have on our business or financial results.
NDA PROCESS. FDA approval is required before any new drug can be marketed.
A New Drug Application or NDA is a filing submitted to the FDA to obtain
approval of a drug not eligible for an ANDA and must contain complete
pre-clinical and clinical safety and efficacy data or a reference to such data.
Before clinical testing can begin, stringent government requirements for
pre-clinical data must be satisfied. The pre-clinical data must provide an
adequate basis for evaluating both the safety and the scientific rationale for
the initiation of clinical trials.
Clinical trials are typically conducted in three sequential phases,
although the phases may overlap. The process of completing clinical trials for
a new drug may take several years and requires the expenditure of substantial
resources. Preparing a NDA involves considerable data collection, verification,
analysis and expense, and we cannot guarantee that the FDA or any other health
authority will approve any of our products on a timely basis, if at all. The
approval process is affected by a number of factors, primarily the risks and
benefits demonstrated in clinical trials as well as the severity of the disease
and the availability of alternative treatments. The FDA or other health
authorities may deny a NDA if the regulatory criteria are not satisfied, or may
require additional testing or information before that NDA is approved.
We believe that the FDA's ANDA procedures will apply to our bioequivalent
versions of controlled-release drugs. We cannot assure you that our
bioequivalence studies and other data will result in FDA approval to market our
drug products. Certain ANDA procedures for bioequivalent controlled-release
drugs and other products are presently the subject of petitions filed by brand
name drug manufacturers, which seek changes from the FDA in the approval
process for bioequivalent drugs. We cannot predict at this time whether the FDA
will make any changes to the ANDA procedures as a result of such petitions,
ongoing rulemakings, or litigation or the effect that such changes may have on
us. Any changes in FDA regulations or policies may make ANDA approvals more
difficult and, thus, may have a material adverse effect on our business.
Patent certification requirements for bioequivalent controlled-release
drugs could also result in significant delays in obtaining FDA approval if
patent infringement litigation is initiated by the holder or holders of the
brand name patents. Delays in obtaining FDA approval of ANDAs and certain NDAs
can also result from a marketing exclusivity period and/or an extension of
patent terms. If some of our drugs do not qualify for ANDA procedures, as will
be the case with certain of our controlled-release formulations, the FDA
approval process may require time consuming and expensive clinical studies and
NDA filings.
The FDA also regulates the development, manufacture, distribution,
labeling and promotion of prescription drugs. It requires that certain records
be kept and reports be made, mandates registration of drug
46
<PAGE>
manufacturers and their products and has the authority to inspect manufacturing
facilities for compliance with cGMP standards. As a distributor of
bioequivalent pharmaceuticals manufactured by third parties, we are subject to
state licensure and other requirements pertaining to the wholesale distribution
of prescription drugs. We could be materially adversely affected by any failure
to comply with licensing and other requirements. Other requirements exist for
controlled drugs, such as narcotics, which are regulated by the DEA.
Finally, the FDA has the authority to withdraw approvals of previously
approved drugs for cause, to request recalls of products, to debar companies
and individuals from future regulatory submissions and, through action in
court, to seize products, institute criminal prosecution or close manufacturing
plants in response to violations. The DEA has similar authority. We could be
materially adversely affected by any such FDA, DEA or comparable state
regulatory agencies' actions.
PRODUCT LIABILITY INSURANCE
The design, development and manufacture of our products or the products we
distribute involve a risk of product liability claims. We have obtained product
liability insurance that covers substantially all products marketed by our drug
distribution operations, in bioequivalence and other studies for our
controlled-release product candidates and for the products we intend to
commercialize. We believe that our product liability insurance is adequate for
our current operations, but may seek to increase our coverage prior to the
commercial introduction of our product candidates. We cannot give assurance
that the coverage limits of our insurance will be sufficient to cover potential
claims. Product liability insurance is expensive and difficult to obtain and
may not be available in the future on acceptable terms or in sufficient
amounts, if available at all. We could be harmed by a successful claim against
us in excess of our insurance coverage.
LEGAL PROCEEDINGS
In addition to the previously described litigation, commencing in August
1998, putative class and individual actions have been filed against Andrx in
Alabama, California, Florida, Illinois, Kansas, Michigan, Minnesota, New York,
Tennessee, Wisconsin, North Carolina and the District of Columbia. The actions
pending in federal court have been consolidated for multi-district litigation
purposes in the U.S. District Court for the Eastern District of Michigan. In
all of these suits Aventis has been named as a co-defendant. The complaint in
each action alleges that Andrx and Aventis, by way of the stipulation, have
engaged in alleged state antitrust and other statutory and common law
violations that allegedly have given Aventis and Andrx a near monopoly in the
U.S. market for Cardizem CD and a bioequivalent version of that pharmaceutical
product. According to the complaints, the monopoly possessed by the defendants
enables Aventis to perpetuate its ability to fix the price of Cardizem CD at an
artificially high price, free from bioequivalent competition, with the result
that direct purchasers such as pharmacies, as well as indirect purchasers such
as medical patients who have been issued prescriptions for Cardizem CD are
forced to overpay for the drug. Each complaint seeks compensatory damages on
behalf of each class member in an unspecified amount and, in some cases, treble
damages, as well as costs and counsel fees, disgorgement, injunctive relief and
other remedies. We are unable to predict the outcome of the litigation,
although we believe that these actions have no merit and we intend to mount a
vigorous defense against each action.
On May 11, 2000, the United States District Court for the Eastern District
of Michigan denied our and Aventis' motions to dismiss the consolidated class
action and other complaints pending before this court, which is handling the
multi-district litigation challenging the stipulation. The motions to dismiss
were premised upon legal arguments as to why the causes of action asserted by
the various claimants are legally inadequate. In denying the motions, the court
was required to assume the truth of the claimants' factual allegations and
rejected our view of certain aspects of state and federal law upon which our
defenses are
47
<PAGE>
premised. We and Aventis will now be required to continue to submit to
discovery and make a substantive response to the factual allegations of each of
the consolidated complaints. The court's interpretation of the applicable law,
with which we disagree, may make our defense of the allegations more difficult.
On March 16, 2000, we were named as a respondent by the FTC in an
administrative action seeking a cease and desist order against future
agreements similar to the stipulation and other remedies. The FTC is not
seeking any fines, penalties, disgorgement or any other monetary remedy in the
administrative proceeding. Contrary to the FTC's position, we believe that the
stipulation was pro-competitive and benefited consumers and intend to
vigorously defend our position before the administrative law judge.
In January 1999, Andrx and our bioequivalent pharmaceutical distribution
subsidiary, Anda, Inc., a Florida corporation, were served with third party
complaints filed against them by certain doctors and distributors who are
defendants in various legal actions relating to the sale of phentermine by Anda
and its usage as a diet drug when taken in combination with fenfluramine,
commonly known as "phen-fen". The substance of the third party complaints is
that the defendants are without fault with respect to the claims in those
actions but, if they are found liable on any of those claims, then allegedly
having obtained one or more of the drugs from Anda, they are entitled to
indemnification in an amount to pay and discharge any judgment entered against
them in the putative class action together with costs, expenses and attorney
fees. We and Anda have never sold fenfluramine and believe that these claims
are without merit.
In November 1999, another phen-fen diet lawsuit was filed against Anda in
the Superior Court of New Jersey by a husband, who claims to have obtained or
purchased, either directly or indirectly, from Anda and others, and thereafter
ingested, phentermine, dexfenfluramine and fenfluramine, causing serious
medical consequences, all to his financial detriment, and his wife, who, on
behalf of herself and her two children, claims monetary damages arising from
emotional distress to herself and her children, loss of spousal/paternal
companionship and expenditure of money, time and care for her husband required
by her husband's alleged injuries which are permanent and continuous in nature.
Anda has never sold dexfenfluramine or fenfluramine and believes that these
claims, including any based solely on the use of phentermine, have no merit.
Other than the patent litigation matters and the above described
litigation, we are not party to a legal proceeding wherein an adverse outcome
would have a material adverse effect on our results of operations, financial
condition or business.
PROPERTIES
We lease approximately 97,000 square feet in a facility in Fort
Lauderdale, Florida, which houses a portion of our executive offices,
warehousing and shipping facilities, a laboratory and pilot manufacturing plant
and a commercial-scale manufacturing facility. The buildings are occupied
pursuant to leases expiring May 31, 2003 at a current total annual rent of
approximately $800,000. Each of the leases affords us five five-year renewal
options, and requires us to pay certain increases in common area costs.
We purchased a 15-acre tract of land in Fort Lauderdale adjacent to our
existing facilities. On this parcel, we are building approximately 160,000
square feet of office, warehouse and manufacturing space sufficient to expand
those portions of the existing square foot facility which are being used for
purposes other than research, product development and manufacturing. We expect
to occupy this facility in mid-2000.
In April 1999, we entered into a one-year lease for an additional 18,000
square feet of warehouse space, at an annual rent of approximately $200,000.
This lease has been renewed for an additional year, as we intend to continue to
use this facility until the new building has been completed and is available
for its intended use.
We lease a 152,000 square foot facility in Weston, Florida, for our
distribution operations and a portion of our executive offices. This lease has
a ten year term expiring in 2009, with two five year renewal options, at an
initial annual rental of approximately $1.4 million.
We also occupy a 2,900 square foot facility in Hackensack, New Jersey, for
our clinical development operations, pursuant to a five year lease expiring
August 2003 at an initial annual rental of approximately $70,000.
We lease a 56,000 square foot facility in Somerset, New Jersey pursuant to
a five year lease expiring in March 2005, with two five year renewal options,
at an initial annual rental of approximately $310,000.
Cybear currently leases 37,600 square feet in Boca Raton, Florida housing
its corporate headquarters and network systems. The lease, which expires in
March 2007, provides for annual rent of $490,000, excluding taxes, insurance,
utilities and common area maintenance charges.
48
<PAGE>
In connection with the Valmed transaction, we acquired an 11,000 square
foot facility in Grand Island, New York for distribution operations.
PERSONNEL
As of May 17, 2000, we had 863 employees, of whom 28 were involved in
corporate administration, 447 were involved in our distribution operations and
110 were involved in Cybear's Internet operation. The remaining 278 employees
were involved in research, pharmaceutical development and manufacturing,
including over 40 scientists, many of whom hold Ph.D., masters or medical
degrees.
49
<PAGE>
MANAGEMENT
Set forth below is certain information concerning the directors and
executive officers:
<TABLE>
<CAPTION>
NAME AGE POSITION
- ---------------------------------------- ----- ---------------------------------------------------
<S> <C> <C>
Alan P. Cohen(1) ....................... 45 Co-Chairman, Chief Executive Officer and Director
Chih-Ming J. Chen, Ph.D.(1) ............ 48 Co-Chairman, Chief Scientific Officer and Director
Elliot F. Hahn, Ph.D.(1) ............... 55 President and Director
Scott Lodin ............................ 44 Vice President, General Counsel and Secretary
Angelo C. Malahias ..................... 38 Vice President and Chief Financial Officer
Melvin Sharoky, M.D.(2) ................ 49 Executive Director and Director
Lawrence J. DuBow(2) ................... 68 Director
Irwin C. Gerson(2)(3) .................. 70 Director
Michael A. Schwartz, Ph.D.(3) .......... 69 Director
</TABLE>
- ----------------
(1) Member of Executive Committee.
(2) Member of Audit Committee.
(3) Member of Compensation Committee.
ALAN P. COHEN is Co-Chairman of the Board, Chief Executive Officer and a
director of Andrx, which he founded in August 1992. Mr. Cohen was the Chairman
and a director of Cybear from February 1997 through August 1998, when he
resigned as Chairman. He remains a director of Cybear. He is a graduate of the
University of Florida and is a registered pharmacist. In 1984, Mr. Cohen
founded Best Generics, Inc., a bioequivalent drug distribution firm ("Best"),
which was sold to IVAX Corporation ("IVAX") in 1988. Mr. Cohen served as
President of Best from April 1989 until June 1990.
DR. CHIH-MING J. CHEN has been Co-Chairman since November 1998 and the
Chief Scientific Officer and a director since November 1992. In January 1992,
Dr. Chen formed his own company, ASAN Labs, Inc., which was acquired by Andrx
in November 1992. Dr. Chen served as the Director of Product Development at
IVAX from 1988 to 1992, where he was the leader of a research team which
specialized in the development of drug formulations, including several
controlled-release products. After graduating with a Ph.D. degree in
pharmaceutics from Ohio State University in 1981, Dr. Chen worked at
Bristol-Myers and Berlex Labs.
DR. ELLIOT F. HAHN has been President and a director of Andrx since
February 1993. From June 1990 to February 1993, Dr. Hahn was employed as Vice
President, Scientific Affairs of IVAX, where he was involved in the evaluation
and international licensing of product opportunities and was responsible for
maintaining the intellectual property of IVAX. From 1988 to 1993, Dr. Hahn also
served as the Vice President of Research of Baker Norton Pharmaceuticals, a
subsidiary of IVAX. Prior to that, he was an Associate Professor at The
Rockefeller University from 1977 to 1988. From 1972 until 1977, Dr. Hahn was an
Assistant Professor at Albert Einstein College of Medicine and a member of the
Institute for Steroid Research at Montefiore Hospital in New York City. Since
1988, he has been an adjunct Associate Professor at the University of Miami
School of Medicine. Dr. Hahn holds a B.S. degree from City College of New York
and a Ph.D. degree in chemistry from Cornell University. Dr. Hahn also serves
as a director of Chesapeake Biological Laboratories, Inc. and Delta
Pharmaceuticals, Inc.
SCOTT LODIN joined Andrx in January 1994 and is its Vice President,
General Counsel and Secretary. Mr. Lodin has also been the Secretary and a
director of Cybear since February 1997. Prior to joining Andrx, Mr. Lodin was
Special Counsel to Hughes, Hubbard & Reed and a predecessor firm in Miami,
Florida, where he practiced primarily in the areas of corporate and commercial
law.
ANGELO C. MALAHIAS joined Andrx as its Vice President and Chief Financial
Officer in January 1996. Mr. Malahias has also been a director of Cybear since
April 1999. From January 1995 to January 1996, Mr. Malahias was Vice President
and Chief Financial Officer of Circa, where he also served as Corporate
Controller from July 1994 to January 1995. From 1983 to July 1994 he was
employed by KPMG LLP. Mr. Malahias is a certified public accountant.
DR. MELVIN SHAROKY, a director of Andrx since November 1995, joined Andrx
as Executive Director on March 1, 1999. Dr. Sharoky has also been a director of
Cybear since April 1999. Dr. Sharoky is also president
50
<PAGE>
of Somerset Pharmaceuticals Inc., 50% owned by Watson. Dr. Sharoky was a
director of Watson from July 1995 to May 1998. From July 1995 through January
1998, Dr. Sharoky was President of Watson. From February 1993 through January
1998, Dr. Sharoky served as the President and Chief Executive Officer of Circa.
From November 1995 to May 1998, Dr. Sharoky served on Andrx' Board of Directors
as the designee of Watson.
LAWRENCE J. DUBOW, a director of Andrx since April 2000, has been Chairman
and Chief Executive Officer of HMS Sales and Marketing Inc., which is presently
engaged in marketing pharmaceutical products, since he founded it in 1991.
Since 1957, he has been engaged in various capacities within the pharmaceutical
industry. Mr. DuBow was the former President of the Drug Wholesalers'
Association and a former Chairman of the National Wholesale Druggists'
Association.
IRWIN C. GERSON, a director of Andrx since November 1993 was the Chairman
of the Lowe McAdams Healthcare division of the Interpublic Group (formerly
William Douglas McAdams, Inc.), a healthcare marketing, communications and
public relations company, from 1987 through January 1998. Mr. Gerson is a
member of the board of trustees of academic institutions, including Long Island
University, Albany College of Pharmacy and is Chairman of the Council of
Overseers of the Arnold and Marie Schwartz College of Pharmacy. Mr. Gerson is
also a director of Cytoclonal Pharmaceutics, Inc., a biotechnology company.
DR. MICHAEL A. SCHWARTZ, a director of Andrx since November 1993, is
currently Dean Emeritus and a Professor at the College of Pharmacy at the
University of Florida having served as Dean of that college from April 1978
through May 1996.
Our Articles provide that the Board of Directors is divided into three
classes and directors serve staggered three-year terms. Dr. Chih-Ming J. Chen,
Irwin C. Gerson and Dr. Michael A. Schwartz will hold office until the 2000
annual meeting. Dr. Elliot F. Hahn and Lawrence J. DuBow will hold office until
the 2001 annual meeting. Alan P. Cohen and Dr. Melvin Sharoky will hold office
until the 2002 annual meeting.
51
<PAGE>
SELLING SHAREHOLDERS
The following table sets forth certain information regarding the beneficial
ownership of the common stock by the selling shareholders as of May 19, 2000
adjusted to reflect the sale of 5,185,128 shares offered hereby by us and
1,164,872 shares offered hereby by a selling shareholder. Some selling
shareholders will only offer to sell shares of common stock subject to the
underwriters' over-allotment option to purchase up to an additional 952,500
shares of common stock. See note (1) to the following table. The underwriters
may exercise this option in full or in part, but the underwriters are not
required to exercise the option at all. The following table does not give effect
to any exercise of the over-allotment option.
<TABLE>
<CAPTION>
BENEFICIAL OWNERSHIP BENEFICIAL OWNERSHIP
PRIOR TO OFFERING AFTER OFFERING
----------------------- SHARES TO ----------------------
NAME SHARES PERCENT BE SOLD SHARES PERCENT
- ----------------------------------------- ----------- --------- ----------- ----------- --------
<S> <C> <C> <C> <C> <C>
Watson Pharmaceuticals, Inc.............. 5,763,476 9.1% 1,164,872 4,598,604 6.7%
Alan P. Cohen(1)(2) ..................... 5,940,888 9.3 -- 4,940,888 8.6
Chih-Ming J. Chen, Ph.D.(1)(3) .......... 6,450,804 10.0 -- 6,450,804 9.3
Elliot F. Hahn, Ph.D.(1)(4) ............. 1,757,780 2.7 -- 1,757,780 2.6
Scott Lodin(1)(5) ....................... 190,000 * -- 190,000 *
Angelo C. Malahias(1)(6) ................ 118,200 * -- 118,200 *
</TABLE>
- ----------------
* Less than 1%
(1) If the underwriters' overallotment option is exercised in full, Mr. Cohen
will sell 358,000 shares of common stock, Dr. Chen will sell 358,000
shares of common stock, Dr. Hahn will sell 179,000 shares of common stock,
Mr. Lodin will sell 45,000 shares of common stock and Mr. Malahias will
sell 12,500 shares of common stock.
(2) Represents 17,500 shares of common stock held jointly by Mr. Cohen and his
spouse, 5,873,388 shares held in family limited partnerships and 50,000
shares of common stock issuable upon the exercise of stock options.
(3) Represents 48,242 shares of common stock owned by Dr. Chen, 5,530,772
shares of common stock held by limited partnerships for which Dr. Chen is
an officer of the corporate general partner, 4,790 shares held by a
charitable family foundation, 850,000 shares of common stock issuable upon
the exercise of stock options, and 17,000 shares of common stock issuable
upon exercise of options held by Dr. Chen's spouse.
(4) Represents 1,707,780 shares of common stock held in family trusts and a
family limited partnership and 50,000 shares of common stock issuable upon
the exercise of stock options.
(5) Represents 190,000 shares of common stock issuable upon the exercise of
stock options.
(6) Represents 115,000 shares of common stock issuable upon the exercise of
stock options and 3,200 shares of common stock held as custodian for his
minor children.
52
<PAGE>
DESCRIPTION OF CAPITAL STOCK
Our authorized capital stock consists of (1) 100,000,000 shares of common
stock, par value $.001 per share, 68,840,890 shares of which will be
outstanding (assuming no exercise of options and warrants) upon completion of
this offering and (2) 1,000,000 shares of preferred stock, par value $.001 per
share, none of which are outstanding.
COMMON STOCK
Subject to the rights of the holders of any preferred stock that may be
outstanding, each holder of common stock on the applicable record date is
entitled to receive such dividends as may be declared by the Board of Directors
out of funds legally available therefor, and, in the event of liquidation, to
share pro rata in any distribution of our assets after payment or providing for
the payment of liabilities and the liquidation preference of any outstanding
preferred stock. Each holder of common stock is entitled to one vote for each
share held of record on the applicable record date on all matters presented to
a vote of shareholders, including the election of directors. Holders of common
stock have no cumulative voting rights or preemptive rights to purchase or
subscribe for any stock or other securities, and there are no conversion rights
or redemption or sinking fund provisions with respect to such stock. All
outstanding shares of common stock are, and the shares of common stock offered
hereby will be when issued, fully paid and nonassessable.
PREFERRED STOCK
Our Board of Directors has the authority to issue 1,000,000 shares of
preferred stock in one or more series and to fix, by resolution, conditional,
full, limited or no voting powers, and such designations, preferences and
relative, participating, optional or other special rights, if any, and the
qualifications, limitations or restrictions thereof, if any, including the
number of shares in such series (which the Board may increase or decrease as
permitted by Florida law), liquidation preferences, dividend rates, conversion
or exchange rights, redemption provisions of the shares constituting any series
and such other special rights and protective provisions with respect to any
class or series as the Board may deem advisable without any further vote or
action by the shareholders. Any shares of preferred stock so issued could have
priority over the common stock with respect to dividend or liquidation rights
or both and could have voting and other rights of shareholders. We have no
present plans to issue shares of preferred stock.
ANTI-TAKEOVER LEGISLATION
Florida has enacted legislation that may deter or hinder takeovers of
Florida corporations. The Florida Control Share Act generally provides that
shares acquired in a "control share acquisition" will not possess any voting
rights unless such voting rights are approved by a majority of the
corporation's disinterested shareholders. A "control share acquisition" is an
acquisition, directly or indirectly, by any person of ownership of, or the
power to direct the exercise of voting power with respect to, issued and
outstanding "control shares" of a publicly held Florida corporation. "Control
shares" are shares, which, except for the Florida Control Share Act, would have
voting power that, when added to all other shares owned by a person or in
respect to which such person may exercise or direct the exercise of voting
power, would entitle such person, immediately after acquisition of such shares,
directly or indirectly, alone or as a part of a group, to exercise or direct
the exercise of voting power in the election of directors within any of the
following ranges: (1) at least 20% but less than 331/3% of all voting power;
(2) at least 331/3% but less than a majority of all voting power; or (3) a
majority or more of all voting power. The Florida Affiliated Transactions Act
generally requires supermajority approval by disinterested shareholders of
certain specified transactions between a public corporation and holders of more
than 10% of the outstanding voting shares of the corporation (or their
affiliates). Florida law and our Articles and Bylaws also authorize Andrx to
indemnify our directors, officers, employees and agents. In addition, our
Articles and Florida law presently limit the personal liability of corporate
directors for monetary damages, except where the directors (1) breach their
fiduciary duties, and (2) such breach constitutes or includes certain
violations of criminal law, a transaction from which the directors derived an
improper personal benefit, certain unlawful distributions or certain other
reckless, wanton or willful acts or misconduct.
53
<PAGE>
Upon completion of the plan of reorganization, Andrx will be incorporated
in the State of Delaware and will be subject to the provisions of Section 203
of the Delaware General Corporation Law, an anti-takeover law. In general, the
statute prohibits a publicly-held Delaware corporation from engaging in a
"business combination" with an "interested stockholder" for a period of three
years after the date of the transaction in which the person became an
interested stockholder, unless the business combination is approved in a
prescribed manner. A "business combination" includes a merger, asset sale or
other transaction resulting in a financial benefit to the stockholder. An
"interested stockholder" is a person who, together with affiliates and
associates, owns or within three years prior to the proposed business
combination, did own 15% or more of the corporation's voting stock.
ANTI-TAKEOVER EFFECTS OF CERTAIN PROVISIONS OF OUR ARTICLES OF INCORPORATION
AND BYLAWS
Certain provisions of our Articles and Bylaws may be deemed to have an
anti-takeover effect and may delay, defer or prevent a tender offer or takeover
attempt, including attempts that might result in a premium being paid over the
market price for the shares held by shareholders. The following provisions may
not be amended in our Articles or Bylaws without the affirmative vote of the
holders of two-thirds of the outstanding shares of common stock.
CLASSIFIED BOARD OF DIRECTORS. The Articles and Bylaws provide for the
Board of Directors to be divided into three classes serving staggered terms. As
a result, approximately one-third of the Board of Directors will be elected
each year. The Articles and Bylaws also provide that directors may only be
removed for cause and only upon the affirmative vote of the holders of at least
two-thirds of the outstanding shares of capital stock entitled to vote. These
provisions, when coupled with the provision of the Articles and Bylaws
authorizing only the Board of Directors to fill vacant directorships or
increase the size of the Board, may deter a shareholder from removing incumbent
directors and simultaneously gaining control of the Board of Directors by
filling the vacancies created by such removal with its own nominees.
SPECIAL MEETING OF SHAREHOLDERS, PROHIBITION OF ACTION BY UNANIMOUS
CONSENT. The Articles and Bylaws prohibit the taking of shareholder action by
written consent without a meeting and provide that special meetings of
shareholders be called only by a majority of the Board of Directors, our Chief
Executive Officer or holders of not less than one-third of our outstanding
voting stock.
ADVANCE NOTICE REQUIREMENTS FOR SHAREHOLDER PROPOSALS AND DIRECTOR
NOMINATIONS. The Bylaws provide that shareholders seeking to bring business
before an annual meeting of shareholders, or to nominate candidates for
election as directors at an annual or special meeting of shareholders, must
provide timely notice thereof in writing. To be timely, a shareholder's notice
must be delivered to or mailed and received at Andrx' principal executive
offices not less than 60 days nor more than 90 days prior to the meeting;
provided, however, that in the event that less than 70 days' notice or prior
public disclosure of the date of the meeting is given or made to shareholders,
notice by the shareholder, to be timely, must be received no later than the
close of business on the 10th day following the day on which such notice of the
date of the meeting was mailed or such public disclosure was made, whichever is
first. The Bylaws also specify certain requirements as to the content and form
of a shareholder's notice. These provisions may preclude shareholders from
bringing matters before the shareholders at an annual or special meeting or
from making nominations for directors at an annual or special meeting.
AMENDMENT OF BYLAWS. Except for the provisions identified above requiring
a two-thirds vote of the outstanding shares to alter, amend or repeal, the
Bylaws may only be altered, amended or repealed by the Board or the affirmative
vote of the holders of at least a majority of our outstanding shares of capital
stock.
TRANSFER AGENT
The transfer agent for the common stock is American Stock Transfer & Trust
Company, New York, New York.
54
<PAGE>
SHARES ELIGIBLE FOR FUTURE SALE
Upon completion of this offering, we will have 68,840,890 shares of common
stock outstanding. Of these shares, 55,450,474 shares will be freely tradable
without restriction under the Securities Act, except for such shares which may
be acquired by an "affiliate" of Andrx as that term is defined in Rule 144
under the Securities Act, which shares generally may be sold publicly without
registration under the Securities Act only in compliance with Rule 144.
In general, under Rule 144 as currently in effect, if a period of at least
one year has elapsed since the later of the date the "restricted shares" (as
that phrase is defined in Rule 144) were acquired from us and the date they
were acquired from an affiliate, then the holder of such restricted shares
(including an affiliate) is entitled to sell a number of shares within any
three-month period that does not exceed the greater of 1% of the then
outstanding shares of the common stock or the average weekly reported volume of
trading of the common stock on the Nasdaq National Market during the four
calendar weeks preceding such sale. The holder may only sell such shares
through unsolicited brokers' transactions or directly to market makers. Sales
under Rule 144 are also subject to certain requirements pertaining to the
manner of such sales, notices of such sales and the availability of current
public information concerning us. An affiliate may sell shares not constituting
restricted shares in accordance with the foregoing volume limitations and other
requirements but without regard to the one-year holding period.
Under Rule 144(k), if a period of at least two years has elapsed between
the later of the date restricted shares were acquired from us and the date they
were acquired from an affiliate, as applicable, a holder of such restricted
shares who is not an affiliate at the time of the sale and has not been an
affiliate for at least three months prior to the sale would be entitled to sell
the shares immediately without regard to the volume limitations and other
conditions described above.
Andrx and each of the directors and executive officers have agreed that
they will not sell or otherwise dispose of any shares of common stock for a
period of 90 days after the date of this prospectus as described more fully in
"Underwriting."
As of the date of this prospectus, options and warrants to purchase
5,498,800 shares of common stock are issued and outstanding.
We can make no predictions as to the effect, if any, that sales of shares
or the availability of shares for sale will have on the market price prevailing
from time to time. Nevertheless, sales of significant amounts of the common
stock in the public market, or the perception that such sales may occur, could
adversely affect prevailing market prices.
55
<PAGE>
UNDERWRITING
The underwriters named below have severally agreed, subject to the terms
and conditions set forth in an underwriting agreement among the underwriters,
Andrx and the selling shareholders, to purchase the number of shares of common
stock indicated below opposite their respective names at the public offering
price less the discounts and commissions to underwriters set forth on the cover
page of this prospectus. The underwriting agreement provides that the
obligations of the underwriters are subject to certain conditions precedent,
and that the underwriters are committed to purchase all of shares of common
stock if any are purchased.
<TABLE>
<CAPTION>
UNDERWRITER NUMBER OF SHARES
- ----------------------------------------- -----------------
<S> <C>
Banc of America Securities LLC .............. 1,768,000
Bear, Stearns & Co. Inc. .................... 1,768,000
CIBC World Markets Corp. .................... 952,000
UBS Warburg LLC ............................. 952,000
Credit Suisse First Boston Corporation....... 130,000
First Union Securities, Inc.................. 130,000
U.S. Bancorp Piper Jaffray Inc............... 130,000
Salomon Smith Barney Inc..................... 130,000
Wasserstein Perella Securities, Inc.......... 130,000
The Buckingham Research Group Incorporated... 65,000
Gruntal & Co., L.l.c......................... 65,000
Ladenburg Thalmann & Co. Inc................. 65,000
Sanders Morris Harris........................ 65,000
---------
Total ..................................... 6,350,000
=========
</TABLE>
The managing underwriters are Banc of America Securities LLC, Bear, Stearns
& Co. Inc., CIBC World Markets Corp. and UBS Warburg LLC. The underwriters have
advised us that the underwriters propose initially to offer the common stock to
the public on the terms set forth on the cover page of this prospectus. The
underwriters may allow to selected dealers a concession of not more than $1.37
per share of common stock, and the underwriters may allow, and such dealers may
reallow, a concession of not more than $.10 per share of common stock to
certain other dealers. After the offering, the offering price and other selling
terms may be changed by the underwriters. The common stock is being offered
subject to receipt and acceptance by the underwriters, and to certain other
conditions, including the right to reject an order in whole or in part. The
underwriters may offer the common stock through a selling group.
The underwriters have been granted an option by some of the selling
shareholders, exercisable during the 30-day period after the date of this
prospectus, to purchase up to a maximum of 952,500 shares of common stock to
cover over-allotments, if any, at the same price as the 6,350,000 shares of
common stock to be purchased by the underwriters. To the extent that the
underwriters exercise this option, each of the underwriters will be committed,
subject to certain conditions, to purchase such additional common stock in
approximately the same proportion as set forth in the table above. The
underwriters may purchase such common stock only to cover over-allotments made
in connection with the offering.
The underwriting agreement provides that Andrx will indemnify the
underwriters and their controlling persons against certain liabilities,
including civil liabilities under the Securities Act of 1933, or will
contribute to payments the underwriters may be required to make in respect
thereof.
One or more of the underwriters may facilitate the marketing of this
offering online, either directly or through one or more of their affiliates. In
those cases, prospective investors may view offering terms and a prospectus
online and, depending upon the particular underwriter, place orders online or
through their financial advisors.
Certain of the underwriters and their affiliates have engaged in, and may
engage in, transactions with, have performed, and may perform, services for, or
have owned, currently own or may own, equity or equity-like securities of Andrx
or its subsidiaries in the ordinary course of their businesses.
The directors and executive officers of Andrx have agreed that they will
not, without the prior written consent of Banc of America Securities LLC and
Bear, Stearns & Co. Inc. (which consent may be withheld in their sole
discretion), directly or indirectly, sell, offer, contract or grant any option
to sell (including, without
56
<PAGE>
limitation, any short sale), pledge, transfer, establish an open "put
equivalent position" within the meaning of Rule 16a-1(h) under the Securities
Exchange Act of 1934 or otherwise dispose of any shares of common stock and
warrants owned either of record or beneficially by them, or publicly announce
the intention to do any of the foregoing, for a period commencing on the date
of this prospectus and continuing through the close of trading on the date 90
days after such date. Banc of America Securities LLC and Bear, Stearns & Co.
Inc. may, in their sole discretion and at any time without notice, release all
or any portion of the securities subject to those lock-up agreements. In
addition, Andrx has agreed that for a period of 90 days after the date of this
prospectus, it will not, without the prior written consent of Banc of America
Securities LLC and Bear, Stearns & Co. Inc. (which consent may be withheld in
their sole discretion), directly or indirectly, issue, sell, offer, contract or
grant any option to sell, pledge, transfer or establish an open "put equivalent
position" within the meaning of Rule 16a-1(h), or otherwise dispose of or
transfer, or announce the offering of, or file any registration statement under
the Securities Act of 1933 in respect of, any shares of common stock, options
or warrants to acquire shares of common stock or securities exchangeable or
exercisable for or convertible into shares of common stock or any securities
substantially similar to the common stock (except the common stock offered
hereby), subject to some exceptions, including granting of options and sales of
shares under existing option plans.
Until the distribution of the common stock is completed, rules of the
Securities and Exchange Commission may limit the ability of the underwriters to
bid for and purchase the common stock. As an exception to these rules, the
underwriters are permitted to engage in certain transactions that stabilize the
price of the common stock. Such transactions consist of bids or purchases for
the purpose of pegging, fixing or maintaining the price of common stock. If the
underwriters create a short position in the common stock in connection with the
offering, i.e., if they sell more common stock than are set forth on the cover
page of this prospectus, the underwriters may reduce that short position by
purchasing common stock in the open market. The underwriters may also elect to
reduce any short position by exercising all or part of the over-allotment
option described above. The underwriters may also impose a penalty bid on
certain selling group members. This means that if the underwriters purchase
common stock in the open market to reduce the underwriters' short position or
to stabilize the price of the common stock, they may reclaim the amount of the
selling concession from the selling group members who sold those common stock
as part of the offering.
In general, purchase of a security for the purpose of stabilization or to
reduce a short position could cause the price of the security to be higher than
it might be in the absence of such purchases. The imposition of a penalty bid
might also have an effect on the price of a security to the extent that it were
to discourage resales of the security. Neither Andrx nor any of the
underwriters make any representations or predictions as to the discretion or
magnitude of any effect that the transactions described above may have on the
price of the common stock. In addition, neither Andrx nor any of the
underwriters make any representations that the underwriters will engage in such
transactions or that such transactions, once commenced, will not be
discontinued without notice.
In connection with the offering, some underwriters and any selling group
members who are qualified market makers on the Nasdaq National Market may
engage in passive market making transactions in the common stock on the Nasdaq
National Market in accordance with Rule 103 of Regulation M. Rule 103 permits
passive market making during the period when Regulation M would otherwise
prohibit market activity by the participants in this offering. Passive market
making may occur during the business day before the pricing of this offering,
before the commencement of offers or sales of the common stock. Passive market
makers must comply with applicable volume and price limitations and must be
identified as a passive market maker. In general, a passive market maker must
display its bid at a price not in excess of the highest independent bid for the
security. If all independent bids are lowered below the passive market maker's
bid, however, the bid must then be lowered when purchase limits are exceeded.
Net purchases by a passive market maker on each day are limited to a specified
percentage of the passive market maker's average daily trading volume in the
common stock during a specified period and must be discontinued when such limit
is reached. Underwriters and dealers are not required to engage in passive
market making and may end passive market making activities at any time.
57
<PAGE>
LEGAL MATTERS
Certain legal matters with respect to the validity of the shares of common
stock offered hereby will be passed upon for us and the selling shareholders by
Broad and Cassel, a partnership including professional associations, Miami,
Florida. Certain legal matters relating to the offering will be passed upon for
the underwriters by Cahill Gordon & Reindel, New York, New York.
EXPERTS
The financial statements included in this prospectus have been audited by
Arthur Andersen LLP, independent certified public accountants, as indicated in
their report with respect thereto, and are included herein in reliance upon the
authority of said firm as experts in giving said report.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and special reports, proxy statements and other
information with the SEC. You may read and copy any report or document we file
at the public reference facilities maintained by the SEC at 450 Fifth Street,
N.W., Room 1024, Washington, D.C. 20549 and at the SEC's regional offices
located at Seven World Trade Center, Suite 1300, New York, New York 10048, and
500 West Madison Street, Suite 1400, Chicago, Illinois 60661. Please call the
SEC at 1-800-SEC-0880 for more information about the public reference rooms.
Our SEC filings are also available from the SEC's website located at
http://www.sec.gov.
Quotations for the prices of our common stock appear on the Nasdaq
National Market, and reports, proxy statements and other information about us
can also be inspected at the offices of the National Association of Securities
Dealers, Inc., 1735 K Street, N.W., Washington, D.C. 20006.
The SEC allows us to "incorporate by reference" the information we file
with it, which means that we can disclose important information to you by
referring you to those documents. The information incorporated by reference is
considered to be part of this prospectus, and later information that we file
with the SEC will automatically update and supersede this information. We
incorporate by reference our Annual Report on Form 10-K for the year ended
December 31, 1999, our Quarterly Report on Form 10-Q for the quarter ended
March 31, 2000 and any future filings made with the SEC under Sections 13(a),
13(c), 14 or 15(d) of the Securities Exchange Act of 1934.
We have filed with the SEC a registration statement on Form S-3 under the
Securities Act with respect to the common stock covered by this prospectus.
This prospectus, which is a part of the registration statement, does not
contain all the information set forth in, or annexed as exhibits to, the
registration statement, as permitted by the SEC's rules and regulations. For
further information about us and the common stock offered under this
prospectus, please refer to the registration statement, including the exhibits.
Copies of the registration statement, including exhibits, may be obtained from
the SEC's public reference facilities listed above upon payment of the fees
prescribed by the SEC, or may be examined without charge at these facilities.
Statements concerning any document filed as an exhibit are not necessarily
complete and, in each instance, we refer you to the copy of the document filed
as an exhibit to the registration statement.
We will provide without charge to each person, including any beneficial
owner, to whom a prospectus is delivered, upon written or oral request of that
person, a copy of any and all of the information that has been incorporated by
reference in this prospectus (excluding exhibits unless those exhibits are
specifically incorporated by reference into the documents requested). Please
direct such requests to Chief Financial Officer, Angelo C. Malahias, 2915
Weston Road, Suite 201, Weston, Florida 33331, telephone number (954) 584-0300.
58
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
PAGE
-----
<S> <C>
CONSOLIDATED FINANCIAL STATEMENTS OF
ANDRX CORPORATION AND SUBSIDIARIES:
Report of Independent Certified Public Accountants ....................... F-2
Consolidated Balance Sheets as of December 31, 1998 and 1999
and March 31, 2000 (unaudited) .......................................... F-3
Consolidated Statements of Income
for the years ended December 31, 1997, 1998 and 1999
and for the three months ended March 31, 1999 and 2000 (unaudited) ...... F-4
Consolidated Statements of Shareholders' Equity
for the years ended December 31, 1997, 1998 and 1999
and for the three months ended March 31, 2000 (unaudited) ............... F-5
Consolidated Statements of Cash Flows
for the years ended December 31, 1997, 1998 and 1999
and for the three months ended March 31, 1999 and 2000 (unaudited) ...... F-6
Notes to Consolidated Financial Statements ............................... F-7
</TABLE>
F-1
<PAGE>
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
To Andrx Corporation:
We have audited the accompanying consolidated balance sheets of Andrx
Corporation (a Florida corporation) and subsidiaries as of December 31, 1998
and 1999, and the related consolidated statements of income, shareholders'
equity and cash flows for each of the three years in the period ended December
31, 1999. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with auditing standards generally
accepted in the United States. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Andrx Corporation and
subsidiaries as of December 31, 1998 and 1999, and the results of their
operations and their cash flows for each of the three years in the period ended
December 31, 1999, in conformity with accounting principles generally accepted
in the United States.
ARTHUR ANDERSEN LLP
Fort Lauderdale, Florida,
March 27, 2000 (except for the April 2000
stock split described in Note 2, as to
which the date is April 4, 2000).
F-2
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
<TABLE>
<CAPTION>
DECEMBER 31, MARCH 31,
--------------------------- ------------
1998 1999 2000
------------ ------------ ------------
(UNAUDITED)
<S> <C> <C> <C>
ASSETS
Current assets
Cash and cash equivalents ......................................... $ 17,459 $ 32,555 $ 26,904
Investments available-for-sale .................................... 5,633 90,863 87,867
Accounts receivable, net of allowances of $2,529 in 1998 and $6,426
in 1999 and $5,285 (unaudited) in 2000........................... 33,811 72,032 64,280
Inventories ....................................................... 42,337 78,771 78,263
Deferred income tax assets, net ................................... -- 18,442 18,435
Prepaid and other current assets .................................. 720 11,658 14,552
--------- -------- --------
Total current assets ............................................ 99,960 304,321 290,301
Property, plant and equipment, net ................................ 20,429 38,271 48,157
Other assets ...................................................... 809 15,362 24,668
--------- -------- --------
Total assets .................................................... $ 121,198 $357,954 $363,126
========= ======== ========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable .................................................. $ 33,616 $ 51,863 $ 46,325
Accrued liabilities ............................................... 10,837 35,639 28,377
Bank loan ......................................................... 4,107 20,226 20,370
Income taxes payable .............................................. 55 15,730 9,387
--------- -------- --------
Total current liabilities ....................................... 48,615 123,458 104,459
Commitments and contingencies (Notes 12 and 17) ....................
Minority interest .................................................. -- 13,524 12,029
Shareholders' equity
Convertible preferred stock; $0.001 par value, 1,000,000 shares
authorized; none issued and outstanding ......................... -- -- --
Common stock; $0.001 par value, 100,000,000 shares authorized;
60,693,600, 62,973,000 and 63,484,700 (unaudited) shares issued
and outstanding as of 1998, 1999 and 2000, respectively ......... 61 63 63
Additional paid-in capital ......................................... 86,274 140,700 149,968
Retained earnings (accumulated deficit) ............................ (13,751) 80,303 96,674
Accumulated other comprehensive loss ............................... (1) (94) (67)
---------- -------- --------
Total shareholders' equity ...................................... 72,583 220,972 246,638
--------- -------- --------
Total liabilities and shareholders' equity ...................... $ 121,198 $357,954 $363,126
========= ======== ========
</TABLE>
The accompanying notes to consolidated financial statements
are an integral part of these consolidated balance sheets.
F-3
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
YEARS ENDED DECEMBER 31, MARCH 31,
-------------------------------------------- -----------------------------
1997 1998 1999 1999 2000
-------------- -------------- -------------- -------------- --------------
(UNAUDITED)
<S> <C> <C> <C> <C> <C>
Revenues
Distributed products .................... $ 146,237 $ 215,903 $ 262,402 $ 63,025 $ 67,826
Manufactured products ................... 3,324 11,472 134,796 4,373 44,114
Stipulation fees ........................ -- 19,130 70,733 10,000 --
Licensing and other ..................... 137 552 8,059 526 3,538
----------- ----------- ----------- ----------- -----------
Total revenues ........................ 149,698 247,057 475,990 77,924 115,478
----------- ----------- ----------- ----------- -----------
Operating expenses
Cost of goods sold ...................... 126,802 188,226 235,346 52,826 63,204
Selling, general and administrative ..... 18,934 30,646 55,266 9,591 11,542
Research and development ................ 11,251 16,837 25,697 4,315 8,211
Cybear, Inc. Internet operating
expenses .............................. 1,473 4,090 14,744 2,795 6,339
Cybear, Inc. merger costs ............... -- -- -- -- 832
----------- ----------- ----------- ----------- -----------
Total operating expenses ................. 158,460 239,799 331,053 69,527 90,128
----------- ----------- ----------- ----------- -----------
Income (loss) from operations ............ (8,762) 7,258 144,937 8,397 25,350
Other income (expense)
Minority interest ....................... 31 85 1,937 51 1,820
Gain on sale of Cybear, Inc. shares ..... -- 700 643 300 --
Interest income ......................... 1,585 1,064 3,603 366 1,531
Interest expense ........................ (490) (380) (1,661) (154) (474)
----------- ----------- ----------- ----------- -----------
Income (loss) before income taxes ........ (7,636) 8,727 149,459 8,960 28,227
Income taxes ............................. -- 333 55,405 2,016 11,856
----------- ----------- ----------- ----------- -----------
Net income (loss) ........................ $ (7,636) $ 8,394 $ 94,054 $ 6,944 $ 16,371
=========== =========== =========== =========== ===========
Basic net income (loss) per share ........ $ (0.13) $ 0.14 $ 1.52 $ 0.11 $ 0.26
=========== =========== =========== =========== ===========
Diluted net income (loss) per share ...... $ (0.13) $ 0.13 $ 1.45 $ 0.11 $ 0.25
=========== =========== =========== =========== ===========
Basic weighted average shares of
common stock outstanding ................ 56,852,400 60,090,800 61,979,800 60,871,900 63,212,600
=========== =========== =========== =========== ===========
Diluted weighted average shares of
common stock outstanding ................ 56,852,400 63,706,800 64,953,200 64,625,300 65,832,200
=========== =========== =========== =========== ===========
</TABLE>
The accompanying notes to consolidated financial statements
are an integral part of these consolidated statements.
F-4
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(IN THOUSANDS, EXCEPT FOR SHARE AMOUNTS)
<TABLE>
<CAPTION>
CONVERTIBLE COMMON
PREFERRED STOCK STOCK
----------------- ---------------------
SHARES AMOUNT SHARES AMOUNT
-------- -------- ------------ --------
<S> <C> <C> <C> <C>
Balance, December 31, 1996 .......................... -- $-- 53,670,000 $54
Shares of common stock issued in connection
with private placements ............................ -- -- 3,520,000 4
Shares of common stock issued in connection
with exercises of warrants and stock options ....... -- -- 2,236,800 2
Options granted to consultants ...................... -- -- -- --
Unrealized gain on investments
available-for-sale ................................. -- -- -- --
Net loss ............................................ -- -- -- --
Comprehensive loss ..................................
Balance, December 31, 1997 .......................... -- -- 59,426,800 60
Shares of common stock issued in connection
with exercises of warrants and stock options ....... -- -- 1,266,800 1
Income tax benefits related to exercises
of stock options ................................... -- -- -- --
Options granted to consultants ...................... -- -- -- --
Capital transactions of Cybear, Inc. ................ -- -- -- --
Unrealized loss on investments
available-for-sale ................................. -- -- -- --
Net income .......................................... -- -- -- --
Comprehensive income ................................
Balance, December 31, 1998 .......................... -- -- 60,693,600 61
Shares of common stock issued in connection
with exercises of warrants and stock options ....... -- -- 2,279,400 2
Income tax benefits related to exercises
of stock options ................................... -- -- -- --
Options granted to consultants ...................... -- -- -- --
Capital transactions of Cybear, Inc. ................ -- -- -- --
Unrealized loss on investments available-for-
sale, net of income tax benefit of $13.............. -- -- -- --
Net income .......................................... -- -- -- --
Comprehensive income ................................
Balance, December 31, 1999 .......................... -- -- 62,973,000 63
== === ========== ===
Shares of common stock issued in connection
with exercises of stock options (unaudited) ........ -- -- 511,700 --
Income tax benefits, related to exercises
of stock options (unaudited) ....................... -- -- -- --
Capital transactions of Cybear, Inc. (unaudited)..... -- -- -- --
Unrealized gain on investments available-
for-sale, net of income tax benefit of $6
(unaudited) ........................................ -- -- -- --
Net income (unaudited) .............................. -- -- -- --
Comprehensive income (unaudited) ....................
Balance, March 31, 2000 (unaudited) ................. $ 63,484,700 $63
=== ========== ===
<PAGE>
<CAPTION>
RETAINED ACCUMULATED
ADDITIONAL EARNINGS OTHER
PAID-IN (ACCUMULATED COMPREHENSIVE COMPREHENSIVE
CAPITAL DEFICIT) INCOME (LOSS) INCOME (LOSS)
------------ -------------- --------------- --------------
<S> <C> <C> <C> <C>
Balance, December 31, 1996 .......................... $ 57,212 $ (14,509) $ 5
Shares of common stock issued in connection
with private placements ............................ 21,339 -- --
Shares of common stock issued in connection
with exercises of warrants and stock options ....... 4,133 -- --
Options granted to consultants ...................... 225 -- --
Unrealized gain on investments
available-for-sale ................................. -- -- 32 $ 32
Net loss ............................................ -- (7,636) -- (7,636)
--------
Comprehensive loss .................................. $ (7,604)
========
Balance, December 31, 1997 .......................... 82,909 (22,145) 37
Shares of common stock issued in connection
with exercises of warrants and stock options ....... 2,835 -- --
Income tax benefits related to exercises
of stock options ................................... 67 -- --
Options granted to consultants ...................... 433 -- --
Capital transactions of Cybear, Inc. ................ 30 -- --
Unrealized loss on investments
available-for-sale ................................. -- -- (38) $ (38)
Net income .......................................... -- 8,394 -- 8,394
--------
Comprehensive income ................................ $ 8,356
========
Balance, December 31, 1998 .......................... 86,274 (13,751) (1)
Shares of common stock issued in connection
with exercises of warrants and stock options ....... 6,681 -- --
Income tax benefits related to exercises
of stock options ................................... 9,368 -- --
Options granted to consultants ...................... 10 -- --
Capital transactions of Cybear, Inc. ................ 38,367 -- --
Unrealized loss on investments available-for-
sale, net of income tax benefit of $13.............. -- -- (93) $ (93)
Net income .......................................... -- 94,054 -- 94,054
--------
Comprehensive income ................................ $ 93,961
========
Balance, December 31, 1999 .......................... 140,700 80,303 (94)
======== ========= =====
Shares of common stock issued in connection
with exercises of stock options (unaudited) ........ 3,019 -- --
Income tax benefits, related to exercises
of stock options (unaudited) ....................... 6,284 -- --
Capital transactions of Cybear, Inc. (unaudited)..... (35) - --
Unrealized gain on investments available-
for-sale, net of income tax benefit of $6
(unaudited) ........................................ -- -- 27 $ 27
Net income (unaudited) .............................. -- 16,371 -- 16,371
--------
Comprehensive income (unaudited) .................... $ 16,398
========
Balance, March 31, 2000 (unaudited) ................. $149,968 $ 96,674 $ (67)
======== ========= =====
</TABLE>
The accompanying notes to consolidated financial statements
are an integral part of these consolidated statements.
F-5
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
---------------------------------------
1997 1998 1999
------------ ------------ -------------
<S> <C> <C> <C>
Cash flows from operating activities
Net income (loss) .................................................... $ (7,636) $ 8,394 $ 94,054
Adjustments to reconcile net income (loss) to net cash provided by
(used in) operating activities:
Depreciation and amortization ....................................... 2,036 2,960 4,516
Provision (credit) for doubtful accounts, net ....................... 619 940 3,897
Options granted to consultants ...................................... 225 433 10
Minority interest ................................................... (31) (85) (1,937)
Gain on sale of Cybear, Inc. shares ................................. -- (700) (643)
Deferred income tax benefit ......................................... -- -- (18,442)
Changes in operating assets and liabilities: ........................
Accounts receivable ................................................ (9,749) (12,119) (42,062)
Inventories ........................................................ (13,661) (16,436) (36,434)
Prepaid and other assets ........................................... (614) (163) (21,672)
Accounts payable and accrued liabilities ........................... 12,162 15,092 42,869
Income taxes payable ............................................... -- 55 15,675
--------- ---------- -----------
Net cash provided by (used in) operating activities ................. (16,649) (1,629) 39,831
--------- ---------- -----------
Cash flows from investing activities
Purchases of property, plant and equipment ........................... (7,715) (7,986) (22,233)
Maturities (purchases) of investments available-for-sale, net ........ 8,006 13,247 (85,323)
Acquisition of Telegraph Consulting Corporation ...................... -- -- (1,181)
Acquisition of Valmed Pharmaceutical, Inc.,
net of cash acquired ............................................... -- -- --
--------- ---------- -----------
Net cash provided by (used in) investing activities ................. 291 5,261 (108,737)
--------- ---------- -----------
Cash flows from financing activities
Proceeds from the issuance of shares of common stock and
exercises of warrants and stock options ............................ 4,135 2,836 6,683
Proceeds from the issuance of shares of common stock in
connection with a 1997 private placement ........................... 21,343 -- --
Income tax benefits related to exercises of stock options ............ -- 67 9,368
Net borrowings (repayments) under bank loan .......................... (5,923) 3,569 16,119
Net proceeds from Cybear, Inc.'s public share offering ............... -- -- 50,778
Other capital transactions of Cybear, Inc ............................ -- 30 379
Proceeds from sale of Cybear, Inc. shares ............................ -- 700 675
--------- ---------- -----------
Net cash provided by financing activities ........................... 19,555 7,202 84,002
--------- ---------- -----------
Net increase in cash and cash equivalents ............................. 3,197 10,834 15,096
Cash and cash equivalents, beginning of period ........................ 3,428 6,625 17,459
--------- ---------- -----------
Cash and cash equivalents, end of period .............................. $ 6,625 $ 17,459 $ 32,555
========= ========== ===========
Supplemental disclosure of cash paid during the period for:
Interest ............................................................. $ 490 $ 380 $ 1,661
========= ========== ===========
Income taxes ......................................................... $ -- $ 210 $ 48,790
========= ========== ===========
<PAGE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
-------------------------
1999 2000
------------ ------------
(UNAUDITED)
<S> <C> <C>
Cash flows from operating activities
Net income (loss) .................................................... $ 6,944 $ 16,371
Adjustments to reconcile net income (loss) to net cash provided by
(used in) operating activities:
Depreciation and amortization ....................................... 862 1,749
Provision (credit) for doubtful accounts, net ....................... 226 (1,141)
Options granted to consultants ...................................... -- --
Minority interest ................................................... (51) (1,820)
Gain on sale of Cybear, Inc. shares ................................. (300) --
Deferred income tax benefit ......................................... -- --
Changes in operating assets and liabilities: ........................
Accounts receivable ................................................ (2,060) 14,489
Inventories ........................................................ (19,277) 4,670
Prepaid and other assets ........................................... (811) (3,478)
Accounts payable and accrued liabilities ........................... 12,741 (16,935)
Income taxes payable ............................................... 2,306 (6,343)
---------- ----------
Net cash provided by (used in) operating activities ................. 580 7,562
---------- ----------
Cash flows from investing activities
Purchases of property, plant and equipment ........................... (4,600) (10,291)
Maturities (purchases) of investments available-for-sale, net ........ (11,188) 3,038
Acquisition of Telegraph Consulting Corporation ...................... -- --
Acquisition of Valmed Pharmaceutical, Inc.,
net of cash acquired ............................................... -- (15,081)
---------- ----------
Net cash provided by (used in) investing activities ................. (15,788) (22,334)
---------- ----------
Cash flows from financing activities
Proceeds from the issuance of shares of common stock and
exercises of warrants and stock options ............................ 1,501 3,019
Proceeds from the issuance of shares of common stock in
connection with a 1997 private placement ........................... -- --
Income tax benefits related to exercises of stock options ............ 1,459 6,284
Net borrowings (repayments) under bank loan .......................... 6,099 144
Net proceeds from Cybear, Inc.'s public share offering ............... -- --
Other capital transactions of Cybear, Inc ............................ 90 (326)
Proceeds from sale of Cybear, Inc. shares ............................ 300 --
---------- ----------
Net cash provided by financing activities ........................... 9,449 9,121
---------- ----------
Net increase in cash and cash equivalents ............................. (5,759) (5,651)
Cash and cash equivalents, beginning of period ........................ 17,459 32,555
---------- ----------
Cash and cash equivalents, end of period .............................. $ 11,700 $ 26,904
========== ==========
Supplemental disclosure of cash paid during the period for:
Interest ............................................................. $ 154 $ 474
========== ==========
Income taxes ......................................................... $ 115 $ 11,915
========== ==========
</TABLE>
The accompanying notes to consolidated financial statements
are an integral part of these consolidated statements.
F-6
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
(1) GENERAL
Andrx Corporation and subsidiaries ("Andrx" or the "Company") was
organized in August 1992 and commenced marketing and distributing generic
pharmaceutical products manufactured by third parties. In February 1993, the
Company began to engage in the development of bioequivalent controlled-release
pharmaceutical products utilizing its proprietary drug delivery technologies.
During 1996, the Company commenced its efforts to develop brand name
controlled-release products and an Internet based software application for
healthcare providers. Through October 9, 1997, the Company's distribution
operations had generated substantially all of its revenues. On October 10,
1997, the United States Food and Drug Administration ("FDA") granted final
approval of the Company's abbreviated new drug application ("ANDA"), for a
bioequivalent version of Dilacor XR/registered trademark/, the Company's first
manufactured product, which it immediately launched as Diltia XT/registered
trademark/.
In September 1997, Andrx entered into a Stipulation and Agreement (the
"Stipulation") with Hoechst Marion Roussel, Inc. (now known as Aventis, S.A.,
"Aventis") and Carderm Capital, L.P. in partial settlement of a patent
infringement claim brought against Andrx by Aventis (the "Aventis Litigation")
in order to reduce the risks that both parties faced as the case was litigated
to its conclusion. Andrx agreed to maintain the status quo in connection with
the marketing of its product and to dismiss certain claims against Aventis.
Aventis agreed to compensate Andrx for any lost profits, stipulated to be
$100,000 per year, if Andrx ultimately prevailed in the Aventis Litigation and
to grant Andrx a license for its patents under certain conditions, including if
Andrx ultimately lost the litigation. Aventis also agreed to make non-
refundable interim quarterly payments of $10,000 to Andrx, beginning upon
Andrx' receipt of final FDA approval for its bioequivalent version of
Cardizem/registered trademark/ CD and continuing until the Aventis Litigation
was resolved or certain other events occurred. In July 1998, the FDA granted
final marketing approval for the Company's ANDA for a bioequivalent version of
Cardizem/registered trademark/ CD. In June 1999, the Aventis Litigation was
resolved and on June 23, 1999, the Company launched its reformulated
bioequivalent version of Cardizem/registered trademark/ CD, Cartia
XT/trademark/, which enjoyed a 180-day period of marketing exclusivity through
December 19, 1999.
On November 20, 1998, Cybear, Inc. ("Cybear"), a Florida corporation, the
Company's subsidiary engaged in the development of Internet applications
designed for the healthcare community, merged with a wholly-owned subsidiary of
1997 Corp., a Delaware corporation, pursuant to a Merger Agreement and Plan of
Reorganization dated July 15, 1998. 1997 Corp. was a "blank check" company that
had a registration statement on file with the Securities and Exchange
Commission to seek a business combination with an operating entity. In June
1999, Cybear completed a public offering of its common shares. As a result of
the public offering, exercises of Cybear stock options, other Cybear stock
issuances, and sales of shares of Cybear common stock by Andrx, Andrx'
ownership in Cybear decreased to approximately 73% as of December 31, 1999.
CYBEAR REORGANIZATION PLAN
In December 1999, Andrx announced a corporate reorganization plan (the
"Reorganization") which, among other things, would give Andrx shareholders the
ability to distinguish between their investments in Andrx and Cybear. In March
2000, Andrx and Cybear entered into a definitive agreement with respect to the
Reorganization. This plan, which was recommended to the Cybear Board of
Directors by its Special Committee and approved by the boards of both Cybear
and Andrx, will create two new classes of Andrx
F-7
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
common stock, Cybear Group Common Stock to separately track the performance of
Cybear and Andrx Group Common Stock representing the equity interests of Andrx
other than its ownership of Cybear. In exchange for their Andrx shares, Andrx
shareholders will receive shares of Andrx Group Common Stock and Cybear Group
Common Stock. The plan will be submitted for approval to the shareholders of
Andrx and Cybear during 2000.
In connection with the Reorganization, Andrx will acquire all of the
publicly traded shares of common stock of Cybear in what should be a tax-free
reorganization. Cybear's public shareholders currently own approximately 4.9
million shares or 27.6% of the common shares of Cybear as of March 31, 2000
and those shareholders will receive one share of Cybear Group Common for every
share of Cybear common stock they currently own. In the Reorganization, the
number of Cybear shares held by Andrx will be reduced from 12.9 million shares
to 10.8 million shares so as to provide the equivalent of a 20% increase in
shares held by the non-Andrx shareholders of Cybear. Upon completion of the
Reorganization, the non-Andrx shareholders of Cybear will own approximately
31.2% of the Cybear Group Common following the closing of the transaction.
Pursuant to the Reorganization, each Andrx common share will be converted into
(i) one share of Andrx Group Common and (ii) approximately .1622 shares of
Cybear Group Common. Upon completion of the Reorganization, (i) Cybear will be
a wholly owned subsidiary of Andrx with 100% of its value publicly traded in
the form of Cybear Group Common, (ii) current Cybear public shareholders will
own approximately 31.2% of the Cybear Group Common; and (iii) current Andrx
shareholders will own 100% of the Andrx Group Common and approximately 68.8% of
the Cybear Group Common. The preceding share ownership and percentages exclude
the potential exercise by Edward E. Goldman, M.D., Cybear's Chief Executive
Officer, of an outstanding warrant to acquire 525,000 shares of Cybear common
stock currently owned by Andrx.
The Reorganization is intended to (i) separate the operating losses of
Cybear from the operating results of Andrx for financial reporting purposes;
(ii) improve liquidity for the publicly traded equity of Cybear; (iii) provide
Cybear with a more viable currency for potential future strategic acquisitions;
and (iv) preserve financial flexibility for Andrx management to maximize the
long-term growth of shareholder value. In addition, the Reorganization should
reestablish certain tax consolidation advantages for Andrx.
Consummation of the transaction is subject to various conditions,
including approval by shareholders of Andrx and Cybear. In addition to
shareholder approval, the transaction will be subject to various Federal and
state regulatory approvals, including the U.S. Securities and Exchange
Commission ("SEC") and accordingly, no assurance can be given that this
transaction will be consummated. Andrx and Cybear will file a preliminary joint
proxy statement and a registration statement with respect to the proposed
transaction.
RISKS AND UNCERTAINTIES
Factors which may affect the Company's results include, but are not
limited to, the risks and uncertainties associated with a drug delivery company
which has only commercialized a few products, has new technologies and limited
manufacturing experience, current and potential competitors with significant
technical and marketing resources, and dependence on key personnel. The Company
is also subject to the risks and uncertainties associated with all drug
delivery companies, including changes in the regulatory scheme, difficulty in
receiving regulatory approval to market new products, compliance with
government regulations and patent infringement and other litigation.
Additionally, the Company is subject to the risks and
F-8
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
uncertainties associated with drug distribution companies, including but not
limited to fierce competition and decreasing gross profits. In addition, the
Company's Internet based healthcare information technology subsidiary is
subject to the risks and uncertainties of an early stage Internet company,
including but not limited to limited operating history and substantial
operating losses, availability of capital resources, ability to effectively
compete, economic conditions, unanticipated difficulties in product
development, ability to gain market acceptance and market share, ability to
manage growth, reliance on short-term non-exclusive contracts, ability to
obtain content, Internet security risks and uncertainty relating to the
evolution of the Internet as a medium for commerce, dependence on third-party
content providers, dependence on key personnel, ability to protect intellectual
property, the possibility that the Reorganization will not be completed and the
impact of future government regulation. Andrx is also subject to other risks
detailed herein or detailed from time to time in the Company's and Cybear's
filings with the SEC.
(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS OF PRESENTATION
The accompanying consolidated financial statements include the accounts of
Andrx Corporation and its majority owned subsidiaries. All significant
intercompany transactions and balances have been eliminated in consolidation.
USE OF ESTIMATES
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those estimates.
The most significant estimates made by management include the provision
for doubtful accounts receivable, inventory writedowns, discounts and rebates
to customers or from vendors, returns, pricing adjustments and other
adjustments related to purchases and sales of products, and provisions for
litigation (see Note 17).
Management periodically evaluates estimates used in the preparation of the
consolidated financial statements for continued reasonableness. Appropriate
adjustments, if any, to the estimates used are made prospectively based on such
periodic evaluations.
CASH AND CASH EQUIVALENTS
All highly liquid investments with an original maturity of three months or
less are considered cash equivalents and are carried at cost.
INVESTMENTS AVAILABLE-FOR-SALE
The Company utilizes the provisions of Financial Accounting Standards
Board ("FASB") Statement of Financial Accounting Standards ("SFAS") No. 115,
"Accounting for Certain Investments in Debt and Equity
F-9
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
Securities". SFAS No. 115 requires that marketable equity securities and all
debt securities be classified into three categories: (i) held to maturity
securities, (ii) trading securities, and (iii) available-for-sale securities.
The Company classifies its investments as available-for-sale and, accordingly,
such investments are carried at market value and any unrealized gain or loss is
reported as a separate component of shareholders' equity. The cost related to
investments available-for-sale is determined utilizing the specific
identification method.
INVENTORIES
Inventories of pharmaceutical products consist primarily of finished goods
held for distribution, and raw materials, work in process and finished goods of
manufactured products. Inventories are stated at the lower of cost (first-in,
first-out) or market. Cost of inventories held for distribution is based on
purchase price, net of vendor discounts, rebates and other allowances.
PROPERTY, PLANT AND EQUIPMENT, NET
Property, plant and equipment are recorded at cost, less accumulated
depreciation or amortization. Depreciation or amortization is provided using
the straight-line method over the following estimated useful lives:
<TABLE>
<S> <C>
Manufacturing equipment ................ 10 years
Laboratory equipment ................... 5 years
Leasehold improvements ................. Term of lease
Computer hardware and software ......... 3 years
Furniture and fixtures ................. 5 years
</TABLE>
Major renewals and betterments are capitalized, while maintenance, repairs
and minor renewals are expensed as incurred.
IMPAIRMENT OF LONG-LIVED ASSETS AND LONG-LIVED ASSETS TO BE DISPOSED OF
The Company utilizes the provision of SFAS No. 121, "Accounting for the
Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of",
which requires that long-lived assets be reviewed for impairment whenever
events or changes in circumstance indicate that the carrying amount of an asset
may not be recoverable. To determine a loss, if any, to be recognized, the
carrying value of the asset would be compared to the market value or expected
undiscounted future cash flow value.
REVENUE RECOGNITION
Sales of distributed and manufactured products and the related cost of
goods sold are recognized at the time a product is shipped. Provisions for
discounts, rebates, returns, pricing adjustments and other adjustments related
to sales to customers are provided in the same period the related sales are
recorded.
The Company has entered into long term supply arrangements with certain
customers related to manufactured products. Prepayments by the Company to
customers related to such arrangements are
F-10
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
capitalized in the Consolidated Balance Sheet as Prepaid and other current
assets and Other assets, as appropriate, and, are amortized in the Consolidated
Statement of Income against Revenues--Manufactured products over the life of
the arrangements, on a straight-line basis, as appropriate. Such assets are
periodically assessed for realizability and any adjustments for impairments are
made as they become known.
Stipulation fees and Licensing and other revenue are recognized when
earned in accordance with the terms of the underlying agreements (see Notes 9
and 17).
RESEARCH AND DEVELOPMENT EXPENSES
Research and development expenses consist of costs related to products
being developed internally as well as costs related to products subject to
licensing agreements in both the Company's bioequivalent (ANDA) and brand (NDA)
programs. Research and development costs are expensed as incurred.
The Company is a 50% partner in ANCIRC Pharmaceuticals ("ANCIRC"). In
addition to Andrx' 50% ownership in ANCIRC, the Company also provides research
and development services to ANCIRC at cost. Accordingly, research and
development expenses in the Consolidated Statements of Income exclude costs of
research and development services rendered to ANCIRC, as such costs are charged
to ANCIRC as incurred. However, Research and development expenses in the
Consolidated Statements of Income include the Company's equity in losses of
ANCIRC (see Note 10).
STOCK-BASED COMPENSATION
In October 1995, the FASB issued SFAS No. 123, "Accounting for Stock-Based
Compensation". Under the provisions of SFAS No. 123, companies can either
measure the compensation cost of equity instruments issued under employee
compensation plans using a fair value based method, or can continue to
recognize compensation cost using the intrinsic value method under the
provisions of Accounting Principles Board Opinion ("APB") No. 25. However, if
the provisions of APB No. 25 are applied, pro forma disclosures of net income
or loss and earnings or loss per share must be presented in the financial
statements as if the fair value method had been applied. For the years ended
December 31, 1997, 1998 and 1999, the Company recognized compensation costs
under the provisions of APB No. 25, and the Company has provided the expanded
disclosure required by SFAS No. 123 (see Note 15).
ISSUANCE OF STOCK BY SUBSIDIARY
The Company accounted for the issuances of shares of common stock by
Cybear as equity transactions within the Consolidated Statements of
Stockholders' Equity and excludes the results of such transactions from the
Consolidated Statements of Income. The Company does not currently intend to
issue shares of common stock of its other subsidiaries.
INCOME TAXES
The provisions of SFAS No. 109, "Accounting for Income Taxes", require,
among other things, recognition of future tax benefits measured at enacted
rates attributable to the deductible temporary differences
F-11
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
between the financial statement and income tax bases of assets and liabilities
and to tax net operating loss carryforwards to the extent that the realization
of such benefits is "more likely than not" (see Note 11). Under SFAS No. 109,
deferred tax assets and liabilities are determined based on the difference
between the financial statement and tax bases of assets and liabilities, using
enacted tax rates in effect for the year in which the differences are expected
to reverse.
EARNINGS (LOSS) PER SHARE
The Company utilizes the provisions of SFAS No. 128, "Earnings Per Share".
For the years ended December 31, 1998 and 1999, in which the Company
generated net income, the diluted basis considers the weighted average shares
of common stock outstanding including common stock equivalents. For the year
ended December 31, 1997, the Company generated net losses, accordingly, all
common stock equivalents were excluded from the calculation of net loss per
diluted share since the effects were anti-dilutive. As such, for the year ended
December 31, 1997 diluted net loss per share is based on the weighted average
shares of common stock outstanding.
A reconciliation of the numerators and denominators of basic and diluted
earnings (loss) per share is as follows:
<TABLE>
<CAPTION>
THREE MONTHS ENDED
YEARS ENDED DECEMBER 31, MARCH 31,
------------------------------------------ ---------------------------
1997 1998 1999 1999 2000
-------------- ------------- ------------- ------------- -------------
(UNAUDITED)
<S> <C> <C> <C> <C> <C>
BASIC EARNINGS (LOSS) PER SHARE:
Net income (loss) ......................... $ (7,636) $ 8,394 $ 94,054 $ 6,944 $ 16,371
=========== =========== =========== =========== ===========
Basic weighted average shares of
common stock outstanding ................. 56,852,400 60,090,800 61,979,800 60,871,900 63,212,600
=========== =========== =========== =========== ===========
Basic net income (loss) per share ......... $ (0.13) $ 0.14 $ 1.52 $ 0.11 $ 0.26
=========== =========== =========== =========== ===========
DILUTED EARNINGS (LOSS) PER SHARE:
Net income (loss) ......................... $ (7,636) $ 8,394 $ 94,054 $ 6,944 $ 16,371
=========== =========== =========== =========== ===========
Weighted average shares of
common stock outstanding ................. 56,852,400 60,090,800 61,979,800 60,871,900 63,212,600
Effect of dilutive items:
Stock options ........................... -- 2,296,000 2,356,600 2,560,800 2,619,600
Warrants ................................ -- 1,320,000 616,800 1,192,600 --
----------- ----------- ----------- ----------- -----------
Diluted weighted average shares of
common stock outstanding ................. 56,852,400 63,706,800 64,953,200 64,625,300 65,832,200
=========== =========== =========== =========== ===========
Net income (loss) per share ............... $ (0.13) $ 0.13 $ 1.45 $ 0.11 $ 0.25
=========== =========== =========== =========== ===========
Anti-dilutive weighted options ............ 3,785,800 100,400 78,400 241,600 81,100
=========== =========== =========== =========== ===========
</TABLE>
The above anti-dilutive weighted options to purchase shares of common
stock were not included in computing diluted earnings per share because their
effects were anti-dilutive for the respective periods.
F-12
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
STOCK SPLITS
On February 25, 2000 Andrx' Board of Directors approved a two-for-one
stock split in the form of a stock dividend to shareholders of record at the
close of business on March 15, 2000. Such stock dividend was distributed April
2000. In connection with the stock split, the Company's authorized shares of
common stock were increased from 50 million to 100 million. Anti-dilutive
adjustments have been made to the Company's stock option plan and the options
outstanding.
In June 1999 and April 2000, the Company effected two-for-one stock splits
in the form of a 100% stock dividend. All share and per share amounts in the
accompanying consolidated financial statements and notes to consolidated
financial statements reflect the June 1999 and April 2000 stock splits.
FAIR VALUE OF FINANCIAL INSTRUMENTS
As of December 31, 1998 and 1999, the carrying amount of Cash and cash
equivalents, Investments available-for-sale, Accounts receivable, net, Accounts
payable, Accrued liabilities, Bank loan and Income taxes payable approximate
fair value due to the short maturity of these instruments.
CONCENTRATION OF CREDIT RISK
The Company invests in U.S. Treasury and government agency securities,
debt instruments of corporations and tax advantaged money market preferreds
with investment grade credit ratings. The Company has established guidelines
relative to diversification and maturities that are designed to help ensure
safety and liquidity.
Accounts receivable are principally due from independent pharmacies,
pharmacy chains, pharmacy buying groups and wholesalers and distributors.
Credit is extended based on an evaluation of the customer's financial condition
and collateral is generally not required. The Company performs ongoing credit
evaluations of its customers and maintains allowances for potential
uncollectable accounts.
The Company has no significant off-balance sheet concentration of credit
risk.
COMPREHENSIVE INCOME (LOSS)
The Company adopted the provision of SFAS No. 130, "Reporting
Comprehensive Income", effective January 1, 1998, as required. SFAS No. 130
establishes standards for reporting and presentation of comprehensive income or
loss and its components in financial statements. The Company has included the
required disclosure of this SFAS in the accompanying Consolidated Statements of
Shareholders' Equity for the years ended December 31, 1997, 1998 and 1999, as
required.
BUSINESS SEGMENTS
The Company adopted SFAS No. 131, "Disclosures about Segments of an
Enterprise and Related Information", which was issued by the FASB in June 1997.
This SFAS replaced SFAS No. 14 "Financial
F-13
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
Reporting for Segments of a Business Enterprise" and establishes new standards
for defining the Company's segments and disclosing information about them. The
provisions of SFAS No. 131 require that the segments be based on the internal
structure and reporting of the Company's operations. (see Note 18.)
DERIVATIVES
SFAS No. 133, "Accounting for Derivative Instruments and Hedging
Activities", establishes accounting and reporting standards requiring that
every derivative instrument (including certain derivative instruments embedded
in other contracts) be recorded in the balance sheet as either an asset or
liability measured at its fair value. The provisions of SFAS No. 133 requires
that changes in the derivative's fair value be recognized currently in earnings
unless specific hedge accounting criteria are met. Special accounting for
qualifying hedges allows a derivative's gains and losses to offset related
results on the hedged item in the income statement, and requires that a company
must formally document, designate, and assess the effectiveness of transactions
that receive hedge accounting. The provisions of SFAS No. 133 must be applied
to (a) derivative instruments and (b) certain derivative instruments embedded
in hybrid contracts that were issued, acquired, or substantively modified after
December 31, 1997 (and, at the Company's election, before January 1, 1998).
SFAS No. 137, "Accounting for Derivative Instruments and Hedging
Activities--Deferral of the Effective Date of FASB Statement No. 133", amends
the effective date of SFAS No. 133 to all fiscal years beginning after June 15,
2000.
The Company expects to adopt the provisions of SFAS No. 133, as required,
and does not expect the effect of the adoption to be significant to the
consolidated financial statements.
RECLASSIFICATIONS
Certain prior years' amounts have been reclassified to conform to the
current year presentation.
(3) ACQUISITION OF VALMED PHARMACEUTICAL, INC.
On March 15, 2000, Andrx acquired Valmed Pharmaceutical, Inc. ("Valmed"),
a privately owned distributor of bioequivalent pharmaceuticals headquartered in
Grand Island, New York. The acquisition was accounted for using the purchase
method of accounting. Accordingly, the excess of the total purchase price of
$15,500, including transaction costs, over the fair value of the net assets
acquired was approximately $8,700, representing goodwill, and is included in
Other assets in the accompanying Unaudited Consolidated Balance Sheet. Such
goodwill is being amortized on a straight-line basis over its estimated life of
15 years.
Pro forma information is not required to be included herein because the
transaction was not significant to the Company.
(4) CYBEAR, INC.
On June 23, 1999, Cybear completed a public offering of 3,450,000 of its
common shares at $16.00 per share raising net proceeds of approximately
$50,800. The Company did not record a gain in connection with this offering.
The transaction was recorded as an equity transaction in the Company's
Consolidated Statements of Shareholders' Equity.
F-14
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
On September 17, 1999, Cybear acquired Telegraph Consulting Corporation
("Telegraph"), the programming, networking and interactive design division of
Telegraph New Technology, Inc. The purchase price of approximately $4,088
includes $1,181 in cash, the issuance of 320,000 shares of restricted Cybear
common stock valued at approximately $2,771 and the assumption of approximately
$136 of Telegraph's debt. The acquisition was recorded using the purchase
method of accounting. Accordingly, the excess of the purchase price over the
fair value of the net assets acquired of approximately $3,933 represents
goodwill, and is included in Other assets in the Consolidated Balance Sheet.
Such goodwill is being amortized on a straight-line basis over its estimated
life of 10 years.
The following summarizes the acquisition:
<TABLE>
<S> <C>
Cash used for acquisition ............................................. $1,181
Cybear common stock issued ............................................ 2,771
Debt assumed .......................................................... 136
------
Purchase price ........................................................ 4,088
Working capital acquired .............................................. (30)
Property and equipment acquired ....................................... (125)
------
Excess of purchase price over fair market value of net assets acquired $3,933
======
</TABLE>
Pro forma information is not required to be included herein because the
transaction was not significant to the Company.
(5) INVESTMENTS AVAILABLE-FOR-SALE
Investments available-for-sale consist of the following:
<TABLE>
<CAPTION>
DECEMBER 31, 1998
--------------------------------------------------------------
GROSS GROSS
AMORTIZED UNREALIZED UNREALIZED MARKET
COST GAINS LOSSES VALUE
-------------- --------------- -------------- ----------
<S> <C> <C> <C> <C>
U.S. Treasury and government
agency securities ............................. $ 5,634 $ 4 $ (5) $ 5,633
========== =========== =========== =======
DECEMBER 31, 1999
-----------------------------------------------------------------
GROSS GROSS
AMORTIZED UNREALIZED UNREALIZED MARKET
COST GAINS LOSSES VALUE
----------- ----------- ----------- -------
U.S. Treasury and government
agency securities ............................. $ 31,186 $ -- $ (127) $31,059
Corporate bonds ................................ 10,163 -- (8) 10,155
Tax advantaged money market preferreds ......... 49,649 -- -- 49,649
------------ ----------- ----------- -------
$ 90,998 $ -- $ (135) $90,863
============ =========== =========== =======
</TABLE>
F-15
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
(6) INVENTORIES
Inventories consist of the following:
<TABLE>
<CAPTION>
DECEMBER 31,
---------------------
1998 1999
--------- ---------
<S> <C> <C>
Raw materials ............... $ 4,846 $ 8,638
Work in process ............. 796 3,182
Finished goods .............. 36,695 66,951
------- -------
Total inventories ......... $42,337 $78,771
======= =======
</TABLE>
(7) PROPERTY, PLANT AND EQUIPMENT, NET
Property, plant and equipment are summarized as follows:
<TABLE>
<CAPTION>
DECEMBER 31,
--------------------------
1998 1999
----------- ------------
<S> <C> <C>
Land .................................................... $ 2,436 $ 2,804
Manufacturing equipment ................................. 7,032 14,029
Laboratory equipment .................................... 2,872 4,926
Leasehold improvements .................................. 6,897 9,042
Computer hardware and software .......................... 6,426 10,067
Furniture and fixtures .................................. 1,739 3,544
Construction in progress ................................ 288 5,636
-------- ---------
27,690 50,048
Less: accumulated depreciation and amortization ......... (7,261) (11,777)
-------- ---------
Property, plant and equipment, net ...................... $ 20,429 $ 38,271
======== =========
</TABLE>
(8) BANK LOAN
In April 1998, Anda, Inc. ("Anda"), the Company's wholly-owned subsidiary
engaged in the distribution of pharmaceutical products, amended its line of
credit agreement to increase the total available borrowings from $10,000 to
$30,000 and, to decrease the interest rate and to potentially further decrease
the interest rate if the Company maintains certain levels of average
outstanding balance. As of December 31, 1999, the interest rate on the bank
borrowings of $20,226 was the prime rate, 8.5%.
Borrowings under the line of credit are available for financing the
Company's operations, are secured by all the assets of Anda and are subject to
a borrowing base related to the value of Anda's accounts receivable and
inventories. The loan is guaranteed by Andrx Corporation and some of its other
subsidiaries. The agreement requires compliance with certain covenants
including the maintenance of minimum working capital and net worth levels by
Anda. As of December 31, 1999, the Company was in compliance with all of the
covenants of this line of credit agreement.
F-16
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
(9) LICENSING AGREEMENTS
In June 1999, Andrx entered into an agreement with Geneva Pharmaceuticals,
Inc. ("Geneva") a member of the Novartis Group, for the sale and marketing of
specified products. Geneva will fund the development costs of certain
controlled-release dosage forms of existing products that the Company is
developing for submissions as brands (NDAs). Andrx granted marketing rights to
Geneva in specified territories for these products including one of the
Company's NDA products for the United States. Upon receiving FDA approval,
Andrx will receive royalties from the sale of such products. Andrx also has
committed to continuing to sell Geneva's bioequivalent products through Anda.
Andrx has entered into various other domestic and international licensing
agreements. These agreements generally contemplate that one of Andrx' drug
delivery technologies will be utilized to commercialize certain pharmaceutical
products, and that the Company will receive fees pursuant to these agreements
and possibly royalties from the sale or license of the subject products.
(10) ANCIRC JOINT VENTURE
In July 1994, and as later amended on October 30, 1995, the Company and
Circa Pharmaceuticals, Inc., now a wholly-owned subsidiary of Watson
Pharmaceuticals, Inc. ("Watson") (the Company and Watson are hereafter
collectively referred to as the "Partners"), formed ANCIRC Pharmaceuticals, a
50/50 joint venture to develop, manufacture and market up to eight
bioequivalent controlled-release pharmaceutical products (the "joint venture"
or "ANCIRC"). The agreement between the Partners contemplates that Andrx
Pharmaceuticals, Inc. ("Andrx Pharmaceuticals"), a wholly-owned subsidiary of
the Company, will perform the research and development formulations for the
joint venture products, that Anda will market and distribute ANCIRC's products
following FDA approval, and that Watson will provide the regulatory support for
the joint venture products and will manufacture the ANCIRC products.
In September 1998, ANCIRC received approval of its first manufactured
product, a bioequivalent version of Trental/registered trademark/ and launched
this product. On March 24, 1999 the FDA approved the ANDA for the second ANCIRC
product, a bioequivalent version of Oruvail/registered trademark/, which was
launched in April 1999. ANCIRC halted the production and sale of ANCIRC's
bioequivalent version of Oruvail/registered trademark/ in June 1999, and is
currently not producing or selling such product.
Capital contributions to, distributions from and net income or loss
generated by ANCIRC are allocated in proportion to the respective Partners'
interest in the joint venture.
ANCIRC is managed by and under the direction of a management committee
which is comprised of six members. Three members are appointed by each Partner.
Based on the equal representation of the management committee and the Company's
inability to unilaterally control the joint venture, the Company utilizes the
equity method to account for this joint venture. Equity in income or losses of
joint venture is included in Research and development expenses in the
accompanying Consolidated Statements of Income.
F-17
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
Condensed balance sheet and statement of operations information for ANCIRC
is as follows:
<TABLE>
<CAPTION>
DECEMBER 31,
---------------------
1998 1999
--------- ---------
<S> <C> <C>
ASSETS
Cash and cash equivalents ........................ $ 695 $ 487
Inventories ...................................... 363 1,115
------ ------
Total assets ................................... $1,058 $1,602
====== ======
LIABILITIES AND PARTNERS' EQUITY
Current liabilities .............................. $ 87 $ 369
Partners' equity ................................. 971 1,233
------ ------
Total liabilities and partners' equity ......... $1,058 $1,602
====== ======
</TABLE>
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
---------------------------------------
1997 1998 1999
------------ ------------ ---------
<S> <C> <C> <C>
Product sales, net ........................ $ -- $ 724 $3,307
======== ======== ======
Gross profit .............................. $ -- $ 360 $1,239
======== ======== ======
Research and development expenses ......... $ 3,392 $ 2,237 $2,004
======== ======== ======
Net loss .................................. $ (3,364) $ (1,862) $ (740)
======== ======== ======
</TABLE>
As of December 31, 1998 and 1999, Andrx Pharmaceuticals was due $139 and
$705, respectively, from ANCIRC for research and development services rendered.
As of December 31, 1998 and 1999 Anda, the distributor of ANCIRC products owed
ANCIRC $627 and $326, respectively, for purchases of ANCIRC's products. Amounts
due to or from ANCIRC, net, are included in Prepaid and other current assets in
the accompanying Consolidated Balance Sheets. Product sales and the related
costs of product sales are recognized by ANCIRC at the time product is shipped
to third-party customers by Anda. Sales to Anda are discounted by an
agreed-upon percentage from the ultimate net selling price realized from the
sale to the third party customers to allow Anda to recover selling and
marketing costs. The Company is committed to the funding of ANCIRC's future
operations. From time to time, the Partners have discussions to potentially
restructure ANCIRC.
(11) INCOME TAXES
For the year ended December 31, 1997, the Company had no income taxes as
its income tax benefits were fully offset by a corresponding increase to the
valuation allowance against its net deferred income tax assets.
For the year ended December 31, 1998, the Company's income tax provision
of $333 resulted from Federal alternative minimum income taxes. The Company's
1998 regular income tax provision was fully offset by the reversal of a
corresponding amount of valuation allowance against its net deferred income tax
assets.
F-18
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
For the year ended December 31, 1999, the Company provided for $55,405 for
Federal and state income taxes or 37% of Income before income taxes. The
Company was not required to provide for income taxes at an effective combined
Federal and state statutory rate of 39% due to the effect of the utilization of
the Company's net operating loss carryforwards. As of June 23, 1999, Cybear was
excluded from Andrx' consolidated tax return and was filed as a separate entity
because Andrx' ownership in Cybear was reduced below 80%. Cybear's net
operating losses after June 23, 1999 did not generate income tax benefits, as
its tax benefits were fully offset by a corresponding increase in the valuation
allowance against its net deferred income tax assets.
For the three months ended March 31, 2000, the Company provided $11,856
for Federal and state income taxes or 42% of income before income taxes. The
Company provided for income taxes of $1,412 in excess of the effective combined
Federal and state statutory rate of 37%, primarily due to Andrx' inability to
utilize its share of Cybear's losses, as Andrx' ownership of Cybear was reduced
below 80% on June 23, 1999. Accordingly, Cybear is excluded from Andrx'
consolidated income tax return and will file as a separate tax entity. Cybear's
net losses did not generate income tax benefits as Cybear's tax benefits of
$2,551 were fully offset by a corresponding increase in the valuation allowance
against its net deferred income tax assets due to the uncertainty of
realization.
For the three months ended March 31, 1999, the Company provided $2,016 for
Federal and state income taxes or 22.5% of income before income taxes, which
was the Company's then estimated annual 1999 effective tax rate. The Company
was not required to provide for Federal and state income taxes for the three
months ended March 31, 1999 at the combined Federal and state statutory rate of
37% primarily due to the reversal of a valuation allowance of $1,299 relating
to deferred tax assets resulting from net operating loss carryforwards.
Under the provisions of SFAS No. 109, as of March 31, 2000, the Company
had recorded a valuation allowance to reserve against 100% of the net deferred
income tax assets of Cybear of $6,508, which resulted after June 23, 1999 as
previously discussed.
The components of the provision for income taxes are summarized as
follows:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
------------------------------
1997 1998 1999
------ ------ ------------
<S> <C> <C> <C>
Current provision .........
Federal ................. $-- $333 $ 69,855
State ................... -- -- 3,992
--- ---- ---------
-- 333 73,847
--- ---- ---------
Deferred benefit
Federal ................. -- -- (17,445)
State ................... -- -- (997)
--- ---- ---------
-- -- (18,442)
--- ---- ---------
Total ..................... $-- $333 $ 55,405
=== ==== =========
</TABLE>
F-19
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
The following table indicates the significant elements contributing to the
difference between the Federal statutory rate and the Company's effective tax
rate:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
----------------------------------
1997 1998 1999
--------- ---------- ---------
<S> <C> <C> <C>
Federal statutory rate ................................................ (35.0)% 35.0% 35.0%
State income taxes, net of Federal effect ............................. (3.6) 3.6 2.0
Change in valuation allowance on net deferred income tax assets ....... 38.6 (36.8) (7.8)
Federal alternative minimum tax ....................................... -- 2.0 --
Other, net ............................................................ -- -- 7.8
----- ----- ----
Effective tax rate .................................................... --% 3.8% 37.0%
====== ===== ====
</TABLE>
Deferred income taxes represent the tax effect of the difference between
book and tax bases of assets and liabilities. The major components of deferred
tax assets and liabilities are as follows:
<TABLE>
<CAPTION>
DECEMBER 31,
-------------------------
1998 1999
----------- -----------
<S> <C> <C>
Net operating loss carryforward ..................... $ 1,857 $ 3,929
Allowance for doubtful accounts ..................... 976 2,377
Other operating reserves ............................ 4,539 17,230
Tax over book depreciation .......................... (465) (1,137)
Charitable contribution carryforward ................ 749 --
Alternative minimum tax credit carryforward ......... 333 --
-------- --------
7,989 22,399
Valuation allowance ................................. (7,989) (3,957)
-------- --------
Deferred income tax assets, net ................... $ -- $ 18,442
======== ========
</TABLE>
The following table indicates the activity in valuation allowance:
<TABLE>
<CAPTION>
YEARS ENDED THREE MONTHS ENDED
DECEMBER 31, MARCH 31,
---------------------------- ---------------------------
1998 1999 1999 2000
------------- ------------ ------------ ------------
(UNAUDITED)
<S> <C> <C> <C> <C>
Beginning balance ............................. $ (10,051) $ (7,989) $ (7,989) $ (3,957)
Utilized ...................................... 2,062 7,989 1,299 --
Provided for Cybear, separate company ......... -- (3,957) -- (2,551)
--------- -------- -------- --------
Ending balance ................................ $ (7,989) $ (3,957) $ (6,690) $ (6,508)
========= ======== ======== ========
</TABLE>
Under the provisions of SFAS No. 109, as of December 31, 1998, the Company
recorded a valuation allowance to reserve against 100% of its net deferred
income tax assets due to the uncertainty of the realization of such assets.
When the uncertainty was resolved in 1999, such valuation allowance was fully
F-20
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
reversed and the only remaining valuation allowance as of December 31, 1999
related to the net deferred income tax assets of Cybear of $3,957 which
resulted after June 23, 1999 as previously discussed.
As of December 31, 1999, the Company had a net operating loss carryforward
for tax purposes of approximately $10,000, which is available to only offset
future earnings of Cybear.
Net operating loss carryforwards are subject to review and possible
adjustment by the Internal Revenue Service and may be limited in the event of
certain cumulative changes in the ownership interest of significant
shareholders over a three-year period in excess of 50%.
(12) COMMITMENTS
PURCHASE COMMITMENTS
The Company has entered into agreements primarily for the construction of
a new manufacturing and research and development facility with future
commitments of approximately $14,000.
OPERATING LEASES
The Company leases manufacturing, laboratory, warehouse, office space, and
various equipment under operating leases which expire at various dates through
2009. The following schedule summarizes future minimum lease payments required
under non-cancellable operating leases with terms greater than one year, as of
December 31, 1999:
<TABLE>
<S> <C>
2000 ................... $ 3,830
2001 ................... 3,822
2002 ................... 3,042
2003 ................... 2,548
2004 ................... 2,224
Thereafter ............. 9,058
-------
$24,524
=======
</TABLE>
Rent expense amounted to $969, $1,189 and $2,674 for the years ended
December 31, 1997, 1998 and 1999, respectively.
F-21
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
EMPLOYMENT AGREEMENTS
The Company has entered into employment agreements with certain officers,
the terms of which expire at various dates through September 2003. The
following schedule summarizes the future minimum payments under the Company's
employment agreements as of December 31, 1999:
<TABLE>
<S> <C>
2000 ............. $ 710
2001 ............. 612
2002 ............. 612
2003 ............. 390
------
$2,324
======
</TABLE>
Cybear entered into an employment agreement effective August 24, 1998 with
Edward Goldman, M.D., Cybear's Chief Executive Officer. Pursuant to the
Employment Agreement, Andrx agreed to issue to Dr. Goldman upon payment of $50,
a warrant to purchase 650,000 shares of Cybear common stock held by Andrx (the
"Warrant") at its then market price of $3.00 per share. In addition, Andrx will
issue to Dr. Goldman stock options for 80,000 shares of Andrx common stock
having an exercise price, per share, of the fair market value of Andrx stock at
the close of business on the date of grant. The stock to be issued pursuant to
the exercise of the Warrant includes piggyback registration rights. The Warrant
is exercisable commencing on April 30, 1999 (the "Warrant Exercise Date"). The
Warrant shall be exercisable for a period of seven years after the Warrant
Exercise Date, subject to contractual obligations with Andrx. In October 1999,
Dr. Goldman exercised a portion of the warrant and received 125,000 shares of
Cybear common stock. Andrx recognized a gain of $343 on the transaction, which
is included in the Consolidated Statement of Income.
(13) RELATED PARTY TRANSACTIONS
The Company is party to a royalty agreement with Dr. Chen, which provides
for royalties to Dr. Chen upon the sale of Andrx' bioequivalent version of
Cardizem/registered trademark/ CD, for which the Company received final
approval in July 1998 from the FDA. In August 1998, the Company amended that
royalty agreement to account for the various contingencies presented by a
Stipulation and Agreement (see Note 17). Royalties paid to Dr. Chen of $637 and
$7,000 for the years ended December 31, 1998 and 1999, respectively were based
on 3.33% of the net sales of Cartia XT/trademark/, as defined, and the
Stipulation fees. Such royalties are included in Selling, general, and
administrative expenses in the accompanying Consolidated Statements of Income.
In September 1998, Andrx agreed to sell 333,333 shares of Cybear common
stock for $1,000 or the then current market value of $3.00 per share to
Cybear's Chairman of the Board. As of December 31, 1998, Andrx had sold 233,333
shares to Cybear's Chairman and in January 1999, Andrx sold the remaining
100,000 shares under this agreement. Accordingly, Gain on sale of Cybear shares
in the Consolidated Statements of Income include $700 and $300, for the years
ended December 31, 1998 and 1999, respectively, from these transactions.
F-22
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
(14) SHAREHOLDERS' EQUITY
In June 1997, Capital Research and Management Company ("Capital"), an
investment management firm, purchased 2,920,000 shares of common stock and
Watson purchased an additional 600,000 shares of common stock. The purchase
price paid by each of Capital and Watson was $6.38 per share, the closing price
of Andrx' common stock on June 11, 1997. In a contemporaneous transaction,
certain of the Company's principals also sold a total of 1,800,000 shares of
Andrx' common stock to Watson on the same terms and conditions. Capital and
Watson were granted certain registration rights under the Securities Act of
1933, as amended, with respect to the shares purchased. Watson entered into a
standstill agreement with the Company pursuant to which it agreed, among other
matters, not to acquire more than a 25.0% equity interest in the Company or to
engage in certain transactions with the Company (including a merger), prior to
June 13, 2000, without the prior approval of the Company's Board of Directors.
In June 1999, Watson exercised a warrant to acquire 1,348,400 shares of
Andrx common stock at an exercise price of $2.23. Such warrant was issued to
Watson in connection with the original investment in the Company in July 1994.
(15) STOCK INCENTIVE PLAN
Under the Company's Stock Incentive Plan as Amended (the "Plan") the
Company's Board of Directors or its Compensation Committee (the "Committee") is
authorized to grant stock options, stock appreciation rights, restricted stock,
deferred stock, performance units, loans and tax offset payments or any
combination thereof, to employees, consultants or advisors of the Company. The
terms for, and exercise price at which any stock option may be awarded is to be
determined by the Committee. Options granted under the Plan must be exercised
within ten years of grant, unless a shorter period is designated at the time of
grant. Options cannot be awarded under the Plan after February 26, 2003. In
1997, the Company's Board of Directors and shareholders approved an increase in
the number of shares available for grant under the Plan to 8,000,000.
The Company accounts for options granted to employees under the Plan in
accordance with the provisions of APB Opinion No. 25. Each stock option has an
exercise price equal to the market price on the date of grant, and accordingly,
no compensation expense has been recorded for any employees' stock option
grants. On rare occasions, the Company may issue an insignificant amount of
equity instruments to non-employees. No such options were granted for the year
ended December 31, 1999. Stock options issued to consultants for the years
ended December 31, 1997 and 1998 were accounted for based on the fair value of
the consideration received or the fair value of the equity instruments issued,
whichever is more reliably measurable, as required by SFAS No. 123. In
instances where the fair value or the goods or services received is not
reliably measurable, the measure is based upon the fair value of the equity
instruments issued, and such value is amortized over the period for which
services are provided. The fair value of equity instruments issued to
consultants are valued using the Black-Scholes option pricing model.
F-23
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
A summary of the Plan's activity is as follows:
<TABLE>
<CAPTION>
OUTSTANDING EXERCISABLE
------------------------------------------------ ------------------------
NUMBER OF
SHARES EXERCISE PRICE PER SHARES WTD. AVG.
UNDER -------------------------------- EXERCISE
OPTION LOW HIGH WTD. AVG. SHARES PRICE
------------- ------- -------- ----------- ----------- ----------
<S> <C> <C> <C> <C> <C> <C>
December 31, 1996 ......... 3,657,400 $ .75 $ 3.63 $ 2.22 1,854,280 $1.67
Granted ................... 1,039,600 5.00 9.47 6.30
Exercised ................. (680,656) .75 3.50 1.84
Forfeited ................. (172,996) 1.63 9.47 5.65
---------
December 31, 1997 ......... 3,843,348 .75 9.47 3.23 1,982,916 2.25
Granted ................... 2,121,000 6.22 10.13 8.24
Exercised ................. (545,172) .75 8.25 2.78
Forfeited ................. (267,184) .75 10.13 5.50
---------
December 31, 1998 ......... 5,151,992 .75 10.13 5.23 2,256,208 2.96
Granted ................... 1,544,800 8.38 30.07 20.05
Exercised ................. (869,086) .75 9.72 4.11
Forfeited ................. (181,100) 1.82 30.07 10.36
---------
December 31, 1999 ......... 5,646,606 $ .75 $30.07 $ 9.24 2,527,456 $4.13
========= ===== ====== ====== ========= =====
</TABLE>
<TABLE>
<CAPTION>
EXERCISABLE OPTIONS
OPTIONS OUTSTANDING AT DECEMBER 31, 1999 AT DECEMBER 31, 1999
- ------------------------------------------------------------------------ -----------------------------
RANGE OF NUMBER OF WEIGHTED AVG. WEIGHTED AVG. WEIGHTED AVG.
EXERCISE SHARES REMAINING LIFE EXERCISE EXERCISE
PRICES UNDER OPTION (YEARS) PRICE SHARES PRICE
- ------------------ -------------- ---------------- --------------- ------------ --------------
<S> <C> <C> <C> <C> <C>
$ .75-$ 5.00 1,891,456 4.31 $ 2.38 1,611,456 $ 2.20
$5.01-$ 9.50 1,884,300 5.73 $ 7.44 815,000 $ 7.08
$9.51-$30.07 1,870,850 7.26 $17.99 101,000 $11.20
- --------------- --------- ---------
5,646,606 5.76 $ 9.24 2,527,456 $ 4.13
========= ---- ------ ========= ======
</TABLE>
The range of weighted average fair value per share as of the grant date
was $2.86 to $6.43, $5.89 to $16.28, and $5.36 to $20.41 for stock options
granted during the years ended December 31, 1997, 1998 and 1999, respectively.
F-24
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
The fair market value of an option was estimated using the Black-Scholes
option pricing model with the following assumptions:
<TABLE>
<CAPTION>
YEARS ENDED
DECEMBER 31,
---------------------------------
1997 1998 1999
--------- --------- ---------
<S> <C> <C> <C>
Risk-free interest rate ................. 5.3% 4.6% 6.4%
Average life of options (years) ......... 4.9 5.1 6.0
Average volatility ...................... 48.0% 99.0% 70.0%
Dividend yield .......................... -- -- --
</TABLE>
The following table summarizes the pro forma consolidated results of
operations of the Company as though the provision of the fair value-based
accounting method of SFAS No. 123 had been used in accounting for stock
options:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
-------------------------------------
1997 1998 1999
------------ --------- ----------
<S> <C> <C> <C> <C>
Net income (loss) ........................... As reported $ (7,636) $8,394 $94,054
======== ====== =======
Pro forma $ (9,317) $5,613 $86,969
======== ====== =======
Basic net income (loss) per share ........... As reported $ (0.13) $ 0.14 $ 1.52
======== ====== =======
Pro forma $ (0.17) $ 0.10 $ 1.46
======== ====== =======
Diluted net income (loss) per share ......... As reported $ (0.13) $ 0.13 $ 1.45
======== ====== =======
Pro forma $ (0.17) $ 0.09 $ 1.39
======== ====== =======
</TABLE>
(16) 401(K) PLAN
In February 1995, the Company adopted a 401(k) retirement plan covering
substantially all of its employees. Monthly contributions to the retirement
plan are made by the Company based upon the employees' contributions to the
plan. During the years ended December 31, 1997, 1998 and 1999, the Company
contributed $167, $229 and $366, respectively, to the 401(k) retirement plan.
(17) LITIGATION
WAXMAN-HATCH PATENT INFRINGEMENT LITIGATION
There has been substantial litigation in the pharmaceutical, biomedical
and biotechnology industries with respect to the manufacture, use and sale of
new products that are the subject of patent rights. Most of the brand name
controlled-release products for which the Company is developing bioequivalent
versions are covered by one or more patents. Under the Drug Price Competition
and Patent Restoration Act of 1984 (the "Waxman-Hatch Amendments"), when a drug
developer files an ANDA for a bioequivalent drug, the developer must make a
certification to the FDA as to whether the developer believes that an unexpired
patent that has been listed with the FDA as covering the relevant brand-name
product will be infringed by the
F-25
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
developer's product. If the developer believes that its product does not
infringe the brand product patent or that any such unexpired patent is invalid
or unenforceable (a "Paragraph IV Certification"), the developer must send a
Paragraph IV Certification to the patent holder, who may then initiate a legal
challenge to the developer's Paragraph IV Certification 45 days from the
Paragraph IV Certification, which will prevent the FDA from approving the ANDA,
until the earlier of 30 months or when the infringement case is decided in
favor of the developer. The outcome of such litigation is difficult to predict
because of the uncertainties inherent in patent litigation.
Patent infringement claims of the nature described above may be made by
other pharmaceutical companies in connection with the Company's filing of other
ANDAs or NDAs with the FDA or with the sale of any of its products. The Company
evaluates the probability of patent infringement litigation with respect to
each of its ANDA and NDA submissions on a case by case basis. Accordingly, the
Company provides for the estimated litigation costs to final resolution of each
case, as appropriate. Although the Company believes it has adequately provided
for such matters based on currently available information, the Company may
incur additional litigation costs in future years which may be material to the
Company's results of operations and financial position.
CARDIZEM/registered trademark/ CD PATENT INFRINGEMENT LITIGATION
In connection with the ANDA filed for Andrx' bioequivalent version of
Cardizem/registered trademark/ CD, Andrx certified to the FDA that its product
did not infringe upon any of the patents listed as covering that brand name
product and sent the required notices to the holders of each of those patents.
In January 1996, Aventis commenced litigation in the United States District
Court, Southern District of Florida, alleging that Andrx' product infringes
upon one of the six patents listed as covering Cardizem/registered trademark/
CD.
In September 1997, Andrx entered into the Stipulation in partial
settlement with Aventis of the patent infringement litigation involving
Cardizem/registered trademark/ CD in order to reduce the risks that both
parties faced as the case was litigated to its conclusion. The Company agreed
to maintain the status quo in connection with the marketing of its product and
to dismiss certain claims against Aventis. Aventis agreed to compensate the
Company for its lost profits, which were stipulated to be $100,000 per year, if
Andrx ultimately prevailed in the litigation and to grant Andrx a license for
their patents under certain conditions, including if the Company ultimately
lost the litigation. Aventis also agreed to make non-refundable interim
quarterly payments of $10,000 to the Company, beginning upon its receipt of
final FDA approval for its bioequivalent version of Cardizem/registered
trademark/ CD and continuing until the litigation was resolved or certain other
events occurred. In July 1998, the Company received both final FDA marketing
approval for its bioequivalent version of Cardizem/registered trademark/ CD and
its first quarterly payment for $9,130 (prorated for the 84 days in the quarter
ended September 30, 1998). For the year ended December 31, 1998 the Company
received a total of $19,130 in interim Stipulation fees. In June 1999, the
Aventis Litigation was settled and the lawsuit was dismissed with prejudice.
For the year ended December 31, 1999, the Company received pursuant to the
Stipulation $70,733 in interim and final Stipulation fees from Aventis. On June
23, 1999, the Company commenced selling Cartia XT/trademark/, its reformulated
bioequivalent version of Cardizem/registered trademark/ CD. Having been the
first Company to have its ANDA with a Paragraph IV Certification accepted as
filed by the FDA relative to Cardizem/registered trademark/ CD, the Company
enjoyed 180 days of marketing exclusivity that expired on or about December 19,
1999.
F-26
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
FDA LITIGATION
In January 1998, the Company filed an action in the United States District
Court for the District of Columbia against the FDA, Biovail Corporation
International ("Biovail") and F.H. Faulding and Co. ("Faulding"), regarding the
FDA's interpretation of certain provisions of the Waxman-Hatch Amendments. The
Company sought, among other things, a final injunction requiring the FDA to
provide the Company a 180-day period of marketing exclusivity for its
bioequivalent version of Cardizem/registered trademark/ CD and its Dilacor
XR/registered trademark/. On March 26, 1998, the Court entered a temporary
restraining order prohibiting Mylan Pharmaceuticals, Inc. from shipping or
otherwise distributing its bioequivalent version of Dilacor XR/registered
trademark/ until the expiration of the Company's 180-day period of marketing
exclusivity for its bioequivalent version of Dilacor XR/registered trademark/.
BIOVAIL ANTI-TRUST LITIGATION
In May 1998, Biovail filed counterclaims against Andrx alleging that the
stipulation violated Sections 1 and 2 of the Sherman-Antitrust Act and a
declaratory judgment as to federal law as well as for alleged violations of
state common law of unfair competition, tortious interference with prospective
advantage and tortious interference with contract. Biovail sought injunctive
relief and treble damages in an unspecified amount, plus interest, with respect
to its federal law claims, and actual and punitive damages in unspecified
amounts, plus interest, with respect to its common law claims. In July 1998,
Andrx filed a motion to dismiss the counterclaim that motion was granted with
prejudice with respect to the federal antitrust claims in January 2000, with
the state law claims being dismissed without prejudice. On February 2, 2000
Biovail filed a motion to vacate the order dismissing its counterclaims and on
or about February 6, 2000 filed a notice of appeal to the United States Court
of Appeals for the District of Columbia. The appeal is still pending.
OTHER CARDIZEM/registered trademark/ CD PATENT INFRINGEMENT CLAIM
On March 7, 2000, Purepac Pharmaceutical Co. (a subsidiary of Faulding
("Purepac")), filed suit against Andrx in the U.S. District Court for the
Eastern District of Pennsylvania claiming patent infringement because of Andrx
making, using, selling and/or offering Cartia XT/registered trademark/ which,
according to Purepac, infringes a patent issued to Faulding on March 7, 2000.
The letter also offered to license that patent to the company. Andrx is
currently evaluating Purepac's infringement claims and licensing offer and in
due course will file an appropriate response.
PUTATIVE CLASS ACTION
In addition to the above Cardizem/registered trademark/ CD patent
infringement litigation with Aventis, commencing in August 1998, putative class
actions have been filed against Andrx Pharmaceuticals in either state or
federal courts in Alabama, California, Florida, Illinois, Kansas, Michigan,
Minnesota, New York, North Carolina, Tennessee, Wisconsin and the District of
Columbia. In all of these suits Hoechst Aktiengesellschaft and Aventis
(collectively "Aventis Group") have been named as co-defendants. The complaint
in each action alleges that Andrx Pharmaceuticals and Aventis Group, by way of
the Stipulation, have engaged in alleged state antitrust and other statutory
and common law violations that allegedly have given Aventis Group and Andrx
Pharmaceuticals a near monopoly in the U.S. market for Cardizem/registered
trademark/ CD and a generic version of that pharmaceutical product. According
to the complaints, the monopoly possessed by the defendants enable
F-27
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
Aventis Group to perpetuate its ability to fix the price of Cardizem/registered
trademark/ CD at an artificially high price, free from bioequivalent
competition, with the result that direct purchasers (such as pharmacies), as
well as indirect purchasers (such as medical patients who have been issued
prescriptions for Cardizem/registered trademark/ CD) are forced to overpay for
the drug. Each complaint seeks compensatory damages on behalf of each class
member in an unspecified amount and, in some cases, treble damages, as well as
costs and counsel fees, disgorgement, injunctive relief and other remedies. In
June 1999, most of these class actions were consolidated for pretrial purposes
in the United States District Court for the Eastern District of Michigan. In
the consolidated proceeding, Aventis Group and Andrx Pharmaceuticals have filed
motions to dismiss the complaints on various grounds and plaintiffs have filed
motions for partial summary judgment. The motions to dismiss filed by Aventis
Group and Andrx Pharmaceuticals were denied on May 11, 2000 and the motions for
partial summary judgment are still pending. The four state court actions (two
in Kansas and two in Florida) that have not been included in the consolidated
proceeding have been temporarily stayed in light of the consolidated proceeding
in Michigan.
FTC ADMINISTRATIVE PROCEEDING
In March 2000, the U.S. Federal Trade Commission ("FTC") commenced an
administrative proceeding against Aventis and Andrx concerning the Stipulation
because it has reason to believe that the Stipulation had or may have had the
capacity or the potential to be anti-competitive. The FTC is not seeking any
fines, penalties, disgorgement or any other monetary remedy in the
administrative proceeding. Despite the views of the FTC, the Company continues
to believe the Stipulation was procompetitive and benefited consumers, and
intends to vigorously defend its position before the administrative law judge.
PRILOSEC/registered trademark/ PATENT INFRINGEMENT LITIGATION
In May 1998, Astra, Aktiebolaget Hassle, Astra Merck Enterprises, Inc. and
Astra Merck, Inc. (collectively, the "Astra Group"), filed suit against Andrx
in the U.S. District Court for the Southern District of Florida claiming patent
infringement because of an ANDA filed by Andrx with the FDA for a bioequivalent
version of Prilosec/registered trademark/. Subsequently, another patent
infringement suit was filed by the Astra Group against Andrx in the same Court
after Andrx made a second Paragraph IV Certification relative to a different
strength of Prilosec/registered trademark/. Andrx responded to these claims by
denying infringement, raising various other defenses, filing certain
counterclaims against the Astra Group and by seeking a declaration that there
has been no infringement and that the patents are invalid. The Astra Group
seeks an injunction enjoining Andrx from further infringing the subject patents
and an order directing that the effective date of any FDA approval of Andrx'
proposed bioequivalent version of Prilosec/registered trademark/ be no earlier
than the expiration date of its patents. In September 1999, for pretrial
purposes, both of these actions were consolidated in the U.S. District Court
for the Southern District of New York with three other patent infringement
suits initiated by the Astra Group relative to ANDAs submitted by other
companies for bioequivalent versions of Prilosec/registered trademark/. The
consolidated suit is still in the discovery phase. In May 2000, the Astra Group
filed two additional patent infringement suits involving ANDAs submitted by
other companies for bioequivalent versions of Prilosec, and is seeking to
consolidate these suits with those in the U.S. District Court for the Southern
District of New York. The Company believes that its product does not infringe
on the subject patents or that such patents are invalid or unenforceable.
F-28
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
TIAZAC/registered trademark/ PATENT INFRINGEMENT LITIGATION
In October 1998, Biovail, Biovail Laboratories Inc. and Galephar Puerto
Rico, Inc. (collectively, the "Biovail Group") filed suit against Andrx in the
U.S. District Court for the Southern District of Florida claiming patent
infringement because of an ANDA filed by Andrx with the FDA for a bioequivalent
version of Tiazac/registered trademark/. Andrx responded to this claim by
denying infringement, raising various other defenses, filing certain
counterclaims against the Biovail Group and by seeking a declaration that there
has been no infringement and that the patent is invalid. The Biovail Group
sought an injunction enjoining Andrx from further infringing the subject patent
and an order directing that the effective date of any FDA approval of Andrx'
proposed bioequivalent version of Tiazac/registered trademark/ be no earlier
than the expiration date of the subject patent. In March 2000, the court
entered an order that Andrx' product does not infringe the Biovail patent.
Biovail has filed a notice of appeal from that order.
NAPRELAN/registered trademark/ PATENT INFRINGEMENT LITIGATION
In October 1998, Elan Corporation, plc ("Elan") filed suit against Andrx
in the U.S. District Court for the Southern District of Florida claiming patent
infringement because of an ANDA filed by Andrx with the FDA for a bioequivalent
version of Naprelan/registered trademark/. Andrx responded to this claim by
denying infringement, raising various other defenses, filing certain
counterclaims against Elan and by seeking a declaration that there has been no
infringement and that the patent is invalid. Elan seeks a judgment enjoining
Andrx from further infringing the subject patent and ordering that the
effective date of any FDA approval of Andrx' proposed bioequivalent version of
Naprelan/registered trademark/ be no earlier than the expiration date of the
patent. The Company believes that its product does not infringe on the subject
patent or that such patent is invalid or unenforceable.
WELLBUTRIN SR/registered trademark/ AND ZYBAN/registered trademark/ PATENT
INFRINGEMENT LITIGATION
In September 1999, Glaxo Wellcome plc ("Glaxo") filed suit against Andrx
in the U.S. District Court for the Southern District of Florida claiming patent
infringement because of the ANDAs filed by Andrx with the FDA for bioequivalent
versions of Wellbutrin SR/registered trademark/ and Zyban/registered
trademark/. Andrx responded to this claim by denying infringement, raising
various other defenses, filing certain counterclaims against Glaxo and by
seeking a declaration that there has been no infringement and that the patent
is invalid. Glaxo seeks an injunction enjoining Andrx from further infringing
the subject patents and orders directing that the effective date of any FDA
approval of Andrx' proposed bioequivalent versions of Wellbutrin SR/registered
trademark/ and Zyban/registered trademark/ be no earlier than the expiration
date of the subject patent. The Company believes that its product does not
infringe on the subject patents or that such patents are invalid or
unenforceable.
DEPAKOTE/registered trademark/ PATENT INFRINGEMENT LITIGATION
In March 2000, Abbott Laboratories ("Abbott") filed suit against Andrx in
the United States District Court for the Northern District Court of Illinois,
claiming infringement of two of its patents because of Andrx's filing of the
aforementioned ANDA. Abbott seeks a judgment enjoining defendants from further
infringing the subject patents and ordering that the effective date of any FDA
approval of the Company's proposed bioequivalent version of Depakote/registered
trademark/ be no earlier than the expiration dates of the two patents in suit.
Although the Company has not yet responded to the complaint, the Company
believes that its product does
F-29
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
not infringe the patents involved or that either or both patents are invalid or
unenforceable. Following Andrx's filing of a motion to dismiss, Abbot filed
suits asserting the same claims against Andrx in the United States District
Court for the Eastern District of Florida and in the United States District
Court of Virginia.
CLARITIN D-24/registered trademark/ PATENT INFRINGEMENT LITIGATION
In February 2000, the Company submitted an ANDA to the FDA to sell the
Company's bioequivalent version of Claritin D-24/registered trademark/. In
March 2000, Schering-Plough Corporation filed suit in the U.S. District Court
for New Jersey claiming patent infringement because of an ANDA filed by the
Company with the FDA for a bioequivalent version of Claritin D-24/registered
trademark/. Although the Company has not yet been served with the complaint,
the Company believes that its product does not infringe the patent involved or
that the patent is invalid or unenforceable.
PHENTERMINE (PHEN-FEN) LITIGATION
In January 1999, Andrx was served with third party complaints filed
against them by certain doctors and distributors who are defendants in various
legal actions relating to the sale of phentermine by the Company and its usage
as a diet drug when taken in combination with fenfluramine, commonly known as
"phen-fen". The substance of the third party complaints is that the defendants
are without fault with respect to the claims in those actions but, if they are
found liable on any of those claims, then allegedly having obtained one or more
of the drugs from Andrx, they are entitled to indemnification in an amount to
pay and discharge any judgment entered against them in the putative class
action together with costs, expenses and attorney fees. Andrx has never sold
fenfluramine and believes that these claims are without merit.
In November, 1999, another Phen-fen diet lawsuit was filed against Andrx
in the Superior Court of New Jersey by (i) a husband, who claims to have
obtained or purchased, either directly or indirectly, from Andrx and others,
and thereafter ingested, phentermine, dexfenfluramine and fenfluramine, causing
serious medical consequences, all to his financial detriment, and (ii) his
wife, who, on behalf of herself and her two children, claims monetary damages
arising from emotional distress to herself and her children, loss of
spousal/paternal companionship and expenditure of money, time and care for her
husband required by her husband's alleged injuries which are permanent and
continuous in nature. Andrx has never sold dexfenfluramine or fenfluramine and
believes that these claims, including any based solely on the use of
phentermine, have no merit.
The Company is being represented and defended in both of these lawsuits by
counsel designated by the Company's insurer.
OTHER LITIGATION
As of December 31, 1999, the Company was involved with other legal
proceedings incidental to its business. Although it is not possible to predict
the outcome of such proceedings, it is the opinion of management, based on the
legal advice of counsel, that the ultimate outcome of those proceedings will
not have any significant adverse effect on the Company's consolidated financial
statements.
F-30
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
(18) SEGMENTS
In 1997, the FASB issued SFAS No. 131, "Disclosures about Segments of an
Enterprise and Related Information." This SFAS establishes new standards for
defining the Company's segments and disclosing information about them. It
requires that the segments be based on the internal structure and reporting of
the Company's operations.
Operating segments are defined as components of an enterprise about which
separate financial information is available that is evaluated regularly by the
chief operating decision maker, or decision making group, in deciding how to
allocate resources and in assessing performance. The operating segments are
managed separately because of the fundamental difference in their operations or
in the uniqueness of their product(s).
The Company operates in four business segments:
/bullet/ Anda
/bullet/ Andrx Pharmaceuticals
/bullet/ Aura Laboratories, Inc. ("Aura Labs")
/bullet/ Cybear
Andrx established Anda, its distribution operation, to complement its
Andrx Pharmaceuticals controlled-release bioequivalent segment in anticipation
of improving overall profitability by managing its products from the laboratory
to the drug store shelf. Anda markets and distributes generic pharmaceuticals
manufactured by third parties. Anda purchases generic pharmaceuticals directly
from manufacturers and wholesalers and markets them through its in-house
telemarketing staff primarily to independent pharmacies, pharmacy chains which
do not maintain their own central warehousing facilities and pharmacy buying
groups. Anda sales exclude participation in sales of Andrx Pharmaceuticals,
Inc. manufactured products. Anda includes the activity of Valmed after the
acquisition date (see Note 3). Anda sales exclude participation sales of Andrx
Pharmaceuticals Inc.'s manufactured products.
Andrx Pharmaceuticals is developing and applying multiple drug delivery
technologies to control the release characteristics of a variety of
orally-administered drugs. Controlled-release products are formulations which
release active drug compounds in the body gradually and predictably over a 12-
or 24-hour period and which therefore need be taken only once or twice daily.
Controlled-release products typically provide numerous benefits over immediate
release drugs, including (i) greater effectiveness in the treatment of chronic
conditions; (ii) reduced side effects; (iii) greater convenience (only once or
twice a day); and (iv) higher levels of patient compliance due to a simplified
dosing schedule. To date, Andrx Pharmaceuticals has developed eight distinct
drug delivery technologies that are patented or for which patent applications
have been filed. Andrx Pharmaceuticals is applying its proprietary drug
delivery technologies and formulation skills either directly or through
collaborative arrangements, to the development of bioequivalent versions of
selected controlled release brand name pharmaceuticals. Andrx Pharmaceuticals
also constructed a commercial-scale
F-31
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
manufacturing facility enabling the Company to make the transition from the
development stages through to the commercial manufacture of the
controlled-release pharmaceuticals. Andrx Pharmaceuticals sells its products
directly to pharmacy chains, wholesalers and distributors and utilizes the
resources of the Anda segment.
Through its wholly-owned subsidiary Aura Labs, the Company is engaged in
applying the proprietary drug delivery technologies developed by Andrx
Pharmaceuticals to clinical programs to the development of brand name
controlled-release formulations of existing immediate-release and
controlled-release drugs. In addition to improving drug efficacy and reducing
side effects, Andrx believes that its drug delivery technologies will provide
pharmaceutical companies with the opportunity to enhance the commercial value
of their existing products and new drug candidates. Aura labs currently has one
product in Phase III clinical trials and one other product will enter Phase III
clinical trials in 2000.
Through its information technology subsidiary Cybear, the Company uses the
Internet and Internet-based browser technologies to develop applications
designed to improve efficiency of administrative and communications tasks of
managing patient care with a secure and reliable transmission of information.
The category "Corporate and Other" consists of corporate headquarters,
including general and administrative expenses, interest income, income taxes
and adjustments for minority interest.
The Company evaluates the performance of the segments after all
intercompany sales are eliminated. The allocation of income taxes is not
evaluated at the segment level.
F-32
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
The following table presents financial information by business segment:
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31, 1997
----------------------------------------------------------------------------------------
ANDRX AURA CORPORATE &
ANDA PHARMACEUTICALS LABS CYBEAR OTHER CONSOLIDATED
------------ ------------------ ----------- ----------- --------------- ----------------
<S> <C> <C> <C> <C> <C> <C>
Revenues .............................. $146,237 $ 3,461 $ -- $ -- $ -- $ 149,698
Income (loss) from operations ......... 7,078 (10,302) (1,104) (1,504) (2,930) (8,762)
Interest income ....................... -- -- -- -- 1,585 1,585
Interest expense ...................... (490) -- -- -- -- (490)
Depreciation and amortization ......... 815 941 1 51 228 2,036
Capital expenditures .................. 1,496 5,305 3 242 669 7,715
Total assets .......................... 65,995 25,823 9 399 (1,381) 90,845
YEAR ENDED DECEMBER 31, 1998
-----------------------------------------------------------------------------------------
ANDRX AURA CORPORATE &
ANDA PHARMACEUTICALS LABS CYBEAR OTHER CONSOLIDATED
--------- ---------------- -------- --------- ----------- -------------
Revenues .............................. $215,903 $ 31,154 $ -- $ -- $ -- $ 247,057
Income (loss) from operations ......... 10,698 9,428 (4,023) (4,135) (4,710) 7,258
Gain on sale of Cybear shares ......... 700 -- -- -- -- 700
Interest income ....................... -- -- -- -- 1,064 1,064
Interest expense ...................... (380) -- -- -- -- (380)
Income tax expense .................... -- -- -- -- (333) (333)
Depreciation and amortization ......... 982 1,536 33 123 286 2,960
Capital expenditures .................. 833 4,572 145 2,340 96 7,986
Total assets .......................... 68,735 29,989 136 3,332 19,006 121,198
YEAR ENDED DECEMBER 31, 1999
-----------------------------------------------------------------------------------------
ANDRX AURA CORPORATE &
ANDA PHARMACEUTICALS LABS CYBEAR OTHER CONSOLIDATED
--------- ---------------- -------- --------- ----------- -------------
Revenues .............................. $262,321 $ 213,399 $ -- $ 270 $ -- $ 475,990
Income (loss) from operations ......... 20,010 157,959 (9,453) (14,550) (9,029) 144,937
Gain on sale of Cybear shares ......... 643 -- -- -- -- 643
Interest income ....................... -- -- -- 1,282 2,321 3,603
Interest expense ...................... (1,661) -- -- -- -- (1,661)
Income tax expense .................... -- -- -- -- (55,405) (55,405)
Depreciation and amortization ......... 1,209 1,923 46 1,080 258 4,516
Capital expenditures .................. 6,960 13,004 44 2,154 71 22,233
Total assets .......................... 123,494 45,623 134 53,105 135,598 357,954
</TABLE>
F-33
<PAGE>
ANDRX CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
DECEMBER 31, 1997, 1998 AND 1999
UNAUDITED WITH RESPECT TO THE THREE MONTHS ENDED MARCH 31, 1999 AND 2000
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE AMOUNTS)
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31, 2000 (UNAUDITED)
-------------------------------------------------------------------------------
ANDRX AURA CORPORATE &
ANDA PHARMACEUTICALS LABS CYBEAR OTHER CONSOLIDATED
---------- ----------------- ----------- ----------- ------------ -------------
<S> <C> <C> <C> <C> <C> <C>
Revenues .............................. $67,611 $47,636 $ -- $ 231 $ -- $115,478
Income (loss) from operations ......... 4,131 33,757 (3,024) (7,149) (2,365) 25,350
Interest income ....................... -- -- -- 559 972 1,531
Interest expense ...................... (474) -- -- -- -- (474)
</TABLE>
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31, 1999 (UNAUDITED)
-------------------------------------------------------------------------------
ANDRX AURA CORPORATE &
ANDA PHARMACEUTICALS LABS CYBEAR OTHER CONSOLIDATED
---------- ----------------- ----------- ----------- ------------ -------------
<S> <C> <C> <C> <C> <C> <C>
Revenues .............................. $63,025 $14,899 $ -- $ -- $ -- $77,294
Income (loss) from operations ......... 6,321 8,121 (1,239) (2,794) (2,012) 8,397
Gain on sale of Cybear shares ......... 300 -- -- -- -- 300
Interest income ....................... -- -- -- 1 365 366
Interest expense ...................... (154) -- -- -- -- (154)
</TABLE>
(19) SELECTED QUARTERLY DATA (UNAUDITED)
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31, 1997
-------------------------------------------------------------------
MARCH 31, JUNE 30, SEPTEMBER 30, DECEMBER 31,
------------- ------------ ----------------- ----------------
<S> <C> <C> <C> <C>
Total revenues ............................... $30,661 $ 32,559 $ 42,661 $ 43,817
Loss from operations ......................... (1,691) (2,385) (3,200) (1,486)
Net loss ..................................... (1,402) (2,261) (2,865) (1,108)
Basic and diluted net loss per share ......... (0.03) (0.04) (0.05) (0.01)
YEAR ENDED DECEMBER 31, 1998
----------------------------------------------------------------------
MARCH 31, JUNE 30, SEPTEMBER 30, DECEMBER 31,
------------- ------------ ----------------- ----------------
Total revenues ............................... $50,695 $ 55,955 $ 67,266 $ 73,141
Income (loss) from operations ................ (1,233) (1,846) 4,374 5,963
Net income (loss) ............................ (959) (1,718) 4,862 6,209
Basic net income (loss) per share ............ (0.02) (0.03) 0.08 0.11
Diluted net income (loss) per share .......... (0.02) (0.03) 0.08 0.09
YEAR ENDED DECEMBER 31, 1999
----------------------------------------------------------------------
MARCH 31, JUNE 30, SEPTEMBER 30, DECEMBER 31,
------------- ------------ ----------------- ----------------
Total revenues ............................... $77,924 $164,560 $111,415 $122,091
Income from operations ....................... 8,448 78,784 27,232 30,473
Net income ................................... 6,944 48,880 17,827 20,403
Basic net income per share. .................. 0.11 0.80 0.28 0.33
Diluted net income per share ................. 0.11 0.75 0.27 0.32
</TABLE>
F-34
<PAGE>
================================================================================
6,350,000 Shares
[ANDRX CORPORATION LOGO]
----------------
Prospectus
May 24, 2000
----------------
JOINT BOOK-RUNNING MANAGERS
BANC OF AMERICA SECURITIES LLC BEAR, STEARNS & CO. INC.
----------------
CIBC WORLD MARKETS
UBS WARBURG LLC
----------------
================================================================================
<PAGE>
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.
The Registrant estimates that expenses payable by the Registrant in
connection with the offering described in this registration statement (other
than underwriting discounts and commissions) will be as follows:
<TABLE>
<S> <C>
Securities and Exchange Commission registration fee ......... $ 121,615
NASD filing fee ............................................. 30,500
Nasdaq listing fee .......................................... 17,500
Printing and engraving expenses ............................. 125,000
Accounting fees and expenses ................................ 250,000
Legal fees and expenses ..................................... 225,000
Transfer Agent's fees and expenses .......................... 10,000
Miscellaneous ............................................... 325,385
----------
Total ..................................................... $1,105,000
==========
</TABLE>
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
The Registrant has authority under Section 607.0850 of the Florida
Business Corporation Act to indemnify its directors and officers to the extent
provided for in such statute. The Registrant's Amended and Restated Articles of
Incorporation and Bylaws provide that the Registrant may insure, shall
indemnify and shall advance expenses on behalf of our officers and directors to
the fullest extent not prohibited by law. We are also a party to
indemnification agreements with each of our directors and officers. The
Registrant has also agreed to indemnify the selling shareholders named in the
Registration Statement against certain liabilities, including liabilities under
the Securities Act.
ITEM 16. EXHIBITS.
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
- -------- -----------------------------------------------------------------------------------
<S> <C>
1.1 Form of Underwriting Agreement(1)
4.1 Specimen common stock Certificate(2)
5.1 Opinion of Broad and Cassel(1)
23.1 Consent of Broad and Cassel (included in its opinion filed as Exhibit 5.1)(1)
23.2 Consent of Arthur Andersen LLP(3)
24.1 Powers of Attorney (included on the signature page of this Registration Statement)
</TABLE>
- ----------------
(1) Previously filed
(2) Filed as an Exhibit of the same number to our Registrant Statement on Form
S-1 (File No. 333- 03614) and incorporated herein by reference.
(3) Filed herewith
ITEM 17. UNDERTAKINGS
The undersigned registrant hereby undertakes:
(a) That, for purposes of determining any liability under the Securities
Act, each filing of the Registrant's annual report pursuant to Section 13(a) or
Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable,
each filing of an employee benefit plans annual report pursuant to Section
15(d) of the Securities Exchange Act of 1934) that is incorporated by reference
in the registration statement shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering
thereof.
(b) To deliver or cause to be delivered with the prospectus, to each
person to whom the prospectus is sent or given, the latest annual report to
security holders that is incorporated by reference in the prospectus
II-1
<PAGE>
and furnished pursuant to and meeting the requirements of Rule 14a-3 or Rule
14c-3 under the Securities Exchange Act of 1934; and, where interim financial
information required to be presented by Article 3 of Regulation S-X are not set
forth in the prospectus, to deliver, or cause to be delivered to each person to
whom the prospectus is sent or given, the latest quarterly report that is
specifically incorporated by reference in the prospectus to provide such
interim financial information.
(c) Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise,
the registrant has been advised that in the opinion of the Securities and
Exchange Commission such indemnification is against public policy as expressed
in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other that the payment by the
registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant will, unless in
the opinion of our counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Act and
will be governed by the final adjudication of such issue.
II-2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended,
the Registrant certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing on Form S-3 and has duly caused this
Registrant Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Fort Lauderdale, State of Florida, on May 23,
2000.
ANDRX CORPORATION
By: /s/ ANGELO C. MALAHIAS
---------------------------------------
Angelo C. Malahias
Vice President and Chief Financial
Officer
Each person whose signature appears below constitutes and appoints Alan P.
Cohen, Elliot F. Hahn and Angelo C. Malahias, or any one of them, as his or her
true and lawful attorneys-in-fact and agents with full power of substitution
and resubstitution for him or her and in his or her name, place and stead in
any and all capacities to execute in the name of each such person who is then
an officer or director of the Registrant any and all amendments (including
post-effective amendments) to this Registration Statement, and any registration
statement relating to the offering hereunder pursuant to Rule 462 under the
Securities Act of 1933, as amended, and to file the same with all exhibits
thereto and other documents in connection therewith with the Securities and
Exchange Commission, granting unto said attorneys-in-fact and agents and each
of them full power and authority to do and perform each and every act and thing
required or necessary to be done in and about the premises as fully as he or
she might or could do in person, hereby ratifying and confirming all that said
attorneys-in-fact and agents; or any of them, or their or his substitute or
substitutes, may lawfully do or cause to be done by virtue thereof.
POWER OF ATTORNEY
Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
- ------------------------------ --------------------------------------------- -------------
<S> <C> <C>
/s/ ALAN P. COHEN Co-Chairman, Chief Executive Officer May 23, 2000
- ------------------------------ and Director
Alan P. Cohen (Principal Executive Officer)
/s/ CHIH-MING J. CHEN Co-Chairman, Chief Scientific Officer May 23, 2000
- ------------------------------ and Director
Chih-Ming J. Chen, Ph.D.
/s/ ELLIOT F. HAHN President and Director May 23, 2000
- ------------------------------
Elliot F. Hahn, Ph.D.
/s/ ANGELO C. MALAHIAS Vice President and Chief Financial Officer May 23, 2000
- ------------------------------ (Principal Financial and Accounting Officer)
Angelo C. Malahias
/s/ LAWRENCE J. DUBOW Director May 23, 2000
- ------------------------------
Lawrence J. DuBow
/s/ IRWIN C. GERSON Director May 23, 2000
- ------------------------------
Irwin C. Gerson
</TABLE>
II-3
<PAGE>
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
- ------------------------------ ---------- -------------
<S> <C> <C>
/s/ MICHAEL A. SCHWARTZ Director May 23, 2000
- ------------------------------
Michael A. Schwartz, Ph.D.
/s/ MELVIN SHAROKY Director May 23, 2000
- ------------------------------
Melvin Sharoky, M.D.
</TABLE>
II-4
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT DESCRIPTION
- --------- -------------------------------
<S> <C>
23.2 Consent of Arthur Andersen LLP
</TABLE>
EXHIBIT 23.2
CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
As independent certified public accountants, we hereby consent to the use
of our report and to all references to our firm included in or made a part of
this registration statement.
ARTHUR ANDERSEN LLP
Fort Lauderdale, Florida,
May 19, 2000.
